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ABSTRACT 
TNF-α, a pro-inflammatory cytokine, is implicated in the immune response in chronic 
obstructive pulmonary disease (COPD) secondary to Alpha-One Antitrypsin Deficiency 
(A1ATD). This thesis firstly describes studies in monocytes from A1ATD-related COPD 
subjects, examining the effect of the rs361525 TNF-A single nucleotide polymorphism, 
previously associated with 100-fold greater TNF-α concentration in the sputum of affected 
patients. Secondly, the autocrine effects of TNF-α on monocytes from healthy subjects are 
considered, in particular the differential roles of its two receptors, TNF-α receptor 1 (TNFR1) 
and 2 (TNFR2), an important topic given recent interest in selective TNFR1 blockade in 
TNF-α associated diseases.  
Unexpectedly, TNF-α mRNA expression and secreted protein was not greater in A1ATD-
related COPD subjects with the rs361525 polymorphism when compared to matched wild-
type subjects. Reasons may include the cell type and stimulus used or inadequate power. In 
monocytes from healthy subjects, autocrine binding of TNF-α increased production of pro-
and anti-inflammatory cytokines. Trends were observed for TNFR1 blockade to reduce both 
types of cytokine, for IL-10 to be reduced by TNFR2 blockade and for TNFR1 expression at 
the monocyte surface to be up-regulated by TNF-α-TNFR2 binding. Further studies are 
required to fully characterise the relative roles of TNFR1 and TNFR2 in monocytes. 
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1 Introduction 
1.1 TNF-α overview 
Tumour necrosis factor alpha (TNF-α) is the most important member of the extensive TNF 
superfamily of inflammatory cytokines (1).  The protein was initially identified in the 1970’s 
after studies revealed that a serum factor induced by the bacterial endotoxin, 
lipopolysaccharide (LPS), could induce tumour regression in mice (2). Since then numerous 
laboratories have investigated the many roles of this pleiotropic protein, in both physiological 
circumstances and pathological disease states. The major source in humans is monocytes and 
macrophages (3), although other immune cells can also secrete TNF-α, including natural killer 
cells (NKCs) and B-lymphocytes (4) and non-immune cells including endothelial cells, 
neurones and fibroblasts (5). TNF-α is initially produced as a 26 kilodalton (kDa) protein (233 
amino acids) which is expressed across the cell membrane in trimerised form before being 
cleaved by the metalloproteinase enzyme, tumour necrosis factor-α-converting enzyme 
(TACE). The resultant soluble cytokine has a molecular weight of 17kDa (157 amino acids) 
and again forms a trimer in order to bind to either either of its two receptors (6). Although 
membrane expressed TNF-α is commonly referred to as pro-TNF-α this form is able to 
activate intracellular signalling pathways in its own right (7). The two TNF-α receptors are 
known as tumour necrosis factor alpha receptor 1 (TNFR1) and TNFR2. TNFR1 is found on 
most cell types in humans whilst TNFR2 is restricted to leukocytes and vascular endothelial 
cells (4). The widespread presence of TNFR1 explains the broad and diverse range of effects 
that TNF-α can induce as the cytokine can essentially trigger intra-cellular signalling events in 
almost any cell type. 
Historically TNF-α was believed to be an entirely pro-inflammatory cytokine, however it has 
become clearer over recent decades that the role of TNF-α is more complex, encompassing 
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pro-inflammatory and  pro-fibrotic effects and also functions that limit and resolve 
inflammation. These effects are dependent on a variety of incompletely understood factors 
such as differential receptor activation and the specific organ involved in each disease process 
(5, 8).  
As an early phase cytokine TNF-α is rapidly up-regulated upon exposure to infectious agents 
or cell injury (3). Subsequent TNF-α receptor ligation is able to induce the relocation of 
transcription factors such as nuclear factor kappa B (NFκB) and activator protein-1 (AP-1) to 
the nucleus in effector cells leading to transcription of pro-inflammatory 
cytokines/chemokines such as interleukin 6 (IL-6), IL-1β and IL-8 (hereafter referred to by its 
alternative name, CXCL8, an alpha chemokine and a key neutrophil chemo-attractant) (9, 10). 
Thus TNF-α plays a vital role in coordinating the necessary cytokine milieu and the 
movement of inflammatory effector cells to sites of both bacterial (11, 12) and viral infection 
(13). The cytokine directly encourages inflammatory cell influx by up-regulating adhesion 
molecules on vascular endothelial cells and leukocytes (14). TNF-α is involved in priming 
neutrophils to release toxic products such as reactive oxygen species (ROS) and can increase 
the random movement of neutrophils (15-17). TNF-α signalling is important in promoting the 
formation of fully functioning granuloma to control intracellular infection such as that caused 
by mycobacteria (18). In addition TNF-α is able to induce cellular apoptosis in some 
scenarios and hence acts as one control mechanism for the eventual termination of 
inflammation in the normal individual (19, 20). 
TNF-α is also an important cytokine in many chronic inflammatory diseases, including 
rheumatoid arthritis, inflammatory bowel disease (IBD), ankylosing spondylitis and psoriasis, 
as evidenced by the clinical effectiveness of monoclonal antibodies (mAbs) targeting the 
TNF-α protein in-vivo in these conditions (21-27). Rarely however, anti-TNF-α therapy can 
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worsen or induce autoimmune disease such as multiple sclerosis (28), vasculitis and lupus-
like syndromes (29). Thus whilst generalised blockade of the TNF-α protein itself has 
undoubtedly revolutionised the treatment of a number of chronic inflammatory diseases, not 
all patients with those diseases respond and the reasons for this are not yet certain but may 
relate to the differential roles of the two TNF-α receptors in particular pathologies. 
In murine and human studies TNF-α is also believed to play a role in the inflammatory 
response of chronic obstructive pulmonary disease (COPD) and is discussed further in 1.4. 
1.2 Chronic obstructive pulmonary disease 
1.2.1 Definition and burden of disease 
COPD is a common chronic inflammatory lung disease, in general associated with a personal 
history of smoking. The disease affects an estimated 3 million people in the UK (30) and was 
recently ranked as the seventh leading cause of death in developed countries in the Global 
Burden of Disease Study (31) making it a significant public health problem. Pulmonary 
symptoms of COPD include the gradual onset of worsening exertional dyspnoea, wheeze and 
productive or non-productive cough. Patients predominantly have irreversible airflow 
obstruction on lung function testing and the degree of obstruction expressed as percentage of 
predicted (referenced against healthy age and sex matched populations) is used in classifying 
subjects into categories of disease severity (30). Many patients experience exacerbations, 
characterised by periodic deterioration of their symptoms. Exacerbations may be driven by 
infection, either bacterial or viral, or by non-infectious causes such as exposure to air 
pollution (32-34).   
COPD is in fact an umbrella term encompassing a number of pulmonary pathologies, which 
often coexist in individual patients but do not all have to be present. Emphysema is the 
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permanent breakdown of extracellular matrix in the parenchyma of the lung leading to 
destruction and enlargement of the alveolar airspaces which lie distal to the terminal 
bronchioles (35). Emphysema is strictly a pathological diagnosis but in reality can now be 
routinely diagnosed using high resolution computed tomography (HRCT) scanning of the 
chest. Chronic bronchitis (CB) is a clinical diagnosis defined by cough productive of sputum 
for at least three months in each of two consecutive years (36). Obstructive bronchiolitis, 
more commonly referred to as small airways disease, is characterised by inflammation and 
remodelling of airways approximately 2mm in diameter (divisions 12-23 of the 28 divisions 
of the human bronchial tree) increasing the resistance to airflow on expiration (37). 
Increasingly it is recognised that many patients with COPD also have coexistent 
bronchiectasis, a condition in which bronchi are permanently dilated and thickened, in a 
localised or more diffuse pattern. Classically this is associated with the expectoration of 
moderate to large volumes of sputum on a daily basis and predisposes potentially to recurrent 
lower respiratory tract infections, although in some patients the condition may be silent (38).  
Patients with COPD also carry a greater risk of developing a number of other diseases such as 
ischaemic heart disease, skeletal muscle wasting, osteoporosis and the metabolic syndrome, 
even after controlling for other risk factors such as smoking (30). Circulating TNF-α which 
may or may not have “spilled over” from the lungs of COPD patients has been implicated in 
the pathogenesis of some of these comorbidities and is discussed further in 1.4 (39).  
The major environmental risk factor for developing COPD is cigarette smoking (40), although 
biomass exposure is also recognised (41) and outdoor air pollution plays a role in 
exacerbations (34). Whilst much work has gone into identifying genetic risks factors the main 
inherited cause of COPD remains Alpha-One Antitrypsin Deficiency (A1ATD) (42), 
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responsible for 1 to 2 % of cases of COPD (43). Unfortunately as yet there exists no truly 
disease modifying pharmacological treatment for COPD.  
1.2.2 Mechanisms of COPD at a cellular level 
Much work has been conducted to investigate the pathological processes that lead to the 
development of COPD. This topic has been extensively reviewed and whilst there still 
remains unanswered questions we now have a broad understanding of the cell types involved 
as summarised below (35).  
Neutrophils release a number of serine proteases, most notably elastase, which when released 
in high enough concentration can overcome buffering anti-protease proteins and cause 
extracellular matrix degradation (44, 45). When this occurs at the acinus, individual alveoli 
are broken down and coalesce to form larger airspaces with a subsequent reduction in surface 
area for gas exchange (emphysema) (46). Another consequence of this extracellular matrix 
breakdown is loss of elasticity of the lung parenchyma which manifests itself as functional 
airway obstruction due to small airway collapse early during expiration (30). 
Neutrophils produce other proteases such as proteinase 3 as well as ROS and inflammatory 
cytokines which contribute to the development of COPD (47-49). Macrophages (and 
monocytes) also produce proteases, in the form of matrix metalloproteases (MMPs), ROS and 
inflammatory cytokines and chemokines such as TNF-α and CXCL8 (50-52). In addition, 
macrophages have a prominent role in surveillance and in the phagocytosis and clearance of 
unwanted or harmful material, such as bacteria, inhaled particles and apoptotic epithelial cells 
(efferocytosis) (53, 54). Efferocytosis is important as reduced clearance of apoptotic cells may 
lead to their unwanted necrosis with amplified inflammation as a result (55). There is 
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evidence to suggest that macrophage and neutrophil function  may be altered in COPD and as 
yet it is unclear whether this is a cause or effect phenomenon (54, 56).  
Other immune cells are also likely to play a role, although this has been less well defined than 
for neutrophils and macrophages. Dendritic cells act as antigen presenting cells (APCs) and 
may be responsible for inducing an adaptive immune response in COPD through presentation 
of bacterial peptides or autoantigens (57). Adaptive immune cells, which in some studies have 
been shown to be up-regulated in COPD patients, include cluster of differentiation (CD) 8 T-
cells, which release cytotoxic mediators such as perforin and granzyme (58), CD4 T-helper 
(TH)-1 cells and lastly plasma B-cells, which might produce autoantibodies (35, 57). In a 
subset of patients eosinophils are increased in the airway secretions and can predict systemic 
corticosteroid responsive disease (59).  
Structural cells within the lung also participate actively in COPD pathogenesis. Epithelial 
cells undergo squamous metaplasia and release pro-inflammatory cytokines (60). Goblet cells 
undergo hyperplasia, contributing to mucus hypersecretion, and hypertrophy (61). The 
smooth muscle of small airways increases in mass, leading to reduced airway radius (62), and 
also releases pro-inflammatory cytokines and growth factors (63). Fibroblasts in moderate to 
severe COPD subjects show a pro-inflammatory phenotype and may be less able to repair 
damaged elastin fibres, thereby contributing to the development of emphysema (64). 
In the circulation, monocytes from COPD subjects who are losing weight secrete more TNF-α 
than monocytes from non weight-losing COPD subjects or healthy controls (65), suggesting 
this cell type might play a role in the systemic effects of the disease. In addition, circulating 
monocytes from COPD subjects appear primed to become pro-inflammatory type 
macrophages irrespective of external stimuli, at least in-vitro (66). 
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1.3 A1ATD-related COPD 
A1ATD is an inherited condition that presents with early onset COPD, of both emphysema 
and CB phenotypes and often goes undiagnosed (42). Spirometric and gas transfer values 
begin to decline in the third decade in those subjects who present with symptoms and disease 
progression is accelerated by smoking (67). Liver disease may also develop depending on the 
specific genotype involved. Other presentations of the disease include neonatal liver failure, 
panniculitis and vasculitis (42). The multiple functions of the A1AT protein are being 
increasingly characterised, and the most important of these is the buffering effect of the 
protein against neutrophil serine proteases such as neutrophil elastase and proteinase 3 (68-
70). A markedly reduced serum concentration of A1AT thus leads to excessive proteinase 
mediated lung damage, as the local pericellular concentration of proteinases vastly exceeds 
that of the A1AT buffer (71). Treatment of A1ATD-related COPD follows that of usual 
COPD and in some countries human intravenous A1AT is given periodically to increase 
systemic and local A1AT concentrations (42). 
The A1AT protein is coded for on chromosome 14 at position 14q32.1 by a gene named 
serpinA1 (“serine proteinase inhibitor A1”), and is manufactured as a 52kDa glycoprotein by 
liver hepatocytes and secreted into the circulation (42). Relative deficiency of the A1AT 
protein occurs as a result of a variety of single nucleotide polymorphisms (SNPs) in the gene. 
The normal allele is termed M and can be expressed in a co-dominant fashion with abnormal 
alleles, most commonly Z or S. Other less common alleles include F, I, P and null alleles. The 
most common genotypes to result in decreased serum concentration of A1AT below the 
recognised protective level of 11 micromolar (µM) include ZZ and SZ. MZ and MS 
genotypes generally produce enough A1AT to protect against the development of lung 
damage and affected subjects are regarded as carriers. Whilst null alleles lead to absence of 
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any production of A1AT the more common Z and S alleles do lead to protein manufacture 
(42). For example, the only difference in the Z variety of A1AT compared to the normal M 
protein is a glutamate to lysine substitution at position 342. However, this change leads to 
profound consequences, specifically the acquired ability of adjacent A1AT protein molecules 
to slot one into the other, with the subsequent formation of polymers which are largely unable 
to be secreted in to the circulation. It is because of this accumulation of polymerised A1ATD 
that liver cirhhosis can develop in later years (72).  What A1AT is secreted into the circulation 
will easily form polymers in the blood and lung (42). It should be noted that the penetrance of 
A1ATD is variable and may depend on other genetic susceptibility factors and/or 
environmental exposures.  
Whilst many of the described cellular mechanisms for the development of usual COPD also 
apply to A1ATD-related COPD there are some features that are especially relevant or unique 
to A1ATD. These are summarised in figure 1.1. 
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Figure 1-1 Mechanisms of pulmonary damage in A1ATD 
1) Neutrophils present in the airway secrete elastase in response to toxic stimuli such as 
cigarette smoke. 2) Elastase stimulates the release of the neutrophil chemoattractant 
leukotriene B4 (LTB4) by macrophages. 3) LTB4 secretion and CXCL8 secretion by 
epithelial cells (73) lead to the recruitment of neutrophils from the circulation. 4) Neutrophils 
pass through the lung interstitium on the way to the airway lumen and elastase and other 
proteases are released to facililate this passage through the connective tissue. The relative lack 
of A1AT in the immediate vicinity of each neutrophil means the pericellular concentration of 
proteases overwhelms the available functioning A1AT and is able to break down elastin fibres 
for a longer time period and in a greater surrounding area (before diffusing outwards until a 
low enough concentration is reached that the available A1AT can meet the buffering needs) 
than neutrophils in non-A1ATD lungs can (71). In addition, any A1AT polymers present are 
themselves pro-inflammatory as they act as a further neutrophil chemoattractant (74). 
Reproduced with the permission of Professor Robert Stockley (42). 
 
1.3.1 The relationship between A1AT and TNF-α 
In recent years work has emerged supporting the concept that A1AT plays an important role 
in modulating TNF-α pathways. Bergin et al showed that neutrophils from patients with ZZ 
A1ATD (but no airway obstruction yet) had more mTNF-α on their surface, secreted more 
sTNF-α and released more secondary and tertiary neutrophil degranulation products than 
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neutrophils from MM control subjects. Exogenous sTNF-α induced more neutrophil 
degranulation in ZZ subjects and importantly this was abrogated by pre-treatment with A1AT. 
The mechanism for this was determined to be due to interruption of TNF-α binding to either 
of its receptors by A1AT binding to them in its place. As a result TNF-α autocrine loops in 
neutrophils were interrupted, down-regulating further production of TNF-α messenger 
ribonucleic acid (mRNA) (75). Thus, increased secretion of TNF-α by neutrophils from ZZ 
subjects can be explained by the relative lack of negative feedback control due to decreased 
circulating A1AT. In addition the same group showed that A1AT inhibits the action of TACE 
(76) and therefore in A1ATD patients enhanced TACE activity may occur leading to greater 
TNF-α and TNFR1 secretion (75). In LPS-stimulated human monocytes the addition of A1AT 
led to an initial increase in TNF-α output but over time caused a marked reduction (77). 
Lastly, Lockett et al also demonstrated in pulmonary microvascular endothelial cells that 
A1AT reduced TNF-α secretion by inhibiting the action of TACE (78). Taken together these 
studies suggest that TNF-α may play a more important role in A1ATD-related COPD than in 
usual COPD. 
1.4 TNF-α in COPD 
Whilst the cytokine network in COPD is undoubtedly complex (79), numerous studies have 
suggested a role for TNF-α in COPD pathogenesis. The principal studies are summarised in 
table 1.1 and can be broadly divided into three categories: animal studies, human cross-
sectional studies and human prospective studies. A general critique of these studies is 
provided below. 
The human studies are subject to a number of significant limitations, the most important being 
that even in well-designed studies any association found between TNF-α and a particular 
outcome or disease process cannot prove causality. Cross sectional studies are limited to 
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investigating patients at one point in time and hence are unable to investigate the role of 
mediators in disease pathogenesis at varying disease stages in the same cohort. Prospective 
studies are less limited for this reason as they allow individual subjects to be followed over 
time hence acting as their own controls, for example when investigating the potential role of 
TNF-α in exacerbations (80, 81). However, no prospective studies have been conducted for 
more than three years, presumably because COPD is a slowly progressive disease, making 
sampling of patients over long periods of time a costly challenge. There remain a number of 
other limitations which make drawing definitive conclusions difficult from the human studies 
outlined in the table. The populations investigated were of varying size, with heterogeneity in 
the COPD groups across studies and only limited matching of COPD and control groups 
within studies.  
Overall, the available evidence varies as to whether TNF-α is increased in the airways 
(sputum), the alveoli (bronchoalveolar lavage (BAL)) and the circulation of patients with 
stable COPD. There is stronger evidence from the larger prospective studies to suggest it is 
increased in the serum and airways during bacterial and non-bacterial exacerbations. It is 
unsurprising that this is the case given the vital role of TNF-α in coordinating the innate 
immune response to viruses and bacteria. The available studies cannot answer the question of 
whether this TNF-α response is excessive, perhaps contributing to the acceleration of disease 
progression observed in patients who are frequent exacerbators (82), or physiological. The 
cross sectional and prospective studies showed that TNF-α correlated (in some cases) with 
clinical indices of severity of disease and co-morbidities such as osteoporosis and skeletal 
muscle inflammation and wasting, suggesting a possible systemic role for TNF-α in COPD.  
The strongest evidence for a role for TNF-α in COPD pathogenesis comes from animal 
studies, whereby mouse models with knockout of both TNF-α receptors are highly protected 
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to impressive extents from developing emphysema in response to cigarette smoke extract 
(CSE). Investigators also in one case confirmed a reduction in the development of small 
airways disease as result of receptor knockout (83). Animal models are undoubtedly useful 
but like human studies have some limitations, namely, questions over their pathological 
resemblance to human disease, particularly to later stages, a lack of exacerbations and the 
automatic cessation of disease progression on removal of CSE (84). 
Taken in the context of the animal model work it is unlikely that all the positive findings in 
human studies are purely related to associations between TNF-α and clinical indices/events, 
suggesting instead that the presence of TNF-α induces a pro-inflammatory cascade that 
contributes to tissue damage. Whilst not causing COPD never-the-less TNF-α is an important 
cytokine in the disease, perhaps especially in A1ATD-related COPD, given the unique role 
the A1AT protein plays in TNF-α regulation as discussed in 1.3.1. 
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Table 1-1 Summary of studies investigating the possible role of TNF-α in the 
pathogenesis of COPD 
Study design Findings Author/ 
reference 
Animal 
models 
Guinea pigs exposed to long term CSE developed 
emphysema with raised plasma TNF-α. Mice exposed to 
acute CSE developed increase in mRNA and plasma 
TNF-α. 
Wright et al 
(46) 
TNF-α receptor KO mice (in contrast to WT mice) do 
not express mRNA for neutrophil and monocyte 
chemokines, do not have an inflammatory cell influx or 
any connective tissue breakdown in the lungs in 
response to acute CSE.  
Churg et al 
(85) 
 
TNF-α receptor KO mice exposed to CSE for 6 months 
had less pulmonary inflammatory cells and proteases 
present on lavage and were 70% protected from the 
development of airspace enlargement (emphysema), 
compared to WT mice. 
Churg et al 
(86) 
 
TNF-α receptor KO mice exposed to CSE for 6 months 
were protected from developing small airways 
remodelling.  
Churg et al 
(83) 
TNF-α receptor KO mice exposed to CSE for 6 months 
did not produce MMP mRNA in the walls of small 
intrapulmonary arteries. MMPs are thought to contribute 
to long term pulmonary vascular changes in COPD. 
Wright  et al 
(87) 
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Study design Findings Author/ 
reference 
Human models 
(cross 
sectional): 
Pulmonary 
 
Induced sputum from stable COPD patients (most 
GOLD stages II and III) contained more TNF-α than 
the induced sputum from healthy smokers and healthy 
controls (n=20 in each group). Higher TNF-α was 
also noted in the sputum from healthy smokers 
compared to healthy controls.  
Hacievliyagil et 
al (88) 
 
Induced sputum from stable COPD subjects (n=14) 
contained more TNF-α than that of non-smokers or 
healthy smoking controls. 
Keatings et al 
(89) 
Induced sputum from stable COPD patients (n=18) 
showed no difference in TNF-α compared to healthy 
smoking controls, but did have more sTNFR1. 
Vernooy et al 
(90)  
BAL fluid from stable COPD subjects classed as 
frequent exacerbators contained more TNF-α than 
healthy smoking and non-smoking controls and from 
COPD subjects who weren’t frequent exacerbators. 
Tumkaya et al 
(91) 
 
 
Lung tissue stimulated with LPS ex-vivo produced 
greater TNF-α in subjects with stable GOLD stage I 
(n=11) or II COPD (n=13) compared to healthy 
controls. 
Hackett et al 
(92) 
Bronchial intraepithelial T-cells from moderate to 
severe stable COPD subjects (n=10) produced more 
TNF-α than T-cells from healthy controls, healthy 
smokers and subjects with mild COPD. TNF-α 
production by these T-cells in the lower airways 
correlated negatively with FEV1.  
Hodge et al (93) 
 
Induced sputum from exacerbating severe COPD 
subjects (n=19) did not contain more TNF-α than 
induced sputum from COPD subjects with mild-
moderate disease (n=20). 
Hacievliyagil et 
al (94) 
Spontaneous sputum samples from exacerbating CB 
subjects (n=45) contained varying concentrations of 
TNF-α depending on the bacteria isolated. 
Sethi et al (33) 
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Study design Findings Author/ 
reference 
Human models 
(cross 
sectional): 
Systemic 
 
Serum TNF-α higher in stable COPD subjects (n=83) 
compared to healthy controls. Serum TNF-α higher in 
COPD subjects with an exacerbation (n=20) compared 
to stable COPD subjects. 
Karadag et al 
(95) 
 
Serum TNF-α higher in COPD subjects (n=27) than 
healthy age matched controls. sTNFR1/2 also higher. 
All 3 parameters correlated negatively with the partial 
pressure of arterial oxygen. All 3 parameters higher in 
COPD subgroup with severe hypoxia vs non-severe 
hypoxia. All 3 parameters highest in malnourished 
subgroup with concomitant hypoxia.  
Takabatake et al 
(96)  
 
No differences in plasma TNF-α or sTNFR1/2 (which 
far exceeded TNF-α in concentration) in CB subjects 
(n=15) compared to non-smoking age matched healthy 
controls. 
Sapey et al (97) 
 
Serum TNF-α was associated negatively with fat free 
mass index in stable COPD subjects (n=222), but not in 
healthy smokers or healthy controls. 
Gaki et al (98) 
 
Serum TNF-α was found to be an independent predictor 
of low bone mineral density (i.e. osteoporosis) in 672 
COPD subjects with mostly moderately severe disease. 
Liang et al (99) 
 
TNF-α induced by LPS stimulation of whole blood was 
greater in severe COPD subjects compared to 
moderately affected patients. The concentration of 
TNF-α induced by LPS stimulation of whole blood 
correlated negatively with FEV1. 
von Haehling et 
al (100) 
 
A higher proportion of circulating CD8 T-cells from 
stable GOLD II-IV COPD subjects (n=30) produced 
TNF-α compared to healthy controls. However, GOLD 
IV subjects had a lower proportion positive for TNF-α 
compared to less severe stages of COPD and the 
proportion positive had a moderate positive correlation 
with gas transfer factor. 
Paats et al (101) 
 
Subjects with mild COPD (n=27) had higher plasma, 
and induced sputum concentration of TNF-α compared 
to age matched healthy controls.  
Foschino et al 
(102) 
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Study design Findings Author/ 
reference 
Human 
models (cross 
sectional): 
Other 
 
Quadriceps muscle biopsies from COPD subjects (n=11) 
had higher TNF-α mRNA expression at rest than those 
from healthy controls. Not all COPD subjects were 
hypoxic. 
Rabinovich  et 
al (103) 
External intercostal muscle biopsies from COPD subjects 
(n=25) had higher TNF-α mRNA and protein expression 
than those from healthy age matched controls. TNF-α 
mRNA correlated negatively with maximum inspiratory 
sustainable pressure in COPD subjects. 
Casadevall et 
al (104) 
No differences in serum TNF-α between 4 groups of COPD 
subjects based upon BMI (n=44 in total). TNF-α mRNA in 
adipose tissue (probably secreted by macrophages) was 
positively correlated with BMI and predicted insulin 
resistance. There was no up-regulation of adipose tissue 
TNF-α mRNA in the cachectic group compared to other 
groups. No healthy control comparison.  
Skyba et al 
(105) 
 
 
Quadriceps muscle biopsies from patients with severe 
COPD and with high TNF-α mRNA expression (n=17), 
had reduced mRNA expression of enzymes involved in 
oxidative metabolism compared to biopsies from mild 
COPD patients (n=17) and healthy controls (n=10) with 
low muscle TNF-α mRNA expression. 
 
Remels et al 
(106) 
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Study design Findings Author/ 
reference 
Human 
models 
(prospective): 
Pulmonary 
and 
Systemic 
 
TNF-α concentration was higher in the sputum of COPD 
patients with a bacterial exacerbation than those with a 
non-bacterial exacerbation. Change in TNF-α concentration 
in sputum from baseline to exacerbation was only 
significant in the subjects with a bacterial exacerbation. 
Bathoorn et al 
(81) 
 
Subjects with moderate to severe COPD (n=14) were 
followed up before and after an exacerbation. TNF-α 
concentration in the sputum increased at the time of the 
exacerbation and had decreased back to baseline levels by 
one month. 
Aaron et al 
(80) 
 
Serum TNF-α higher in COPD subjects (n=1755) than in 
healthy controls but lower than in healthy smokers/ex-
smokers. Having a persistently raised inflammatory 
phenotype (2 or more serum biomarkers, which could 
include TNF-α) raised at baseline and one year was 
predictive of increased risk of exacerbation and all-cause 
mortality at 3 years. 
Agusti et al 
(107) 
COPD subjects (n=408) with “high” plasma TNF-α (>2.2 
pg/ml) at years 0 and 1 had a greater decline in fat free 
mass over time if cachectic at baseline.  
Eagan et al 
(108) 
 
Serum TNF-α higher in GOLD III and IV disease (n=253) 
than other stages. A model combining IL-6, CXCL8, IL-16 
and TNF-α results predicted worse lung function, 
symptoms and mortality if in the highest quartile for those 
pro-inflammatory biomarkers. No difference in BMI 
between highest and lowest quartiles for TNF-α levels.  
Pinto-Plata et 
al (109) 
 
Serum TNF-α raised in COPD subjects (n=63) at the time 
of an exacerbation compared to resolution and in the stable 
state. 
Krommidas et 
al (110) 
 
Serum TNF-α raised in COPD subjects (n=93) at the time 
of an exacerbation compared to resolution and in the stable 
state. 
Markoulaki et 
al (111) 
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The table summarises the evidence suggesting a role for TNF-α in COPD pathogenesis from 
human and animal studies. A general critique of these studies is provided in the text. 
BAL- bronchoalveolar lavage; BMI- body mass index; CB- chronic bronchitis; CSE- cigarette 
smoke extract; COPD- chronic obstructive pulmonary disease; FEV1- Forced expiratory 
volume in one second ; GOLD- Global initiative for chronic obstructive lung disease; KO- 
knock out ; LPS- lipopolysaccharide; MMP- matrix metalloprotease; mRNA- messenger 
ribonucleic acid; sTNFR- soluble TNF-α receptor; WT- wild type. 
 
1.4.1 TNF-α blockade in COPD  
In view of the animal and human studies which suggested a role for TNF-α in COPD, clinical 
studies were designed to test the effects of TNF-α blockade in the disease. Two types of anti-
TNF-α molecules are available. Monoclonal antibodies which bind to TNF-α can be chimeric, 
containing mouse and human deoxyribonucleic acid (DNA) (infliximab), humanised 
(certolizumab) or fully human in source (adalimumab, golimumab) (112). Etanercept is a 
receptor fusion protein whereby the DNA coding for TNFR2 and the constant end of human 
immunoglobulin 1 (IgG1) were sequenced and combined to produce a molecule which is 
capable of binding trimerised TNF-α. All five agents can bind both soluble TNF-α (sTNF-α) 
and membrane TNF-α (mTNF-α) (112). Anti-TNF-α mAbs had initially been developed to 
treat sepsis, without success, but following promising early trials by Feldmann et al’s group 
of a chimeric mAb in rheumatoid arthritis interest in these mAbs exploded and they are now 
routinely used in rheumatoid arthritis, psoriasis, ankylosing spondylitis and IBD (23). 
The first study in COPD was a small phase 2 randomised controlled trial (RCT) in which 14 
mild/moderate COPD patients were randomised to receive three doses of infliximab over a six 
week period and eight to receive placebo. TNF-α blockade in this short term study had no 
effect on the primary outcome of sputum neutrophilia, nor on lung function or quality of life 
(113). A larger RCT conducted by Rennard et al randomised patients with moderate to severe 
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COPD to one of two doses of infliximab (n=79) or to placebo (n=77) for a total of six doses 
over 24 weeks, following patients up for 44 weeks from the start of the trial (114). The 
primary end-point for this study was a clinical outcome, the Chronic Respiratory 
Questionnaire, along with multiple secondary clinical outcomes, such as exacerbation 
frequency, and physiological outcomes. All outcomes were negative, although post-hoc 
analysis revealed significant improvements in the 6 minute walk distance of young or 
cachectic subjects. Of note a greater number of patients in the active treatment group 
developed cancer or pneumonia and although this was not statistically significant, raised 
serious issues about this therapeutic approach.  
Whilst it is disappointing that these studies have not shown positive results it must be 
considered that blockade of TNF-α in moderate to severe COPD may be too late in the disease 
trajectory to make any clinical difference. In addition the individuals studied were from an 
unselected population of COPD patients and in general the systemic TNF-α levels were low. 
It may be that a particular TNF-α dependent phenotype of COPD would be responsive to 
TNF-α blockade or that local delivery of anti-TNF-α therapy to the airways would be more 
appropriate. However, the potential risks of malignancy and infection in this group, raised as a 
concern in the aforementioned trials mean that there may be a reduced appetite for revisiting 
this issue.  
1.5 TNF-A 
1.5.1 Location of the TNF-A gene 
TNF-A, the gene coding for the TNF-α protein is located on the short arm of chromosome 6 at 
position 6p21.3 (115) and lies within the class III region of the major histocompatibility 
complex (MHC) genes. Class III genes are found between the class I region, which codes for 
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human leukocyte antigen (HLA)-A, B and C antigens (antigen presenting molecules found on 
all nucleated cells and which present to CD8 T-cells) and the class II region, which codes for 
HLA-DP, DQ and DR antigens (antigen presenting molecules found on classical APCs such 
as dendritic cells and which present to CD4 T-cells). The MHC region of the chromosome 
measures 4 mega base pairs (bp) in length, has a high degree of genetic variation and is well 
known to undergo linkage disequilibrium, in which particular genes are not randomly 
separated at meiosis and hence are often co-inherited as an extended haplotype (115). Figure 
1.2 shows the TNF-A locus. 
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Figure 1-2 The TNF-A gene 
The TNF-A gene is shown located between the lymphotoxin beta (LTB) and lymphotoxin 
alpha (LTA) genes (not to scale) within the class III region of the MHC genes. The TNF-A 
gene contains 4 exons and a promoter region, covering approximately 3 kilobase pairs. Exon 
1 begins with nucleotides coding for the 5’ untranslated region (UTR) of the gene and exon 4 
ends with nucleotides coding for the 3’ UTR, with the remaining exon nucleotides coding for 
the actual TNF-α protein. The expanded region highlights the promoter region of the gene. 
Position 0 relates to the first nucleotide in exon 1 and bp upstream of this in the promoter 
region are assigned negative numbers dependent on their distance from this nucleotide. Bp -1 
to -200 comprise the proximal part of the promoter region. Position 237 has been highlighted 
and is the location of one particular SNP, the rs361525 polymorphism, studied in this thesis. 
Adapted from Posch et al (116). 
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1.5.2 Polymorphisms in the TNF-A gene 
SNPs are substitutions of the usual nucleotide found at a position in a gene sequence by one 
of the other three possible nucleotides (A-adenine; T-thymine; C-cytosine; G-guanine). SNPs 
can affect either one (heterozygous) or both (homozygous) copies of the gene that an 
individual carries. As the MHC complex on chromosome 6 displays more genetic variation 
than any other chromosome (115) it is unsurprising that the TNF-A gene has been identified 
as having multiple SNPs. The majority (ten) of these are located in the promoter region of the 
gene. However, nine of these are situated beyond the highly conserved proximal promoter, 
upstream of bp -1 to -200, a region whose role in affecting gene transcription has been less 
well established. Others are located in the introns or exons and one is within the exon coding 
for the 3’ UTR of the transcript (116). It has been speculated that SNPs may alter the binding 
capabilities of transcription factors, which bind to the promoter region and facilitate gene 
transcription, and hence may affect mRNA expression of the gene, either positively or 
negatively, and that this in turn may affect phenotypes of disease. To that end genetic 
association studies, either case-controlled or family based, and more recently genome-wide 
association studies (GWAS), have investigated many SNPs in a vast number of diseases. This 
thesis will in part concentrate on the investigation of one particular SNP in TNF-A, the 
rs361525 polymorphism, in A1ATD-related COPD.  
1.6 COPD and the relevance of genetic variation 
There has been a move in recent years to divide COPD into particular phenotypes, with the 
aim of being able to classify patients into groups that would provide a clearer idea about an 
individual’s prognosis and response to available treatment (117). Phenotypes can be chosen 
based on clinical, radiological or physiological parameters. However, it is also important to 
consider the effect that an individual’s genetic make-up might have on the clinical expression 
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of the disease as this may have a greater impact on designing effective tailored treatments 
than by considering clinical phenotypes alone. The only well characterised example of 
genotype influencing the development of COPD is that of defects within the serpinA1 gene in 
A1ATD.  
It is possible that polymorphisms within other genes also contribute to COPD pathogenesis 
and might partly explain the heterogeneity of clinical expression of the disease between 
individuals and why only 25% of smokers develop clinically significant COPD (40). To this 
end genetic association studies have been performed investigating whether a wide range of 
SNPs are more frequent in COPD patients. A number of systematic reviews have attempted to 
collate results from these studies to determine which gene polymorphisms, (generally SNPs 
within inflammatory or antioxidant genes or genes involved in protease/anti-protease 
processes) are relevant to COPD, with conflicting results (118-122). There are a number of 
limitations with these case-control genetic association studies, including differences in clinical 
characteristics between cases and controls, methodological differences in defining COPD 
between studies and differences in the ethnicity and geographical location of groups within 
and between studies. These limitations make replication of results in other case-control 
populations and the combining of individual studies in meta-analyses a significant challenge. 
More recently we have witnessed the emergence of GWAS which have tested very large 
populations of individuals for a multitude of SNPs across the whole genome and then 
determined which of these confer susceptibility for particular diseases. Whilst GWAS 
importantly eliminate some of the issues observed with smaller case control or family based 
association studies there are still limitations, namely the dilution or loss of association of a 
SNP when a population is viewed globally. For example, SNPs causing A1ATD are not 
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shown to be associated with COPD when individuals of all ages were considered as opposed 
to a younger subset (123).  
1.7 The rs361525 TNF-A polymorphism  
The rs361525 polymorphism occurs at position -237 in the promoter region of the TNF-A 
gene (figure 1.2) whereby there is a substitution of the more common G nucleotide by the A 
nucleotide.  The estimated allele frequency of the minor allele was 6.8% based on a small 
study in a healthy population (124). Evidence for its role in A1ATD-related COPD is 
considered here. 
1.7.1 The rs361525 TNF-A polymorphism in A1ATD-related COPD case control 
studies 
The importance of selecting the relevant population of patients when aiming to detect 
important associated SNPs is illustrated by a study by Wood et al (125). TNF-A gene 
polymorphisms have been studied in genetic association and laboratory based studies in a 
number of inflammatory diseases, including COPD (115, 118, 119). Wood et al studied four 
previously identified polymorphisms of the gene, including the rs361525 polymorphism, in a 
cohort of 424 unrelated patients with A1ATD-related COPD (125). Each patient was 
phenotyped based on the presence of emphysema and/or bronchiectasis and/or CB. The 
rs361525 allele was seen with greater frequency in subjects with CB (odds ratio of having the 
minor A allele in the CB group was 2.08, p = 0.01), independent of the presence of other 
phenotypes. No association was observed for the other polymorphisms. Previous meta-
analyses of genetic association studies have not shown an association between the rs361525 
polymorphism and usual COPD (118, 119). The study by Wood et al however is unique in 
that it identified an association between a TNF-A polymorphism and CB, a particular 
phenotype of COPD, specifically in A1ATD-related COPD. 
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1.7.2 The rs361525 TNF-A polymorphism in A1ATD-related COPD in-vitro studies 
Sapey et al investigated this polymorphism further in a cohort of twelve A1ATD patients with 
COPD in in-vitro studies. Clinically, 83% of patients with the polymorphism (all 
heterozygotes with the AG genotype) were found to have a CB phenotype compared to 31% 
of patients with COPD without the polymorphism (GG) (p<0.0001), concurring with Wood et 
al’s findings at case-control level (17). Affected patients also had a lower body mass index 
(BMI) and a greater decline in FEV1 over three years compared to the GG group, suggesting 
a more aggressive disease phenotype. In laboratory experiments a number of statistically 
significant results were obtained. Spontaneous sputum samples from ten AG patients were 
found to contain 100 times greater concentrations of TNF-α than sputum from ten matched 
GG patients (figure 1.3). There was also a 20 times greater concentration of CXCL8 and 10 
times greater concentration of myeloperoxidase (MPO- a marker of neutrophil activation) 
than GG patients (figure 1.4). CXCL8 plays a key role in COPD as it is an important 
neutrophil chemo-attractant and is induced by TNF-α (79). However, no significant 
differences were observed in plasma concentrations of TNF-α between the two groups, 
indicating the importance of local production in the airways. 
 
 
 
 
 
 
27 
 
 
Figure 1-3 sTNF-α and receptors in sputum of AG and GG subjects 
The graph shows the differences in mean logged concentrations of sTNF-α and soluble 
TNFR1 (sTNFR1) and sTNFR2 in the sputum of COPD patients with (AG) or without (GG) 
the rs361525 polymorphism. Each point equates to one subject's data. The mean is shown as a 
horizontal bar. Significant differences were observed in sTNF-α and sTNFR1 concentrations 
between the two groups. Reproduced from Sapey et al (17). 
 
 
Figure 1-4 CXCL8 and MPO in sputum of AG and GG subjects 
The graph shows the differences in mean logged concentrations of CXCL8 and MPO in the 
sputum of COPD patients with (AG) or without (GG) the rs361525 polymorphism. Each point 
equates to one subject's data. The mean is shown as a horizontal bar. Reproduced from Sapey 
et al (17). 
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These data show that patients carrying the rs316525 polymorphism have a far greater 
concentration of sTNF-α in their airways and slightly less sTNFR1 (but not sTNFR2) and 
hence there is more free sTNF-α to act upon other cell types and induce downstream 
inflammation as evidenced by increased CXCL8 and MPO. These data strongly suggest 
functionality of the SNP in altering TNF-α output by cells in the patients’ airways.  
The strongest evidence for an association of the rs316525 polymorphism with other disease is 
seen in psoriasis and psoriatic arthritis. A recent meta-analysis of a large number of case 
control studies showed an odds ratio of developing either psoriasis or psoriatic arthritis of 
2.23 (95% confidence interval (CI) of 1.63-3.05) when patients carried the minor A allele. 
Again the results may be limited by heterogeneity of study populations and disease 
characteristics (126). 
1.7.3 Assessing if the rs361525 TNF-A polymorphism is functional 
Given the associations of SNPs with clinical disease in case control studies many authors 
have attempted to determine if the presence of a particular SNP, including the rs361525 TNF-
A polymorphism, affects gene transcription and hence protein production, at a cellular level. 
A study conducted by Fong et al identified that the region of the promoter sequence of the 
TNF-A gene lying between bp -254 to -230 acts a repressor of TNF-α transcription. This was 
determined because replacement of this region in monocytic cell lines with DNA constructs 
lacking this section of the gene led to greater than usual output in reporter gene expression 
assays (127). This suggested that if the rs361525 polymorphism genuinely is functional it is 
occurring through loss of wild-type gene repression. In contrast, another more recent study, 
suggested that the presence of the A allele actually acts as a promoter of gene transcription 
(128).  
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Proving functionality of a SNP is clearly therefore difficult and as with other polymorphisms, 
studies examining the rs361525 polymorphism have shown conflicting results, as summarised 
in table 1.2. The methods used in investigating SNP functionality and their limitations are 
discussed below. 
Chromatin immunoprecipitation (ChIP) assays can be used to detect preferential binding of 
RNA polymerase to the non-wild type allele in heterozygotes (129), with the inference 
therefore that the presence of the SNP affects gene transcription.  Reporter gene assays can be 
used to transfect immortalised cell lines with an altered promoter sequence, attached to a gene 
which encodes for a measurable and quantifiable product. Examples include the 
chloramphenicol acetyltransferase (CAT) assay which measures acetylation of radioactively 
labelled chloramphenicol (127) and the luciferase assay which catalyses a reaction involving 
luciferin to emit light (130). Stimulation of transfected cells will lead to a quantifiable output 
from the assay dependent upon the function of the altered promoter sequence. Other authors 
have directly measured the mRNA or protein concentrations of TNF-α in plasma/serum or 
stimulated whole blood, monocytes or peripheral blood mononuclear cells (PBMCs- 
monocytes and lymphocytes) from patients carrying the SNP compared to wild-type subjects 
(131-140). With the exception of ChIP assays, all of these techniques have been used to 
investigate the rs361525 polymorphism (table 1.2). 
There are limitations to all of these methods. Reporter gene assays may affect the complicated 
higher level structure that DNA forms with histone proteins to make nucleosomes. Slight 
changes in structure may therefore affect the binding capability of transcription factors and 
this may be wrongly attributed to an effect or lack of effect of a polymorphism. Measuring 
protein or mRNA content in serum might not reflect what is occurring within a particular 
organ system and indeed this was observed in the study by Sapey et al whereby a marked 
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increase in TNF-α concentration was seen in the rs361525 polymorphism group  in the 
sputum but not in the plasma (17). Definitive conclusions from in-vitro work are also difficult 
to draw because of methodological differences, such as the cell type and stimulus employed, 
concentration of stimulant and time points measured post stimulation and the disease or 
ethnicity of the population studied. Ethnicity is potentially important as although the presence 
of the SNP under investigation can be easily identified it may be that linkage disequilibrium 
may vary between different populations and hence a SNP in one population may be inherited 
as part of an extended haplotype that is different to the extended haplotype in another 
population. If it is the inheritance of several SNPs together that affects functionality of a 
promoter region or inheritance of another gene in linkage disequilibrium with the SNP under 
investigation, then looking at an isolated SNP in one population may yield a different 
conclusion to that obtained from another. It is evident therefore that is important not to 
discount the relevance of a SNP based upon conflicting results from heterogenous studies but 
to concentrate instead on investigating the SNP within a single disease and homogenous 
population, as has been done by Wood et al (125) and Sapey et al (17) and presently in the 
current thesis, in A1ATD-related COPD. 
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Table 1-2 Studies investigating the cellular effects of the rs361525 TNF-A polymorphism 
 
Study population 
 
 
Healthy controls. N=50 10% AG; 90% GG 
Ethnicity Unspecified (North European study) 
Methods Monocytes- 4 hours stimulation 
mRNA quantified  by RT-qPCR and protein by ELISA. 
 
Stimulant Basal; LPS 
Outcome (AG vs GG) No difference 
Author/reference Mekinian et al (131) 
 
Study population 
 
 
Immortal cell lines 
Ethnicity N/A 
Methods a) U937 and MonoMac6 cells (monocytic cells) - transfected with 
DNA construct and luciferase reporter gene. Stimulated for 4 
hours. 
b) Jurkat (T-cell line) and Raji (B-cell line) cells - transfected 
with CAT reporter gene. 24 hours stimulation. 
 
Stimulant a) Basal ; LPS+/- PMA            b) Basal; PMA+/- anti-CD3 mAb 
Outcome (AG vs GG) a) No difference                       b) No difference 
Author/reference Kaijzel et al (130) 
 
 
Study population 
 
 
Immortal (mouse) cell lines 
Ethnicity N/A 
Methods T-cell clone Ar-5 and B-cell lymphoma line A20. 
- transfected with DNA construct and CAT reporter gene.18 
hours stimulation. 
 
Stimulant Basal;  PMA and ionomycin 
Outcome (AG vs GG) No difference 
Author/reference Uglialoro et al (141) 
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Study population 
 
 
Healthy controls and subjects with positive T. cruzi serology 
N=214; 22% AA; 16% AG; 62% GG 
 
Ethnicity Unspecified (South American study) 
Methods PBMCs. 48 hours stimulation. Protein measured by ELISA. 
Stimulant LPS; PHA; T. cruzi antigen 
Outcome (AG vs GG) In all patients- LPS induced slightly more TNF-α in combined 
AA/AG group vs GG group. In T.cruzi positive subjects- LPS 
and T.cruzi antigen induced more TNF-α in combined AA/AG 
group vs GG group. 
 
Author/reference Pissetti et al (132) 
 
Study population 
 
 
Psoriasis N=48 30% AG; 70% GG 
Immortal cell lines 
 
Ethnicity Unspecified (North European study) 
Methods PBMCs (from patients) - 24 hours stimulation. Protein measured 
by ELISA. 
Jurkat and Raji cells- transfected with DNA construct and 
luciferase reporter gene. Stimulated for 8 and 15 hours 
respectively. 
DNA constructs contained haplotypes of SNPs-  -308G/-238A;  
-308A/-238G; -308G/-238G. 
 
Stimulant Basal ; LPS; PMA; antiCD3 mAb; strep antigen; PHA (PBMCs) 
Basal; Ionomycin and PMA (cell lines) 
 
Outcome (AG vs GG) PBMCs- AG subjects secreted less TNF-α than GG subjects if 
stimulated with antiCD3 mAb or streptococcal antigen. No 
difference with other stimuli. 
Jurkat cells- reduced activity in stimulated AG cells. Raji cells- 
reduced activity in basal and stimulated AG cells. 
 
Author/reference Kaluza et al (140) 
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Study population 
 
 
Relatives of subjects with severe sepsis N=183  
11% AG; 89% GG 
 
Ethnicity Unspecified (North European study) 
Methods Whole blood- stimulated ex-vivo for 6 hours. 
Protein measured by ELISA. 
 
Stimulant LPS 
Outcome (AG vs GG) No difference 
Author/reference Westendorp et al (133) 
 
Study population 
 
 
Healthy controls N=78  
Ethnicity Unspecified (North European study) 
Methods Monocytes- 18 hours stimulation. Protein measured by ELISA. 
Stimulant LPS 
Outcome (AG vs GG) No difference 
Author/reference Pociot et al (136) 
 
Study population 
 
 
Healthy controls (some families)  N=752 
1% AA; 12% AG; 87% GG 
 
Ethnicity Caucasian 
Methods Plasma. Protein measured by ELISA. 
Stimulant N/A 
Outcome (AG vs GG) No difference 
Author/reference Haddy et al (134) 
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Study population 
 
 
Rheumatoid arthritis N=50 
Healthy controls N=50 
 
Ethnicity Unspecified (South European study) 
Methods PBMCs- mRNA quantified by RT-qPCR. 
Plasma -protein measured by ELISA. 
 
Stimulant N/A 
Outcome (AG vs GG) No difference in healthy controls. 
GG subjects produced 2X as much TNF-α mRNA and1.3X as 
much protein in the plasma 
 
Author/reference Oregon-Romero et al (135) 
 
Study population 
 
 
Ankylosing spondylitis N=67  7% AG; 93% GG 
 
Ethnicity Chinese 
Methods PBMCs- mRNA quantified by RT-qPCR. Stimulated for 2 hours. 
Stimulant LPS 
Outcome (AG vs GG) No difference 
Author/reference Lu et al (137) 
 
Study population 
 
 
Healthy controls (including some families) 
N=179 12% AG; 88% GG 
 
Ethnicity Unspecified (North European study) 
Methods Whole blood- stimulated ex-vivo for 6 hours. Protein measured 
by ELISA.  
 
Stimulant LPS 
Outcome (AG vs GG) GG subjects produced 1.5X as much TNF-α if stimulated with 10 
ng/ml of LPS (familial contribution controlled for). No difference 
observed with 1000 ng/ml LPS. 
 
Author/reference Huizinga et al (142) 
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Study population 
 
 
Severe sepsis N=62 
13% carried A allele (genotype unspecified); 87%  GG 
 
Ethnicity Caucasian 
Methods PBMCs at 24 hours post admission- mRNA quantified by RT-
qPCR. 
Plasma -protein measured by ELISA. 
Stimulant N/A 
Outcome (AG vs GG) No difference 
Author/reference O’Dwyer et al (138) 
 
Study population 
 
 
Sarcoidosis N=83; 4% carried A allele (genotype unspecified); 
96% GG 
Healthy controls N=155; 5% carried A allele; 95% GG 
 
Ethnicity North Indian 
Methods Serum. Protein measured by ELISA. 
Stimulant N/A 
Outcome (AG vs GG) In the sarcoidosis subjects 23X greater TNF-α protein in the 
serum of AG group. No difference in the healthy control group. 
 
Author/reference Sharma et al (139) 
 
Study population 
 
Ethnicity 
 
Methods 
 
 
 
Stimulant 
 
Outcome (AG vs GG) 
 
 
Author/reference 
 
Immortalised cell line (mouse) 
 
N/A 
 
DNA constructs with either A or G allele and a luciferase reporter 
assay transfected into RAW 264.7 cells (murine macrophage-like 
cells) 
 
LPS; lipoteichoic acid 
 
2.2 to 2.8 greater transcriptional activation in A-allele transfected 
cells. 
 
Kiss-Toth et al (128) 
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Study population 
 
 
COPD/A1ATD N=20  50% AG; 50% GG (purposely matched) 
 
Ethnicity Caucasian 
Methods Sputum and plasma 
Stimulant N/A 
Outcome (AG vs GG) 100X greater TNF-α protein in the sputum of AG group than in 
GG group. No difference in plasma. 
 
Author/reference Sapey et al (17) 
 
The table summarises the results of all studies investigating if the rs361525 TNF-A 
polymorphism affects TNF-α secretion by cells. For studies involving reporter gene assays- 
reporter genes were attached to DNA constructs encoding a portion of the TNF-A promoter 
region containing the -237 A allele or WT -237 G allele. A general critique of the methods 
used in these studies is provided in the text above. 
CAT- chloramphenicol acetyltransferase; COPD- chronic obstructive pulmonary disease; 
DNA- deoxyribonucleic acid; ELISA: enzyme linked immunosorbent assay; LPS: 
lipopolysaccharide; ml: millilitre; mRNA: messenger RNA; ng: nanogram; PHA: 
phytohaemagglutinin; PMA: phorbol 12-myristate 13-acetate; RT-qPCR: real-time 
quantitative polymerase chain reaction; strep: streptococcus; T. cruzi: Trypanosoma cruzi 
 
1.8 Control of TNF-α production 
It is important to recognise that whilst binding of transcription factors or release of gene 
silencers at the promoter is vital, multiple other steps are also involved in the control of 
production of TNF-α, from transcription through to the post-transcriptional stages and 
processing of the protein itself.  These are complex affairs, varying between cell types, in 
response to different stimuli and showing a high degree of redundancy (143-145).  
Broadly, control mechanisms can be considered to act at specific stages: 1) through changes 
to chromatin structure allowing or preventing transcription factors access to the promoter 
region of a gene (epigenetic regulation), 2) binding of transcription factors to the promoter or 
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release of repressive factors allowing gene transcription, 3) alterations to the gene itself which 
may enhance or repress subsequent transcription (epigenetic regulation), 4) splicing of pre-
mRNA transcripts into the final mRNA sequence 5) post-transcriptional stabilisation of the 
mRNA transcript prior to translation (epigenetic regulation), 6) cleavage of pro-TNF-α from 
the cell surface and 7) functional blockade of sTNF-α by soluble TNFR1 and TNFR2. Some 
examples of these mechanisms are considered below but are by no means exhaustive. 
1.8.1 Control of TNF-A transcription 
At the histone level acetylation by acetyltransferases can facilitate the binding of transcription 
factors to the promoter region by relaxing chromatin fibres and allowing access to DNA and 
conversely histone deacetyltransferases will repress this process (145-148). For example, an 
increase in acetylation of histone H4 at the TNF-A locus was associated with TNF-A 
transcription in human monocytes (149). In addition, these enzymes can regulate gene 
transcription in other ways, for example, histone deacetyltransferase 3 can decrease the 
phosphorylation of the enzyme MAPK11 leading to inhibition of activity of the transcription 
factor activating transcription factor 2 (ATF-2) with a resultant decrease in TNF-A 
transcription (150). Broadly when considering all cell types, histone methylation and 
phosphorylation are also believed to both promote and repress TNF-A transcription through 
changes to chromatin structure affecting the binding capabilities of transcription factors and 
may play a role in control of TNF-A transcription (146, 151). At the DNA level direct 
methylation of the TNF-A gene in monocyte cell lines represses gene transcription (146). 
Following changes to chromatin structure, for genes to undergo transcription it is necessary 
for protein transcription factors to bind to specific areas of the gene DNA, usually in the 
promoter region and/or for gene silencers to detach themselves (10). TNF-α is secreted in 
response to a broad range of stimuli, including bacteria and bacterial products, other 
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cytokines, mitogens and viruses (144). It is unsurprising therefore that a large number of 
different transcription factors have been identified as being possible TNF-A gene activators 
and these may be cell and stimulus specific (144).  
The region of the promoter lying between -1 to -200 bp has been most well investigated with 
respect to identifying binding sites and their complementary transcription factors. This area 
contains a TATA box, several cis-acting regulatory elements (CREs), six nuclear factor of 
activated T-cells (NFAT) binding sites, two specificity protein 1 (Sp1) binding sites, four E26 
transformation-specific transcription factor (Ets) and ETS domain-containing protein (Elk) 
binding sites and an Early growth response protein (Egr) binding site (144). Members of the 
NFAT transcription factor family and the transcription factors ATF-2 and c-jun (the latter two 
acting in heterodimer form) bind separately to NFAT and CRE binding sites respectively but 
act in unison as an enhancesome. Of note the NFAT transcription factors are not believed to 
be involved in TNF-A transcription specifically in monocytes and macrophages (144).  
In monocytes LPS induces TNF-A transcription by up-regulating the Extracellular-signal-
regulated kinase (ERK) substrates ETS and Elk-1 which bind in conjunction with a number of 
other transcription factors, ATF-2, c-jun, Egr-1, and Sp1, and two co-activator proteins, cyclic 
AMP response element-binding protein (CREB) and p300, to the proximal promoter region of 
the gene and act as an enhancesome. Of interest the binding site for this complex is the same 
sequence of the TNF-A promoter region that usually binds NFAT transcription factors in T-
cells upon T-cell receptor ligation by antigen presenting cells, demonstrating the cell and 
stimulus specific nature of TNF-A transcription (144).  
Transcription factor binding sites (and their respective transcription factors) in the promoter 
region upstream of position -200, defined as the distal promoter and including the -237 
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position of the rs361525 SNP under study, are less well characterised. However, ChIP assays 
have implicated other transcription factors including NFκB members, particularly p65, in 
TNF-A transcription in LPS-stimulated monocytic cells (144) and that binding sites for these 
in the promoter region lie within the distal promoter (152, 153), making LPS an attractive 
stimulant to use in the studies in this thesis. The transcription factors involved in TNF-A 
transcription in monocytes in response to LPS are summarised in figure 1.5. 
 
 
 
Figure 1-5 Transcription factors involved in the transcription of TNF-A in monocytes in 
response to LPS 
The diagram illustrates the promoter region of the TNF-A gene. The proximal part of the 
promoter lies between 0 bp and -200 bp. Transcription factors bind to their respective binding 
sites (shown as coloured boxes) within the promoter, for example Ets-1 binds to Ets-1 binding 
site. ATF-2 and c-jun bind to a CRE. CREB and p300 are co-activator proteins that also bind 
within the proximal promoter, downstream of -200 bp, and altogether act as an enhanceosome 
to facilitate TNF-A transcription. The distal promoter lies upstream of -200 bp; the sequence 
containing the -237 position is shown. The only transcription factor identified via ChIP assays 
to bind in this region between -345 bp and -195 bp following LPS stimulation is the NFκB 
family member p65. The exact location of the binding site for p65 is unknown. Adapted from 
Falvo et al (144) and Suriano et al (152). 
ATF-2: activating transcription factor 2; CRE: cis-acting regulatory element; CREB: cyclic 
AMP response element-binding protein; Egr-1: Early growth response protein 1; Ets: E26 
transformation-specific transcription factor; Elk: ETS domain-containing protein; Sp1: 
specificity protein 1. 
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1.8.2 TNF-A transcript regulation 
Once TNF-A has been transcribed the pre-mRNA is spliced to remove introns. Splicing of 
TNF-α mRNA transcripts is regulated in part by binding of protein kinase R (154). The 
mRNA transcript is then subject to post transcriptional regulation within the cytoplasm, 
without which the transcript rapidly degrades (155) . Modulation occurs at two locations: 
adenosyl-uridyl-rich elements (AREs) and microRNA binding sites, both located in the 3’ 
UTR of the transcript. Up-regulation of p38 MAP kinase (MAPK) by the original stimulus, 
for example LPS, leads to the phosphorylation of two proteins, MAP kinase-interacting 
serine/threonine-protein kinase 1 (Mnk1) and MAPK-activated protein kinase-2 (MK-2), 
which subsequently bind to the ARE in the 3’ UTR of the TNF-α mRNA. These proteins act 
either via deactivating constitutive repressor proteins or by functioning as enhancers (156). 
The end result is increased transcript stability and translation. MicroRNAs are short lengths of 
RNA which have no coding function but can bind approximately complementary nucleotide 
strands on mRNA transcripts and so affect stability of the mRNA (156). 
 
1.8.3 Control of the TNF-α protein 
Although active at the cell surface TNF-α is also cleaved and released into the circulation or 
peri-cellular environment. In AMs, cleavage of mTNF-α from the cell surface is controlled for 
the most part by the enzyme TACE, expressed on the cell surface and TNF-α has been 
demonstrated to regulate further TACE expression in a negative feedback loop. In addition, 
proteinase 3 secreted by neighbouring neutrophils was able to cleave mTNF-α from the 
surface of AMs by binding to the cell membrane (157). Lastly, soluble TNFR1 and TNFR2 
also act as circulating inhibitors of sTNF-α (4) and the receptors are discussed further in 1.9. 
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1.9 TNF-α receptors 
1.9.1 Overview 
The two TNF-α receptors, TNFR1, a 55kDa protein and TNFR2, a 75kDa protein, are coded 
for on chromosomes 12 and 1 respectively (158). The receptors are composed of 
glycoproteins which span the cell membrane and have similar extracellular structure but 
different intracellular domains (159). Each receptor has four extracellular cysteine-rich 
domains (CRD) and TNF-α binds to CRD 2 and 3 (160). For binding to occur to either 
TNFR1 or TNFR2, both receptors must first form a trimer with two other receptors, creating a 
complex to which a TNF-α trimer can then bind. The domain on each receptor responsible for 
this is separate to the site for TNF-α ligation and is termed the pre-ligand-binding assembly 
domain (161). Lymphotoxin-alpha, secreted by lymphocytes, is the only other member of the 
TNF superfamily also able to bind both TNFR1 and TNFR2, but is thought to elicit its 
functions through alternative receptors (11, 162).  
TNFR1 is expressed on most cell types in humans. In contrast TNFR2 is found only on the 
surface of immune cells and vascular endothelial cells (4). Each of the receptors can be 
cleaved from the cell surface to circulate freely and act as endogenous inhibitors of TNF-α 
(163). Both receptors have high affinity for soluble TNF-α with TNFR1 having greater 
affinity at physiological temperatures. Dissociation of TNF-α from TNFR1 is far slower than 
from TNFR2, with a half life time of 33.2 minutes versus 1.1 minutes respectively, when 
internalisation of the receptor-ligand complex is controlled for (163, 164). For these reasons 
soluble TNFR1 is likely to be the more effective inhibitor. The membrane form of TNF-α is 
also metabolically active, stimulating both TNF-α receptors (165, 166), in a paracrine and 
autocrine manner (166). However whilst sTNF-α and mTNF-α can bind to either receptor, 
only mTNF-α can activate TNFR2 (165, 167). 
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1.9.2 Role of TNFR1 and TNFR2 in physiological and pathological processes 
Many studies have been conducted to investigate the relative roles of TNFR1 and TNFR2, 
mainly using animal models. Initial work suggested that TNFR2 did not directly trigger an 
intracellular signalling cascade but instead acted as a “ligand passer”, concentrating sTNF-α 
at the cell surface as a result of its high affinity for binding followed by rapid dissociation, 
thereby making more of the cytokine available to bind to TNFR1 (163, 168). Subsequent 
investigation indicated this was unlikely to be correct for several reasons. Firstly, dissociation 
constants which suggested the presence of TNFR2 was needed to facilitate binding of sTNF-α 
to TNFR1 were calculated from experiments conducted at 0oC (168). When repeated at 
physiological temperatures it became evident that in fact TNFR1 was actually the higher 
affinity receptor, thereby obviating the need for ligand passing (164). Secondly, many cell 
types express only TNFR1 and yet can still signal effectively (4).  
The discovery that TNFR2 could only be activated by mTNF-α (165, 169) led to elegant 
studies showing that TNFR2 activation by agonist mAbs simulating the action of  mTNF-α 
could in fact activate NFκB, leading to pro-inflammatory IL-6 secretion by an immortalised 
human cell line. However IL-6 was secreted to a far lesser extent than that induced by sTNF-
α-TNFR1 signalling (169). Fascinatingly, whilst TNFR2 signalling only led to a modest 
NFκB effect, dual receptor ligation increased the apoptotic capability of TNF-α by 1000 fold 
compared to TNFR1 signalling alone and this was dependent on the presence of the adaptor 
molecule TNF receptor-associated factor 2 (TRAF2) binding to the intracellular portion of 
TNFR2 (169). Later work identified this to be due to TNFR2 mediated depletion of TRAF2 
from the TNFR1 signalling complex rather than as a result of induction of downstream 
TNFR2 signalling pathways (see 1.9.3) but indicates the synergistic effect of both receptors in 
TNF-α induced apoptosis.   
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Table 1.3 outlines the results of studies that have attempted to define the roles of the two 
receptors further. In summary, data specifically from studying human cells are severely 
limited with most work having been conducted in animal models. The available evidence 
illustrates the complexity of differential TNFR1/2 roles, precluding a straightforward 
delineation into pro- versus anti-inflammatory signalling, at least in animal models. Both 
receptors clearly play a role in immune function, with TNFR2 perhaps being especially 
important in virus elimination and regulation of the immune response. Certainly its 
preferential expression on human CD4+FoxP3+ T-reg cells (a subgroup of T-reg cells which 
have a vital role in preventing excessive immune responses) over effector T-cells is important 
in controlling the function of the latter group of cells (170). Of note, in some animal disease 
models TNFR2 mediates an anti-inflammatory role (multiple sclerosis, rheumatoid arthritis) 
whereas in others its role is less certain or it contributes in part to pro-inflammatory effects 
(IBD, inflammatory lung diseases). Whilst animal studies are undoubtedly useful their 
findings may not bear close resemblance (in all cases) to human disease and global deletion or 
over-expression of the receptors in mice does not help identify particular cells which may be 
responsible for noted effects. Studies of TNFR2 especially in human cells are lacking to date. 
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Table 1-3 Evidence for the differential roles of TNFR1 and TNFR2 in health and disease 
Immune system Details 
 
Model Ref 
TNFR1 Normal development of Peyer’s 
patches, follicular dendritic cell 
clusters and germinal centres 
Genetically modified 
mice (KO model) 
(171) 
Mediates response to intracellular 
bacteria and effective granuloma 
formation 
Genetically modified 
mice (KO models) +/-
antagonist mAbs 
(11, 
12, 
18) 
Mediates septic shock Genetically modified 
mice (KO model); 
antagonist mAbs 
(11, 
12, 
172) 
TNFR2 T-cell proliferation; Memory T-
cell clonal expansion; expansion 
and increased suppressive activity 
of foxP3+T-regs 
Human thymic cells and 
agonist mAbs; genetically 
modified mice (KO 
models); human T-cells 
(12, 
173-
175) 
Apoptosis of mature CD8 T-cells 
(not CD4 cells) 
Genetically modified 
mice (KO model); 
antagonist mAbs 
(176) 
Induction of adaptive immune 
responses (cross-talk between 
dendritic cells and NKCs) 
Genetically modified 
mice (KO model) 
(177) 
Mediates CD8 T-cell responses to 
hepatic viruses; viral clearance 
Genetically modified 
mice (KO/over expression 
models); antagonist 
selective TNFR1 mAb 
(178, 
179) 
Protection against septic shock 
(?soluble TNFR2) 
Genetically modified 
mice (KO model); 
antagonist mAbs 
(11, 
12, 
172) 
Lungs Details Model Ref 
TNFR1 Mediates neutrophil migration into 
lung 
Genetically modified 
mice (KO model-response 
to Mycobacterium faeni) 
(11) 
Contributes to development of 
inflammatory cell influx in 
response to cigarette smoke 
Genetically modified 
mice (KO model) 
(180) 
TNFR2 Protects against neutrophil 
migration into lung 
Genetically modified 
mice (KO model in 
response to 
Mycobacterium. faeni) 
(11) 
Involved in neutrophil, 
lymphocyte, macrophage 
accumulation in BAL fluid; 
activates T-cells; drives weight 
loss and  emphysema 
Genetically modified 
mice (KO model) 
(180) 
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Rheumatological 
system 
Details Model Ref 
TNFR1 Drives chronic inflammatory 
arthritis 
Genetically modified 
mice (KO and over 
expression model); use of 
antagonist selective 
TNFR1 mAb 
(179, 
181) 
Increases osteoclast number Genetically modified 
mice (KO model) 
(182) 
TNFR2 Suppression of development of 
chronic inflammatory arthritis 
Genetically modified 
mice (KO and over 
expression model); use of 
antagonist selective 
TNFR1 mAb 
(179, 
181) 
Decreases osteoclast number Genetically modified 
mice (KO model) 
(182) 
Intestine/Liver Details Model Ref 
TNFR1 Drives IBD Genetically modified 
mice (KO models) 
(181, 
183) 
Involved in hepatitis and inducing 
fibrosis 
Genetically modified 
mice (KO model) +/-
antagonist selective 
TNFR1 mAb 
(184, 
185) 
Mediates liver regeneration Genetically modified 
mice (KO model) 
(186) 
TNFR2 Drives IBD (in TNF-α over-
expression model). Doesn’t drive 
IBD in CD4+ transfer model of 
colitis. TNFR2 required for down-
regulation of disease enhancing 
CD4+ cells 
Genetically modified 
mice (KO models) 
(181, 
183) 
Neurological 
system 
Details Model Ref 
TNFR1 Initiates multiple sclerosis-like 
pathology;  
drives TH-1/TH-17 infiltration 
Genetically modified 
mice (KO models); 
antagonistic selective 
TNFR1 mAb 
(187-
189) 
TNFR2 Protects against/resolves MS-like 
pathology. Allows oligodendrocyte 
regeneration 
Genetically modified 
mice (KO models); 
antagonistic selective 
TNFR1 mAb 
(187-
189) 
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Cardiovascular 
system 
Details Model Ref 
TNFR1 Mediates contractile dysfunction 
after MI. Exacerbates post-MI 
remodelling, hypertrophy and 
inflammation leading to cardiac 
failure. Mediates oxidative stress 
and diastolic dysfunction (additive 
effect with TNFR2) 
Genetically modified 
mice 
(KO and over 
expression models) 
(190, 
191) 
TNFR2 Protects against post-MI 
myocardial remodelling, 
ventricular dilatation and 
inflammation. Mediates oxidative 
stress and diastolic dysfunction 
(additive effect with TNFR1) 
Genetically modified 
mice 
(KO and over 
expression models) 
(190, 
191) 
Mediates E-selectin, VCAM-1 and 
ICAM-1 expression on vascular 
endothelium, facilitating leukocyte 
transmigration 
Genetically modified 
mice (KO model) 
(192) 
 
The table summarises the available evidence, mainly from animal models, by body system.  
BAL- bronchoalveolar lavage; IBD: inflammatory bowel disease; ICAM: intercellular 
adhesion molecule 1; KO: knock out: mAb: monoclonal antibody; myocardial infarction; 
mRNA- messenger RNA; MS- multiple sclerosis; NKC: natural killer cell; VCAM: vascular 
adhesion molecule  
 
1.9.3 Intracellular signalling pathways for TNFR1 and TNFR2 
A body of evidence accumulated from various cell lines, including monocytes in some 
studies, suggests that signalling via TNFR1 leads to increased gene transcription in three ways 
(9, 10, 193, 194), as illustrated in figure 1.6. The figure shows how transcription factors, 
activated downstream in the signalling cascade, translocate to the nucleus and bind to the gene 
of interest (point 8). With respect to CXCL8 gene transcription specifically, the evidence 
suggests that it is necessary for the two transcription factors, NFκB (p50/p65) and AP-1 to 
bind to the gene near to a molecule known as NFκB repressing factor (NRF), which in 
unstimulated cells suppresses CXCL8 transcription. Binding of these three molecules to the 
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gene forms an enhanceosome, believed necessary for promotion of gene transcription (10, 
193). 
There is a relative paucity of data regarding TNFR2 signalling, in particular in monocytes. 
Available data obtained from various human and murine cell lines suggests that mTNF-α 
signals through TNFR2 via two main pathways (4, 9, 167) as shown in figure 1.7.  
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Figure 1-6 TNFR1 downstream signalling cascade activated by sTNF-α and mTNF-α 
1) mTNF-α or sTNF-α binds to TNFR1. 2) TNF-α -receptor binding leads to release of SODD 
from the intracellular portion of TNFR1 enabling binding of an adaptor protein complex 
consisting of TRADD, RIP-1, TRAF2 and cIAP. 3) The adaptor protein complex activates 
several MAP3Ks. 4) Activated MEKK-3, TAK-1 and NIK phosphorylate IκBα leading to the 
release of NF-κB subunits p50 and p60 which are then free to translocate to the nucleus. 5) 
ASK-1 activates MAPKKs which 6) activate three MAPKs: ERK, JNK, P38 MAPK. 7) ERK 
and JNK activate AP-1 which translocates to the nucleus. 8) p50/p60, AP-1 and NRF form an 
enhancesome which leads to gene transcription. 9) p38 MAPK is able to act upon the 
subsequent mRNA transcript leading to transcript stabilisation.  
AP-1: activating protein 1; ASK-1: apoptosis signal-regulating kinase 1; cIAP: cellular 
inhibitor of apoptosis; ERK: extracellular-signal-regulated kinase; IκBα: NFκB inhibitory 
protein; JNK: c-Jun N-terminal kinase; MAPK(K): MAP kinase (kinase); MAP3Ks: MAP 
kinase kinase kinases; MEKK-3: mitogen activated protein kinase kinase kinase; NIK: NF-
kappa-B-inducing kinase;  NRF: NFκB repressing factor; RIP-1: receptor activating protein 1;  
SODD: silencer of death domain; TAK-1: transforming growth factor-beta-activated kinase; 
TRADD: tumour necrosis factor receptor type 1-associated death domain; TRAF2: TNF 
receptor-associated factor 2. 
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Figure 1-7 Intracellular signalling pathway activated upon TNFR2 ligation by mTNF-α 
1) mTNF-α binds to TNFR2 on the surface of a TNFR2-bearing cell. 2) Upon TNF-α binding 
an adapter protein complex consisting of TRAF2, TRAF1 and cIAP1/2 forms, which binds 
the intracellular portion of the receptor. 3) The adaptor complex activates PI3K. 4) This 
initiates a downstream signalling cascade which leads to the release and translocation of 
NFκB p50/p65 subunits to the nucleus where it binds to DNA at its specific binding site 
(canonical pathway). 5) The TRAF2, TRAF1 and cIAP1/2 complex is also able to dissociate 
from the receptor and 6) activate NIK, 7) resulting in the conversion of p100/RELB NFκB 
dimer to p52/RELB which translocates to the nucleus to also act as a transcription factor (non-
canonical pathway).  
cIAP: cellular inhibitor of apoptosis; DNA: deoxyribonucleic acid; PI3K: 
phosphatidylinositide 3-kinase; TRAF: TNF receptor-associated factor  
50 
 
Apoptosis of cells as a result of TNF-α signalling occurs by the following mechanism. 
Release of SODD from the intracellular component of TNFR1 frees its death domain motif 
and allows the TRADD/RIP-1/TRAF2/cIAP complex to assemble with the receptor. This sets 
in motion the signalling pathways outlined previously which rapidly lead to NFκB release. 
Within an hour the TRADD/RIP-1/TRAF2/cIAP complex is released from TNFR1 into the 
cytoplasm whereby the death domain in TRADD can recruit FAS-associated death domain 
(FADD) which has the potential to go on to activate caspase-8, which in turn initiates 
apoptosis (20).  However, much of the time apoptosis does not occur as the events in the 
apoptotic pathway occur more slowly over a period of several hours (in contrast with 
signalling induced by other apoptosis-inducing members of the TNF family such as Fas-
ligand) allowing TNF-α induced NF-κB to up-regulate the anti-apoptotic protein FLICE-like 
inhibitory protein (FLIP) which switches off apoptosis (19). cIAP molecules are also anti-
apoptotic (195). TNFR2 does not contain a death domain but may be able to influence 
apoptosis by depleting TNFR1 of TRAF2 and cIAP molecules which are needed to induce the 
pro-inflammatory signals which switch off apoptosis. However, the physiological 
circumstances and cell types in which that might occur are unclear (195). 
It is unlikely that these proposed models of downstream TNFR1 and TNFR2 signalling apply 
to all cell types and stimuli employed, but they highlight potentially important broad 
differences in signalling pathways between the two receptors. 
Another interesting area of research, at its early stages, is that of reverse signalling. Over-
expression studies have suggested that soluble TNF-α receptors may be able to bind mTNF-α 
and activate reverse “outside-in” signalling, rather than just acting as inhibitors of mTNF-α. 
Whilst this may modulate cellular function (7) it is unlikely that the spectrum of downstream 
effects as a result of reverse signalling is as broad as those arising as result of classical 
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pathways, as otherwise binding of the receptor fusion protein, etanercept, would lead to a 
range of pro-inflammatory effects. 
1.10 Monocytes 
Monocytes are mononuclear phagocytic cells which comprise approximately 10% of the 
leukocytes circulating in human blood. They originate from precursor monoblast cells which 
themselves differentiate from a common granulocyte-macrophage progenitor, both of which 
reside in the bone marrow (196). The bone marrow is stimulated to produce monocytes by 
cytokine stimuli such as macrophage colony stimulating factor (M-CSF), granulocyte 
macrophage colony stimulating factor (GM-CSF) and IL-3 (multi-colony stimulating factor) 
(197). Monocytes are the principal secretors of TNF-α (3). 
Monocytes are active cells, capable of phagocytosis and the release of cytokines and tissue 
damaging mediators such as ROS (198-200). At a microscopic level monocytes vary 
significantly in their diameter, granularity and nuclear appearance and much work has been 
conducted to characterise both murine and human monocyte subsets. Mouse monocytes are 
predominantly classified on the presence or absence of the murine-specific Ly6C (lymphocyte 
antigen 6C) cell surface marker. Models have suggested that the Ly6C -ve CXC3R1 ++ve 
monocytes form a minor population known as “patrolling” monocytes which due to a lack of 
the monocyte chemotactic protein 1 (MCP-1) chemokine receptor CCR2 do not generally 
leave the blood stream to travel to sites undergoing an infectious insult, but instead may be 
important in monitoring the vascular endothelium and can infiltrate tissues in the presence of 
endothelial damage (201). The Ly6C ++ve CCR2++ve monocytes are termed “inflammatory” 
as they are able to respond to a MCP-1 chemotactic gradient (202) and hence leave the 
circulation to traffic to sites of infection, where they release pro-inflammatory mediators and 
phagocytose bacteria (203).  
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1.10.1 Monocyte subsets 
Human monocyte subsets can divided into three subsets: classical, intermediate and non-
classical, based upon cell surface expression of two key markers, CD14 and CD16 (204). 
Classical monocytes comprise 90% of circulating monocytes and express CD14 but not 
CD16. These cells, like Ly6C ++ve murine monocytes, express CCR2 and so can respond to 
an MCP-1 chemoattractant gradient and leave the circulation. Their main roles are thought to 
be in responding to infectious insults as they are highly phagocytic and also in tissue repair 
(204). Although they can secrete pro-inflammatory cytokines such as TNF-α they are notably 
the main monocyte producers of the anti-inflammatory cytokine IL-10 (204). Intermediate 
monocytes express CD14 at a similar level to classical monocytes but also express CD16 at 
low levels. The final subset are termed non-classical and express little CD14 but high levels 
of CD16. Like Ly6C -ve murine monocytes they express CXC3R1, which can bind CXC3 
anchored to vascular endothelial cells (205) and allow endothelial patrolling (206). They do 
not express CCR2. Evidence suggests that it is the non-classical subset which produces the 
most TNF-α in response to LPS, although all subsets do (204, 207). It is postulated that the 
three subtypes represent a progression of maturity from classical to intermediate to the non-
classical phenotype (204). Table 1.4 summarises these subsets.  
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Name % in 
circulation 
(size) 
Distinguishing 
cell surface 
markers 
Other key 
cell 
surface 
markers 
Cytokine/chemokine 
profile (after LPS 
stimulation) 
Mouse 
equivalent 
      
Classical 90%  
(large) 
CD14++CD16-
(CD64+) 
CCR2+; 
CXC3R1+ 
CD32++ 
CCR5++ 
MHC Class 
II+ 
IL-6; IL-10;  
G-CSF; CCL2; 
RANTES;  
TNF-α; IL-1β;  
CXCL8;  
 
Ly6C++ 
CCR2++ 
CXC3R1- 
      
Non-classical  
 
10% 
(small) 
CD14+CD16++ CXC3R1++ 
CCR5+ 
MHC Class 
II++ 
IL-1β;  
TNF-α; IL-10; 
RANTES; 
CXCL8;  
IL-6;  
 
LyC6- 
CXC3R1++ 
CCR2- 
     
Intermediate CD14++CD16+ 
CD64+ 
MHC 
Class II++ 
CCR5++ 
IL-1β; TNF-α;       
IL-10;  RANTES; 
CXCL8; IL-6 
 
References 
(203, 204) 
     
 
Table 1-4 Human monocyte subsets 
The table shows the expression patterns of the most important cell surface markers delineating 
the three subtypes of human monocytes and their murine equivalents. Cytokine/chemokine 
profiles are based on work by Wong et al (204), whereby mediator concentrations were 
measured by enzyme linked immunosorbent assay (ELISA) 18 hours post stimulation with 
increasing concentration of LPS. Mediators shown in bold reflect the subset of monocyte 
which secreted most of that particular cytokine.  
CD14 forms part of the LPS receptor; CD16 is also known as FcγRIII, (Fcγ are receptors for 
the Ig superfamily allowing induction of phagocytosis of opsonised bacteria); CD64 is also 
known as FcγRI; CCR2: C-C chemokine receptor type 2, binds MCP-1; CXC3R1: CXC3 
chemokine receptor 1, binds CXC3; CD32 is also known as FcγRII; Ly6C: lymphocyte 
antigen 6C. RANTES: regulated on activation, normal T cell expressed and secreted; binds to 
CCR5. 
+ indicates moderate expression; ++ indicates high expression; - indicates low or no 
expression.  
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1.10.2 Macrophages 
Macrophages are considered in brief here, as they are a possible culprit cell for the findings in 
airway secretions of Sapey et al’s study in rs361535 TNF-A polymorphism subjects (17) and 
in some circumstances may originate from blood monocytes (208).  
Macrophages are found within tissues/organs throughout the body and as such play a role in 
many infection related and inflammatory diseases (208). They are essential for surveying their 
surroundings and reacting appropriately to maintain immune tolerance, clear undesirable 
material or initiate innate and adaptive immune responses and can survive several months 
(52). Alveolar macrophages (AMs) and interstitial macrophages (IMs) are specific to the lung, 
the former within the airways and the latter the lung interstitium (209). In general two subsets 
of macrophages have been identified, termed M1 and M2 macrophages, perhaps with a third 
type known as regulatory macrophages which predominantly produce IL-10. It is thought that 
M1 macrophages are pro-inflammatory, producing mediators such as TNF-α and IL-12 
(which drive naïve TH-cells in a TH-1 direction and activate NKCs), IL-23 (which drives 
naïve TH-cells to become pro-inflammatory TH-17 cells) and nitric oxide, in-vitro. In 
contrast, in-vitro studies suggest M2 macrophages are anti-inflammatory and pro-repair (and 
possibly as a result, tumour promoting and pro-fibrotic), producing IL-10, transforming 
growth factor beta (TGF-β), platelet-derived growth factor, tissue inhibitors of 
metalloproteinases, and chemokines to attract T-regs. M2 macrophages also release chemo-
attractants which attract TH-2 cells to drive anti-parasitic and allergic type eosinophilic 
inflammation (202). It is unlikely however that macrophage differentiation is so proscriptive 
in-vivo and indeed they show significant plasticity, with the ability to switch from a pro- to an 
anti-inflammatory phenotype (210, 211).  
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Historically it was believed that macrophage numbers could only be increased by recruitment 
of blood monocytes with subsequent differentiation. Recent reviews of available evidence 
have challenged this theory and propose instead that macrophages arise from precursor cells 
which populate the relevant organ during embryonic development (208, 212, 213). In addition 
macrophages can replicate themselves in situ and don’t always require the recruitment of 
monocyte-derived macrophages (MDMs), although the latter can still occur in some organs 
under normal conditions such as the gut and skin (208). Specifically, fate-mapping studies in 
mice have shown that knock-out of monocytes, for example using Cre recombinase gene 
techniques, does not affect lung macrophage numbers (214, 215). Similarly parabiotic mice 
which have their circulation surgically joined for prolonged periods, display inevitable mixing 
of their circulating monocyte populations but do not show development of chimeric tissue 
macrophages, indicating that blood monocytes are not contributing to tissue macrophage 
numbers (215). At present it is still unclear if and to what extent MDMs might contribute to 
the pulmonary macrophage population during times of inflammation but experts believe this 
is likely to occur (208, 212). In keeping with this Desch et al have recently demonstrated for 
the first time the presence of five types of mononuclear phagocyte cells in non-diseased whole 
lung donated post-mortem (216). They identified that alveolar macrophages, isolated via 
bronchoalveolar lavage, differed from another mononuclear phagocyte with macrophage 
features but which shared surface markers in common with monocytes. They labelled the 
latter group “tissue monocytes” and hypothesised that this form of macrophage may be 
derived from circulating blood monocytes. These studies highlight the importance of 
interpreting studies using MDMs in-vitro with caution as data may not be applicable to 
macrophages in-vivo. 
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1.10.3 TNF-α autocrine feedback loops in monocytes 
Surprisingly, given the wealth of evidence available concerning the effects of TNF-α on other 
cell types, there is a relative lack of data regarding the specific autocrine or paracrine effects 
of TNF-α on human monocytes/macrophages and particularly the differential roles of its two 
receptors. The importance of TNF-α and monocytes/macrophages in a range of acute and 
chronic inflammatory diseases suggests there is considerable value in determining how TNF-
α acts upon its cells of origin.   
In human MDMs and murine macrophages sTNF-α has been shown to induce transcription of 
the TNF-A gene and production of interferon-β, the latter feeding back to up-regulate 
transcription factors which influence late response inflammatory genes (217). TNF-α 
autocrine signalling also prolonged macrophage survival in murine macrophages stimulated 
with LPS (218). In a further study of bone-marrow derived murine macrophages, TNF-α acted 
in an autocrine manner to induce macrophage terminal differentiation (219). In human 
myelomonocytic cell lines TNF-α autocrine feedback augmented pre-existing expression of 
the HLA-DR gene (220). The complicated nature of TNF-α autocrine signalling effects on its 
own expression is highlighted in a study in which sTNF-α induced further TNF-α and also IL-
1β gene expression, but in addition caused the up-regulation of nuclear factor (erythroid-
derived 2)-like 2 (NrF2), a transcription factor activating anti-oxidant genes, which was also 
shown to have an inhibitory effect on TNF-α gene transcription (221). Lastly, TNF-α 
autocrine feedback has been shown to up-regulate the production of the predominantly anti-
inflammatory cytokine IL-10 in monocytes (222-224). 
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1.11 Conclusion and hypothesis 
In conclusion, given the importance of A1ATD as a cause of COPD, the special relevance of 
TNF-α in A1ATD and the findings of Sapey et al’s work suggesting 100 fold greater TNF-α 
in the airways of affected subjects and a more aggressive disease trajectory (17) there was a 
clear rationale for investigating the rs361525 polymorphism further in A1ATD-related 
COPD, at a cellular level. Sapey et al identified a lower BMI in AG subjects (17), suggesting 
systemic effects of greater TNF-α production. As such the focus of this thesis was initially on 
studying monocytes, the principal TNF-α secreting cell type, before considering studying the 
effects of the polymorphism in MDMs or in macrophages harvested directly from the airways. 
As monocytes express both TNFR1 and TNFR2, studying this cell type afforded the potential 
benefit of considering the effects of excess TNF-α secretion on autocrine feedback loops, via 
its two receptors.  
Therefore, the overarching hypothesis of this thesis was that the presence of the rs361525 
TNF-A polymorphism would lead to greater TNF-α output by monocytes from affected 
A1ATD-related COPD subjects compared to matched controls and that this would lead to 
greater output of other pro-inflammatory mediators and have an enhancing effect on other 
monocyte/macrophage functions relevant to COPD, via an autocrine feedback loop occurring 
via TNFR1.  
The primary component of this hypothesis was not proven using the current model of study, 
specifically monocytes from A1ATD-related COPD subjects with the rs361525 
polymorphism did not produce more TNF-α. The possible reasons for this are discussed in 
chapter 4. However, a TNF-α autocrine feedback loop leading to enhanced CXCL8 
production by monocytes from both groups was identified and as such further studies 
focussed on autocrine feedback loops in monocytes from healthy subjects, specifically 
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considering the relative roles of TNFR1 and TNFR2. The overall aims of the thesis in light of 
this change of focus are considered below. Hypotheses relevant to each area of study are 
covered in detail in each chapter along with specific objectives and strategies for addressing 
those objectives.  
1.12 Aims and structure of this thesis 
The aims were two-fold:  
Firstly, to investigate the effects of the rs361525 TNF-A polymorphism in our cohort of 
A1ATD-related COPD patients at a cellular level and secondly to investigate the autocrine 
effects of TNF-α on monocytes via its two receptors.  
Specifically, three key areas/questions were addressed. 
1. Do monocytes (as the principal producers of TNF-α) of A1ATD-related COPD 
patients with the rs361525 TNF-A polymorphism produce more TNF-α than 
monocytes of matched wild-type subjects from the same cohort?  
Chapter 3 examines exogenous mediators used to stimulate TNF-α production by monocytes 
from healthy subjects. Concentration response and time course experiments were conducted 
to determine optimum dosing of the chosen stimuli and optimum timing for harvesting of cell 
supernatants and mRNA from A1ATD subjects in subsequent experiments. Chapter 4 
examines the expression of TNF-α and CXCL8 mRNA and secreted protein in quiescent and 
activated monocytes in A1ATD-related COPD patients with and without the rs361525 TNF-A 
polymorphism.  
2. Does TNF-α have an autocrine effect on monocytes? 
Chapter 4 considers the effect of TNF-α blockade on CXCL8 output monocytes in A1ATD-
related COPD patients with and without the rs361525 TNF-A polymorphism. 
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Chapter 5 examines the effect of TNF-α blockade on pro- and anti-inflammatory cytokine 
output from activated monocytes from healthy control subjects by measuring mRNA and 
secreted protein output. In addition, the autocrine effect of TNF-α on the expression of its 
own cell surface receptors on monocytes was assessed using flow cytometry. 
3. What are the differential roles of TNFR1 and TNFR2 in TNF-α autocrine feedback 
loops in monocytes? 
Chapter 5 also examines the effects of selective or dual blockade of TNFR1 and TNFR2 on 
pro- and anti-inflammatory cytokine output from activated monocytes from healthy subjects 
by measuring mRNA and secreted protein output. Lastly, the effect of selective receptor 
blockade on the expression of cell surface TNFR1 and TNFR2 was assessed using flow 
cytometry. 
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CHAPTER  2 
 
MATERIALS AND METHODS 
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2 Materials and methods 
2.1 Ethical approval 
Ethical approval for the project was obtained from South Birmingham Research Ethics 
Committee (local research and ethics committee number- 3359a). All patients gave written 
informed consent to undergo physiological testing and peripheral blood sampling. Healthy 
control subjects gave verbal consent to donate blood samples. 
2.2 Subject characteristics 
The characteristics of patients with COPD and A1ATD are described in detail in chapter 4. 
All patients were homozygous for the Z variant of the serpinA1 gene (ZZ genotype) with a 
serum A1AT concentration below the putative protective level of 11 µM and the presence of 
COPD was diagnosed according to Global Strategy for Diagnosis, Management, and 
Prevention of COPD criteria (225). CB was defined as a cough productive of sputum for at 
least three months in each of two consecutive years (36). Patients in our cohort had previously 
undergone genotyping using TaqMan® genotyping technology to determine the allele they 
carried at position -237 on each copy of the TNF-A gene (125). We were subsequently able to 
match patients with and without the rs361525 polymorphism based on the following criteria: 
gender, age (within 10 years) and FEV1 (within 10% greater or less than the AG patient’s 
FEV1), current smoking status, treatment with inhaled corticosteroids and where possible for 
the presence or absence of CB symptoms. 
Healthy control subjects were non-smokers, free from any disease or symptoms and taking no 
medication at the time of the study. In total, 23 subjects donated peripheral blood samples 
(median age- 31 years, interquartile range (IQR-) 25 to 32.5 years; range- 21 to 45 years; 13 
males).  
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2.3 Pulmonary function testing  
Pulmonary function testing for subjects with COPD was conducted by trained respiratory 
physiologists in the Lung Function and Sleep Department at the Queen Elizabeth Hospital, 
Birmingham, according to national guideline standards (226). Patients performed post-
bronchodilator spirometry, multiple breath helium dilution lung volume assessment, the single 
breath diffusing capacity test and underwent arterialised capillary blood gas sampling to 
determine the following measurements: forced expiratory volume in one second (FEV1), vital 
capacity (VC), effective alveolar volume (VA), total diffusing capacity of the lung for carbon 
monoxide (DLCO), transfer coefficient (DLCO/VA) and the partial pressures of oxygen 
(PaO2) and carbon dioxide (PaCO2) in the arterial circulation, measured in kilopascals (kPa). 
Table 2.1 summarises the interpretation of pulmonary function measurements commonly used 
in diagnosing and assessing the severity of COPD. All patients had undergone an HRCT scan 
either at their local hospital or our centre. The presence or absence of emphysema was 
determined by the reporting radiologist at the hospital where the scan took place. 
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Measurement     Classification 
 
FEV1/FVC 
% predicted 
 
<70% = obstructive airways disease 
FEV1  
% predicted 
GOLD stage 1   Mild                
 
GOLD stage 2   Moderate  
 
GOLD stage 3   Severe 
 
GOLD stage 4   Very severe     
FEV1 >/= 80% (with symptoms) 
 
FEV1 >/= 50% 
 
FEV1 >/= 30% 
 
FEV1 < 30% (< 50% if 
respiratory failure present) 
 
DLCO and 
DLCO/VA 
 
Measurements less than 1.64 standardized residuals are indicative 
of reduced transfer of carbon monoxide. Reduced DLCO/VA 
suggests the presence of emphysema. 
 
Arterialized 
blood gas 
sample 
Type I respiratory failure    
 
Type II respiratory failure 
PaO2 < 8.0 kPa (hypoxia) 
 
PaO2 < 8.0 kPa  
and PaCO2 > 6 kPa (hypercapnia) 
 
 
Table 2-1 Pulmonary function testing in COPD 
On the basis of GOLD, COPD is diagnosed when the patient has an obstructive FEV1/FVC 
ratio (<70%) and one of the four FEV1 % predicted categories (225). FEV1/VC may be 
utilized as an alternative in order to minimize the risk of underestimating the degree of the 
obstructive ratio. This will occur if FVC is lower than VC as a result of early airways closure 
being exacerbated by a forced manoeuvre.  
 
2.4 Isolation of human CD14+CD16- monocytes 
A peripheral blood sample was obtained from each subject using a vacutainer system into 
lithium heparin-containing tubes (Becton Dickinson Vacutainer Systems, Franklin Lakes, 
USA). The monocyte extraction process was started within 30 minutes of obtaining the blood 
sample and was carried out in an ESCO class 2 biosafety cabinet. Whole blood was layered 
over LymphoprepTM (Axis Shield, Dundee, UK) and centrifuged at 800g for 20 minutes at 
3oC in a Hettich Rotina 46R centrifuge. As a result of centrifugation the blood components 
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separated into the following layers from top to bottom: plasma; buffy coat (containing 
mononuclear cells); LymphoprepTM; erythrocytes and granulocytes. The buffy coat was 
removed using a Pasteur pipette, the cells washed with sterile phosphate buffered saline (PBS) 
containing 2mM Ethylenediaminetetraacetic acid (EDTA) and 0.1% bovine serum albumin 
(BSA), hereafter referred to as PBS-1, in a sterile universal container and then centrifuged for 
10 minutes at 1600g (3oC). The cell pellet was then re-suspended in 20ml of PBS-1. A 10 
microlitre (µl) sample of the suspension was mixed with trypan blue and the leukocytes were 
counted on a haemocytometer with improved Neubaur markings. The suspension was washed 
and centrifuged again as before.  
The Dynabeads® Untouched™ Human Monocytes kit (Life Technologies Limited, Paisley, 
UK) was then used to isolate monocytes via a negative selection process, following the 
product protocol. The principle of this technique involves adding mouse IgG antibodies to the 
cell mixture which bind to specific leukocyte and erythrocyte cells surface markers (CD3, 
CD7, CD16, CD19, CD56, CDw123 and CD235a). The antibodies, bound to the unwanted 
cells, later bind to the magnetic Dynabeads® during a short incubation period. The CD14+ 
monocytes can then be separated from the Dynabeads®-cell complexes using a magnet, to 
leave the monocytes in suspension. In this technique the 10% of human monocytes that 
express CD16 on their cell surface (non-classical monocytes) are lost as it is critical for the 
antibody mixture to contain anti-CD16 antibodies in order to remove any neutrophils which 
may have contaminated the buffy coat layer. The benefit of the negative immune-selection 
technique however, is that it leaves the remaining 90% of monocytes “untouched” by any 
antibodies and hence unlikely to be activated by the isolation procedure.  
In brief, the cell pellet was re-suspended in PBS-1.  Blocking reagent and antibody mix 
supplied in the kit was then added to the suspension, each at a volume of 20 µl for every 
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1x107 mononuclear cells and the mixture was left to incubate at 2-8 oC for 20 minutes. The 
cells were washed with PBS-1 as before and centrifuged for 6 minutes at 2000g at 3oC. The 
cell pellet was re-suspended and mixed with Dynabeads® suspended in sterile PBS-1 (100 µl 
of beads for every 1x107 mononuclear cells).The beads were first washed by adding PBS-1 
and applying the tube to a magnet from which the PBS-1 was removed by pipette. The 
mixture was incubated for 15 minutes at 2-8 oC with gentle agitation. The mixture was then 
applied to the magnet for 2 minutes at which time the supernatant was pipetted off into a 
sterile universal container. Further PBS-1 was added to the tube containing the beads and the 
process repeated. The cells in the supernatant were counted as before on a haemocytometer to 
determine the total number of monocytes retrieved. All cell suspensions were of greater than 
95% viability as assessed by trypan blue exclusion. The mixture was centrifuged for 6 
minutes at 2000g at 3oC and the cell pellet re-suspended in sterile Roswell Park Memorial 
Institute 1640 medium (RPMI, Sigma-Aldrich Chemicals Ltd, Poole, UK) supplemented with 
10% fetal bovine serum (FBS), 10% L-glutamine and 10% penicillinV and streptomycin, 
hereafter referred to as culture medium (CM). 
2.5 Tissue culture 
Experiments which required a period of culture were conducted in 12 or 24-well tissue culture 
plates (Costar, Sigma-Aldrich Chemicals Ltd, Poole, UK). Immediately following isolation 
monocytes were plated out at a concentration of between 0.25 and 0.45 million per ml of CM, 
as specified in individual experiments. The following stimulants were used in experiments: 
recombinant human TNF-α, IL-1β or MCP-1 (R and D Systems Ltd, Abingdon, UK), 
Salmonella Enteritidis derived LPS and phorbol 12-myristate 13-acetate (PMA) (both Sigma-
Aldrich Chemicals Ltd, Poole, UK). A number of human mAbs were used in experiments, 
either as blocking antibodies, to prevent ligand binding to it receptor(s) or for flow cytometry 
66 
 
experiments where they were labelled with fluorophores, as listed in table 2.2. Written 
communication with R and D Systems Ltd (Abingdon, UK) confirmed that exact binding sites 
of the blocking mAbs to their specified ligands, TNF-α, TNFR1 and TNFR2, is not known. 
Antibodies are designed to bind to a single site on the TNF-α molecule or to the extracellular 
domain of receptors. All three blocking mAbs are able to neutralise the effect of TNF-α 
induced cytotoxicity in mouse fibroblasts, in a concentration dependent manner and 
presumably through competitive antagonism of the receptor(s) or TNF-α (direct 
communication with Dr E. Fioravanti, Scientific Coordinator, R and D Systems Ltd, 27th 
November 2015). 
Culture plates containing cells incubated with blocking mAbs were gently agitated for 20 
minutes prior to the addition of LPS. Cells were incubated for pre-determined time periods at 
37 0C and in 5% CO2. Monocyte supernatants were collected and then centrifuged in order to 
remove any cellular debris, before storing at -800C until analysed. Adherent cells were gently 
removed from the culture wells using a cell scraper (Sigma-Aldrich Chemicals Ltd, Poole, 
UK) and the cell pellet stored in RNAlater® (Invitrogen, UK) at -800C for future use in real-
time quantitative polymerase chain reaction (RT-qPCR) experiments. 
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Antibody Clone 
number 
  Fluorophore Function Manufacturer 
Mouse 
IgG1TNF-α 
mAb 
28401 N/A Neutralisation R and D Systems 
Abingdon, UK 
Mouse IgG1  
TNFR1 mAb 
16805 N/A Neutralisation R and D Systems 
 
Mouse IgG1 
TNFR2 mAb 
22210 N/A Neutralisation R and D Systems 
 
Mouse IgG1 
isotype control 
Ab 
11711 N/A Control R and D Systems 
 
Mouse 
IgG1TNFR1 
mAb 
16803 Phycoerythrin (PE) Flow 
cytometry 
R and D Systems 
 
Mouse IgG2A 
TNFR2 mAb 
22235 FITC Flow 
cytometry 
R and D Systems 
 
Mouse IgG1 
control Ab 
11711 PE Flow 
cytometry 
R and D Systems 
 
Mouse IgG2A  
control Ab 
X39 Fluoroscein (FITC) Flow 
cytometry 
BD Biosciences, 
Oxford, UK 
Mouse IgG1 
CD14 mAb 
134620 Peridinin chlorophyll 
protein complex 
(PerCP) 
Flow 
cytometry 
R and D Systems 
 
Mouse IgG2A  
CD16 mAb 
3G8 Allophycocyanin 
(APC) 
Flow 
cytometry 
Life 
Technologies, 
Paisley, UK 
Mouse IgG1 
control Ab 
11711 PerCP Flow 
cytometry 
R and D Systems 
 
Mouse IgG2A 
control Ab 
PPV-04 APC Flow 
cytometry 
Life Technologies 
  
Table 2-2 Antibodies used in the course of this thesis 
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2.6 Measurement of soluble mediators 
The ELISA is used to detect and quantify the concentration of a protein of interest in a liquid 
sample. Figure 2.1 outlines the principles of this technique.  
 
Figure 2-1 Principles of the ELISA 
1) Cell-free supernatant is added to a 96-well plate pre-coated with a capture mAb capable of 
binding an epitope specific to the analyte of interest. The plate is then washed to remove 
unwanted molecules. 2) A detection (HRP-labelled) polyclonal antibody specific to different 
epitopes on the analyte of interest is added and will bind to any analyte. The detection 
antibody is labelled with HRP. 3) After a wash step to remove excess detection antibody, 
substrate solution is added, a mixture of stabilised hydrogen peroxide and stabilised 
chromogen (TMB). 4) TMB is oxidised by the HRP enzyme, using hydrogen peroxide as the 
oxidising agent to produce a blue colour. 5) The reaction is terminated at an assigned time 
point by the addition of stop solution (sulphuric acid) which changes the blue colour to 
yellow. The intensity of the colour is proportional to the quantity of analyte present in each 
well and is measured in a microplate reader. A standard curve produced by running known 
concentrations of analyte supplied in the assay kit is used to calculate actual concentrations of 
analyte by interpolation. Horse radish peroxidise- HRP; tetramethylbenzidine- TMB. 
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Table 2.3 shows the steps required for each of the ELISA kits used to measure the following 
mediators: TNF-α, CXCL8, TNFR1 and TNFR2. Each sample of cell-free supernatant, 
standard or control was run in duplicate and a mean reading taken. An Orbital Shaker S03 
(Stuart Scientific, UK) set at 150 resolutions per minute was used to ensure adequate mixing 
for each incubation step. An LT-3500 microplate washer (Labtech.com, Uckfield, UK) was 
employed for each of the washing steps. The Synergy HT microplate reader (BioTek, 
Winooski, USA) read the optical density of each well at a set absorbance value and 
wavelength correction. The wavelength correction corrects for optical imperfections in the 
plate. The concentration of mediator in each sample was determined by using the forecast 
function in Excel (Microsoft Office 2010), which uses linear regression to calculate the 
concentration of mediator in a sample from the following values: the log value of the optical 
density of the sample and the log values of known standard concentrations and their optical 
densities. Values are given in picograms (pg)/ml and nanograms (ng)/ml.  
 
 
 
 
 
 
 
 
 
 
 
70 
 
Mediator  TNF-α 
R & D systems, UK 
CXCL8 
R & D systems, UK 
TNFR1 
Invitrogen, UK 
TNFR2 
Invitrogen, UK 
Step One Add 50 µl assay 
diluent per well. 
Add 100 µl assay 
diluent per well. 
  
Step Two Add 200 µl of  
standard, control or 
sample per well 
(samples were diluted 
in calibrator diluent if 
necessary) 
Add 50 µl of  standard, 
control or sample per 
well (samples were 
diluted in calibrator 
diluent if necessary) 
Add 50 µl of 
standard, control 
or sample per 
well 
Add 50 µl of  
standard, control 
or sample per 
well 
Step Three Incubate 2 hours at 
room temperature 
Incubate 2 hours at 
room temperature 
  
Step Four Aspirate and wash 4 
times (300 µl of wash 
buffer per well each 
wash) 
Aspirate and wash 4 
times (300 µl of wash 
buffer per well each 
wash) 
  
Step Five Add 200 µl of anti-
sTNF-α HRP-
conjugate solution to 
wells 
Add 100 µl of anti-
sCXCL8  HRP-
conjugate solution to 
wells 
Add 200 µl of 
anti-sTNFR1 
HRP-conjugate 
solution to wells 
Add 200 µl of 
anti-sTNFR2 
HRP-conjugate 
solution to wells 
Step Six Incubate 1 hour at 
room temperature 
Incubate 1 hour at 
room temperature 
Incubate 1 hour 
at room 
temperature 
Incubate 1 hour at 
room temperature 
Step Seven Aspirate and wash 4 
times (300 µl of 
diluted wash buffer 
per well each wash) 
Aspirate and wash 4 
times (300 µl of 
diluted wash buffer per 
well each wash) 
Aspirate and 
wash 4 times 
(300 µl of 
diluted wash 
buffer per well 
each wash) 
Aspirate and wash 
4 times (300 µl of 
diluted wash 
buffer per well 
each wash) 
Step Eight Add 200 µl of 
substrate solution to 
each well, protect 
from light and 
incubate at room 
temperature for 20 
minutes 
Add 200 µl of 
substrate solution to 
each well, protect from 
light and incubate at 
room temperature for 
30 minutes 
Add 50 µl of 
substrate 
solution to each 
well, protect 
from light and 
incubate at room 
temperature for 
15 minutes 
Add 50 µl of 
substrate solution 
to each well, 
protect from light 
and incubate at 
room temperature 
for 15 minutes 
Step Nine Add 50 µl of stop 
solution to each well. 
Read optical density 
in microplate reader 
set to 450 nM with 
wavelength correction 
set to 570 nanometre 
(nm) 
Add 50 µl of stop 
solution to each well. 
Read optical density in 
microplate reader set 
to 450 nM with 
wavelength correction 
set to 570 nm 
Add 200 µl of 
stop solution to 
each well. Read 
optical density 
in microplate 
reader set to 450 
nM with 
wavelength 
correction set to 
630 nm 
Add 200 µl of 
stop solution to 
each well. Read 
optical density in 
microplate reader 
set to 450 nM 
with wavelength 
correction set to 
630 nm 
 
Table 2-3 ELISA protocols 
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Figures 2.2 shows examples of standard curves generated for each of the four assays, with the 
linear regression equation and the correlation coefficient displayed. The lower and upper 
limits of quantification and the minimum detectable concentration for each of the assays are 
shown in table 2.4. The minimum detectable concentration of each measured mediator was 
determined by the manufacturers by adding two standard deviations to the mean optical 
density of twenty blank samples and from this calculating the corresponding concentration 
from the x-axis. The lower limit of quantification was equal to the minimum detectable 
concentration for the TNFR1 and TNFR2 assays which is deemed acceptable (227). 
 
 
Figure 2-2 Standard curves for the TNF-α, CXCL8, TNFR1 and TNFR2 ELISAs 
The graphs illustrate example standard curves with mean absorbance for each standard plotted 
on the y-axis against the concentration (pg/ml) on the x-axis, both displayed as logarithmic 
scales. A best fit curve is drawn through the points on the graph. The linear regression 
equation and R2 values are shown. 
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Assay Minimum 
detectable 
concentration 
Lower limit of 
quantification 
Upper limit of 
quantification 
TNF-α 1.6 pg/ml 15.6 pg/ml 1000 pg/ml 
CXCL8 3.5 pg/ml 31.3 pg/ml 1000 pg/ml 
TNFR1 50 pg/ml 50 pg/ml 45000 pg/ml 
TNFR2 100 pg/ml 100 pg/ml 138000 pg/ml 
 
Table 2-4 Minimum detectable concentration and lower and upper limits of 
quantification of the ELISAs 
The table outlines the sensitivity and limits of quantification of the four ELISAs used in this 
thesis. 
 
2.7 Measurement of mRNA 
2.7.1 RNA extraction 
Messenger RNA was extracted from each thawed cell pellet using the Isolate RNA Minikit 
(Bioline, London, UK). The cells within a pellet were lysed using 450 µl of Lysis Buffer R, 
re-suspended by pipetting and then incubated at room temperature for 3 minutes. The lysis 
buffer inactivated any ribonuclease (RNAase) enzymes, protecting the released RNA from 
enzymatic breakdown. All further steps were performed on ice, unless otherwise specified. 
Each lysate was transferred to a Spin Column R1, spun at 10,000g for 2 minutes in a Stuart 
Microcentrifuge SCF2 within a collection tube and the filtrate saved. Any genomic DNA was 
thus removed from the lysate. An equal volume of 70% ethanol was added to the filtrate and 
the sample transferred to spin column R2. The spin column was spun at 10,000g for 2 minutes 
and the filtrate discarded. 500 µl of Wash Buffer AR (diluted with ethanol) was added to the 
spin column and spun at 10,000g for 1 minute. The filtrate was discarded and 700 µl of Wash 
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Buffer BR (diluted with ethanol) was added to the spin column and spun at 10,000g for 1 
minute. The spin column was placed in a new collection tube and spun again at 10,000g for 3 
minutes. These steps were necessary to wash the RNA bound to the silica membrane of Spin 
Column R2, removing any cellular debris. In the final step 50 µl of RNAase free water was 
added to the spin column, in a fresh collection tube, incubated for 1 minute at room 
temperature and then spun at 6000g for 1 minute, collecting the eluted RNA into an RNAase 
free eppendorph. Eppendorphs were stored at -800C for future use in RT-qPCR experiments. 
 
2.7.2 Nucleic acid quantification and purity assessment 
Prior to reverse transcription, the quantity and purity of extracted RNA in each sample was 
determined. This was done by measuring the absorbance of ultraviolet light at a wavelength of 
260 nm, by 1 µl of each sample on a Nanodrop 2000c spectrophotometer. A one µl sample of 
RNA’ase free water was used in the first instance as a blank sample. Nucleic acids absorb 
ultraviolet light at this wavelength and hence the degree of absorption is proportional to the 
concentration of RNA in the sample. The purity of each sample was measured by calculation 
of the ratio of absorbance of light at 260 nm and 280 nm. Other molecules such as proteins 
may contaminate the RNA sample and absorb light better at the 280 nm wavelength. Ideally 
the 260/280 ratio for RNA should be between 1.8 and 2. A ratio lower than this may due to 
contamination of the sample with residual reagents from the extraction protocol or due to low 
concentrations of RNA (less than 10 ng/µl of nucleotide). A ratio higher than 2 indicates no 
contamination (228).  
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2.7.3 Reverse transcription 
Once RNA had been extracted from the cells it was converted to complementary DNA 
(cDNA) for use in RTq-PCR. Figure 2.3 outlines the principles of reverse transcription.  
 
 
 
 
Figure 2-3 Reverse transcription of RNA to cDNA 
1) Extracted RNA includes mRNA and pre-mRNA. mRNA is mature RNA which has 
undergone post transcriptional modification to aid stabilisation. This involves splicing, 
cleavage of the nucleotides at the 3’ end of the molecule and addition of a polyadenine (poly-
A) tail and also capping of the 5’ end of the RNA molecule (229). The process of reverse 
transcription whereby single stranded cDNA is formed from RNA can occur from any type of 
RNA. Primers bind to sequences within an RNA transcript. Oligo dT-16 primers bind to the 
polyA tail of mature mRNA molecules. Random octamer primers are single strands of DNA 
consisting of every possible combination of 8 nucleotide bases, meaning there will be a 
complementary primer to bind to whichever sequences of RNA are present in the sample. 2) 
The primers act as templates for reverse transcriptase to begin assembling the complementary 
dNTPs in sequence. 3) This results in single stranded cDNA corresponding to all RNA 
transcripts present, both from immature and mature RNA. RNAase inhibitors are also present 
in the reaction to prevent inadvertent degradation of RNA (230) dNTPs: deoxyribonucleotide. 
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Reverse transcription of RNA to cDNA was achieved using a High Capacity RNA-to-
cDNA™ Kit (Life Technologies, Paisley, UK). All components of the reaction were thawed 
on ice. Nine µl of a sample of RNA was added to 10 µl of 2x reverse transcriptase buffer mix 
(containing deoxyribonucleotide (dNTPs), random octamers, and oligo dT-16) and 1 µl of 20x 
enzyme mix (containing murine leukemia virus acting as the reverse transcriptase and also 
RNAase inhibitor protein). The sample, held in an RNA’ase free eppendorph, underwent 
reverse transcription in the Takara PCR Thermal Cycler Dice (Takara Bio, Otsu, Japan). The 
reaction mixtures were incubated at 37oC for 60 minutes to allow reverse transcription to 
occur and the reaction terminated by heating to 95oC. The samples were then cooled to 4oC. 
Each sample containing cDNA was frozen at -28oC for future analysis. A constant volume of 
9 µl of each sample of RNA was added to each eppendorph for ease of setting up the reverse 
transcriptase reaction. As such the total weight (ng) of RNA in each reaction varied, but as 
each starting concentration was known it was then possible to calculate the volume of 
completed reverse transciptase reaction (cDNA) that would be needed in the subsequent RT-
qPCR reaction to give an equivalent starting concentration of 1 ng of RNA per well of the 
RT-qPCR plate. 
2.7.4 The real-time quantitative polymerase chain reaction  
RT-qPCR relies on detection of fluorescence. In brief, addition of a primer designed to bind a 
specific sequence of cDNA (the gene of interest) and a DNA polymerase enzyme will lead to 
an exponential amplification of that sequence of DNA with each thermal cycle of the PCR 
machine. The process is illustrated in figure 2.4. 
A thermal cycle involves heating the PCR plate containing the reaction mixture to a 
temperature of 950C to allow all double stranded DNA (dsDNA) to denature into two single 
strands. On the first cycle denaturation does not need to occur as only single stranded cDNA 
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is present. This is followed by a short period of lower temperature (usually 600C) in which the 
primer, specific to the gene of interest, binds to its complementary sequence on the relevant 
cDNA strand. DNA polymerase then catalyses the assembly of complementary dNTPs to 
begin the process of replicating each copy of the gene of interest during that cycle. The 
hydrolysis probe, also specific for the gene of interest, binds upstream of the primer. An MGB 
(minor groove binder) molecule attached to the 3’ end of the hydrolysis probe is present in 
order to bind to a minor groove formed in the DNA upon probe binding. This stabilises probe-
DNA binding. Attached to the probe are two fluorophore dyes. The reporter dye (green) has a 
shorter wavelength and hence higher energy of emission than the quencher dye (red). The 
three dimensional structure of the probe is such that the two dyes are close together and 
therefore as the green reporter dye fluoresces its energy is transferred to the red quencher dye, 
a process termed fluorescent resonant energy transfer (FRET).  
DNA polymerase possesses 5’ nuclease activity so that when it reaches the probe as it extends 
the newly formed DNA sequence it is able to cleave the probe from the original DNA strand. 
This leads to a change in the conformational structure of the probe and hence separation of the 
quencher and reporter dye, termination of FRET and emission of fluorescence from the 
reporter dye at a specific and detectable wavelength. The temperature of the reaction is raised 
to allow denaturation of the newly formed amplicon (dsDNA of interest) and the cycle is 
repeated. In subsequent cycles a reverse primer also binds to the antisense strand of the gene 
of interest so that both sense and antisense strands are doubled with each cycle. 
Each duplication of the gene of interest is accompanied by an increase in fluorescence 
emission. The degree of fluorescence increases with each cycle (usually up to a total of 40-45 
cycles) and crucially, increases sooner the greater the starting concentration of the gene of 
interest. A predetermined threshold for fluorescence detection is set by the machine and once 
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this is crossed for a particular sample the cycle threshold (CT value) is reached. The CT value 
is then used to quantify the original amount of gene of interest present using the relative 
quantification method, as described in 2.7.5.  
 
Figure 2-4 Cycle one of the real-time quantitative polymerase chain reaction using 
TaqMan® technology 
1) A primer, specific to the gene of interest, binds to its complementary sequence on the 
relevant cDNA strand. 2) DNA polymerase catalyses the assembly of complementary dNTPs 
to replicate each copy of the gene of interest during that cycle. 3) A hydrolysis probe, specific 
for the gene of interest, binds upstream of the primer. Attached to the probe are two 
fluorophore dyes. The three dimensional structure of the probe is such that the two dyes are 
close together and therefore as the green reporter dye fluoresces its energy is transferred to the 
red quencher dye, a process termed FRET (fluorescent resonant energy transfer). 4) DNA 
polymerase cleaves the probe from the original DNA strand. 5) FRET is terminated leading to 
the emission of fluorescence from the reporter dye. The temperature of the reaction is raised 
to denature the newly formed amplicon and the cycle is repeated. In subsequent cycles a 
reverse primer also binds to the antisense strand of the gene of interest so that both sense and 
antisense strands are doubled with each cycle. MGB: minor groove binder. 
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For each sample, a volume of cDNA in solution, equivalent to 1.0 ng of starting mRNA 
unless otherwise specified, was added to PCR-grade water to a volume of 9 µl and mixed with 
10 µl of Light Cycler 480 Probe PCR Master master mix (Roche Applied Science, Burgess 
Hill, UK) and 1 µl of the relevant TaqMan® gene expression assay, containing both primer 
and hydrolysis probe for the particular gene of interest (Life Technologies, Paisley, UK). The 
Light Cycler 480 Probe PCR Master mix contained FastStart Taq DNA Polymerase, capable 
of initiating PCR at high temperatures. In some cases where expression of some genes was 
low, for example in freshly isolated cells, a greater starting amount of cDNA was used, 
including in the wells carrying the reference gene expression assay. 
This mixture, made up to a total volume of 20 µl, was added to duplicate wells of a clear 96-
well PCR plate (Roche Applied Science, Burgess Hill, UK). A singleplex technique was used 
in which only one specific TaqMan® gene expression assay was used in any one duplicate set 
of wells. On each 96-well plate, control wells for each TaqMan® gene expression assay were 
run in which the cDNA was absent, replaced instead by PCR grade water as a non-template 
control. Detectable amplicon product in this control reflects the presence of contaminating 
completed PCR reaction product which can occasionally become aerosolised in the laboratory 
environment from previous finished reactions.  
The RT-qPCR reaction was run on a Roche Lightcycler 480 PCR machine (Roche Applied 
Science, Burgess Hill, UK). The program was set to include a pre-incubation phase at 950C 
for 10 minutes, 40 amplification cycles at 950C for 10 seconds each, 600C for 30 seconds and 
720C for 1 second, and lastly a cooling phase for 30 seconds. The following TaqMan® assays 
were used: Glyceraldehyde 3-phosphate dehydrogenase (GAPDH); TNF-α; CXCL8; IL-1β; 
IL-6; TGF-β1; IL-10 (Life Technologies, Paisley, UK). All assays were attached to the 
fluorophore dye, FITC. Details of each assay are given in table 2.5. Assays where the probe 
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and/or primer span an exon junction are less likely to amplify any contaminating genomic 
DNA. This is because genomic DNA contains introns lying between two exons, disrupting the 
sequence of nucleotides complementary to the primer/probe and hence preventing binding of 
the DNA to the primer/probe. The Isolate RNA Minikit (Bioline, London, UK) is designed to 
efficiently remove genomic DNA during the RNA extraction process. Examples of 
amplification curves for each assay are shown in figures 2.5 to 2.11. Figure 2.5 is annotated to 
show the different phases of a complete amplification curve. 
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Gene symbol Assay-on- 
demand number 
NCBI RefSeq 
transcript 
number 
Amplicon 
length and 
position 
Primer/probe 
position 
GAPDH Hs99999905_m1 NM_002046.5 122 bp; spans 
3-3 exon 
boundary 
Probe and one 
of the primers 
sit within one 
exon 
TNF-α Hs00174128_m1 NM_000594.3 80 bp; spans 3-
4 exon 
boundary 
Probe spans 
exon 
CXCL8 Hs00174103_m1 NM_000584.3 101 bp; spans 
1-2 exon 
boundary 
Probe spans 
exon 
IL-1β Hs01555410_m1 NM_000576.2 91 bp; spans 3-
4 exon 
boundary 
Probe spans 
exons 
IL-6 Hs00985639_m1 NM_000600.3 
 
66 bp; spans 2-
3 exon 
boundary 
Probe spans 
exons 
TGF-β Hs00998133_m1 NM_000660.4 
 
57 bp; spans 6-
7 exon 
boundary 
Probe spans 
exons 
IL-10 Hs00961622_m1 NM_000572.2 
 
74 bp; spans 4-
5 exon 
boundary 
Probe spans 
exons 
 
Table 2-5 TaqMan® gene expression assays 
 The table highlights the identification numbers of each assay, the NCBI RefSeq (National 
Center for Biotechnology Information reference sequence) database numbers of the DNA 
transcripts produced in the PCR reaction, the length and position of those transcripts, and the 
binding position of the primers and/or probes. 
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Figure 2-5 CXCL8 RT-qPCR amplification curves 
The figure shows amplification curves for six separate wells containing RNA and other RT-
qPCR reagents, including the TaqMan® CXCL8 assay. Initiation phase- the PCR reaction is 
occurring but fluorescence is not yet great enough to be distinguished from background 
fluorescence. Exponential phase- PCR product and hence fluorescence doubles with each 
cycle. Plateau phase- reagents are exhausted and hence no further increase in fluorescence 
occurs with each cycle. A threshold level is set by the Roche Lightcycler 480 PCR machine. 
The CT value is determined from the point at which fluorescence from each well exceeds this 
threshold.  
 
 
Figure 2-6 TNF-α RT-qPCR amplification curves 
The figure shows amplification curves for six separate wells containing RNA and other RT-
qPCR reagents, including the TaqMan® TNF-α assay. Plateau phase has not been reached by 
45 cycles. 
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Figure 2-7 IL-1β RT-qPCR amplification curves 
The figure shows amplification curves for six separate wells containing RNA and other RT-
qPCR reagents, including the TaqMan® IL-1β assay. 
 
Figure 2-8 IL-6 RT-qPCR amplification curves 
The figure shows amplification curves for six separate wells containing RNA and other RT-
qPCR reagents, including the TaqMan® IL-6 assay. Plateau phase has not been reached by 45 
cycles. 
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Figure 2-9 IL-10 RT-qPCR amplification curves 
The figure shows amplification curves for six separate wells containing RNA and other RT-
qPCR reagents, including the TaqMan® IL-10 assay. 
 
Figure 2-10 TGF-β RT-qPCR amplification curves 
The figure shows amplification curves for six separate wells containing RNA and other RT-
qPCR reagents, including the TaqMan® TGF-β assay. 
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Figure 2-11 GAPDH RT-qPCR amplification curves 
The figure shows amplification curves for six separate wells containing RNA and other RT-
qPCR reagents, including the TaqMan® GAPDH assay. Plateau phase has not been reached 
by 45 cycles. 
 
2.7.5 Relative quantification method 
The CT value is used in the relative quantification method, which negates the need for 
calculating the precise copy number of the amplicon. In this method any errors in the obtained 
CT value for the gene of interest, which might have arisen as a result of a number of potential 
factors (such as reverse transcription inefficiency or minor differences between efficiency of 
PCR reactions in different plates), are corrected for by subtracting the CT value for a stably 
expressed reference gene obtained from another well using the same cDNA sample. This is 
known as the ΔCT value. The fold change in expression of the gene of interest relative to that 
reference gene is then calculated using the equation 2-ΔCT. This fold change can then be 
compared as a number against results obtained from other subjects’ samples or different 
experimental conditions in the same subject, as the CT value for the reference gene should not 
be affected by these different experimental conditions or between subjects, making 
differences in fold changes between subjects/conditions genuine rather than reflecting 
experimental error. Alternatively a further step can be added in which the ΔCT value of an 
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unstimulated baseline sample from the same subject (known as a calibrator sample), is 
subtracted from the first ΔCT value. The fold change in expression of the gene of interest in a 
particular sample relative to its own baseline is then calculated using the equation 2-ΔΔCT 
(231). This number can again be compared with other subjects or experimental conditions. 
Examples are shown below in tables 2.6 and 2.7. Each sample was run in duplicate and the 
mean of two CT values taken. GAPDH was used as the reference gene in these studies. All 
genes of interest and GAPDH were run in singleplex reactions with equal starting quantities 
of cDNA. 
Gene of interest 
(mean of 2 CT 
values) 
Reference gene 
(mean of 2 CT 
values) 
ΔCT 
=CTgene of interest -
CTreference gene 
Fold change 
compared to 
GAPDH 
=power(2-ΔCT) 
21.6 26.2  -4.6 24.7 
 
Table 2-6 Example of the 2-ΔCT relative quantification method 
The table outlines an example calculation of gene of interest mRNA expression relative to the 
normalising gene, GAPDH. 
 
ΔCT of stimulated 
sample 
=CTgene of interest -
CTreference gene 
ΔCT of calibrator 
(e.g.unstimulated) 
sample 
=CTgene of interest -
CTreference gene 
ΔΔCT 
= ΔCTstimulated sample - 
ΔCTcalibrator sample 
Fold change compared 
to calibrator sample 
=power(2-ΔΔCT) 
-4.6 0.8 -5.4 42.2 
 
Table 2-7 Example of the 2-ΔΔCT relative quantification method 
The table outlines an example calculation of the fold change of a gene of interest mRNA from 
baseline expression, relative to the normalising gene, GAPDH. 
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2.8 Analysis of cell surface markers using flow cytometry 
Flow cytometry was used to confirm the purity of monocyte isolates obtained by the 
Dynabeads® Untouched™ Human Monocytes kit (Life Technologies Limited, Paisley, UK), 
to detect and quantify the expression of cell surface TNFR1 and TNFR2 on monocytes under 
various experimental conditions and to detect apoptotic cells. Figure 2.12 outlines the 
principles of flow cytometry. 
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Figure 2-12 Principles of flow cytometry 
1) Isolated cells suspended in PBS-1 are streamed through the flow cytometer in single file. 2) 
Each cell individually passes through a laser beam. As the light hits each cell it is scattered in 
different directions. The intensity of forward scatter is approximately proportional to the 
diameter of the cell and the intensity of side scatter is approximately proportional to the 
degree of granularity and complexity of the intracellular contents of the cell type in question. 
3) The scattered light is detected by light detectors and the intensity converted to a voltage 
pulse. 4) Cells under study can also be labelled with mAbs to a particular cell surface marker. 
In turn, the antibody is pre-labelled with a specific fluorophore. The fluorophore is excited by 
absorption of light from the laser. On return to its ground state energy level the fluorophore 
emits light (fluoresces) at a wavelength specific to the fluorophore chosen. The emitted light 
is detected by a detector capable of sensing that particular wavelength of light (a band pass 
filter). The intensity of light detected is proportional to the number of cell surface receptors 
labelled with the mAb. A range of fluorophores, emitting light at different wavelengths can be 
utilised in order to detect different surface markers. 
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Monocytes (0.25 x 106 per sample) underwent flow cytometry immediately after isolation or 
after a period in culture. Cells in culture plates were first gently de-adhered by removing the 
culture media and replacing it for 20 minutes with 750 µl of Accutase® solution (Sigma-
Aldrich Chemicals Ltd, Poole, UK). Accutase® solution contains non-mammalian and non-
bacterial sources of enzymes to de-adhere cells and is marketed as being a more gentle 
method than trypsin or collagenase, preserving most epitopes for subsequent flow cytometry 
studies (232).  
Monocytes were washed and re-suspended with sterile PBS-1. 10 µg of human IgG was 
added per 1 x 105 cells as an Fc-receptor blocking step for 15 minutes, followed by incubation 
in the dark for 30 minutes at room temperature, with 10 µl per 1 x 106 monocytes of each 
fluorophore-labelled mAb to the cell surface markers under study, as per product protocols. A 
maximum of two mAbs per sample were used. Samples were then washed twice with PBS-1 
before re-suspending in 300 µl of PBS-1 for final flow cytometric analysis. Samples were 
kept on ice throughout.  
Control samples labelled with equivalent volume of isotype matched control Abs were run 
simultaneously to identify any binding to Fc-receptors, despite the use of a blocking step 
earlier in the protocol, or binding to non-specific cell surface targets. These samples were 
used in the gating process as described in 2.8.1 and in presenting fluorescence intensity data. 
Positively-labelled samples were run in duplicate; control samples and unstained cells were 
not, due to limitations to available cell numbers. Where possible, approximately 10000 events 
within the gate set over the monocyte population were collected per sample. In some cases 
this was not possible with cells which had been de-adhered from culture plates at later time-
points, as a proportion of these cells were shown to undergo apoptosis over time and hence 
less viable cells were available for gating and analysis. Of 138 positively labelled samples 
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which underwent analysis of TNFR1 and TNFR2 expression the median number of 
monocytes gated per plot was 9914 and the IQR was 5560 to 10684. All results were included 
in analyses. The limitations of this are discussed in chapter 5. 
The following antibodies were used in experiments, as previously outlined in full in table 2.2: 
mouse anti-human IgG1 TNFR1 mAb; mouse anti-human IgG2A TNFR2 mAb; mouse IgG1 
isotype control Ab; mouse anti-human IgG1 CD14 mAb; mouse anti-human IgG1 control Ab 
(all R and D Systems, Abingdon, UK); mouse IgG2A control Ab (BD Biosciences, Oxford, 
UK); mouse anti-human IgG2A CD16 mAb and mouse anti-human IgG2A control Ab (2 µl of 
each) (Life Technologies, Paisley, UK). Fluorescence was recorded using a BD Accuri™ C6 
flow cytometer (BD Biosciences, UK). Excitation of the fluorochromes FITC, PE and PerCP 
was achieved using an argon laser at 488 nm and at 640 nm for APC. Fluorescence emitted 
from each fluorophore was detected through different band pass filters: 530 nm for FITC, 585 
nm for PE, 670 nm for PerCP and 675/25 nm for APC.  
Flow cytometry data was analysed using BD Accuri C6 software (BD Biosciences, Oxford, 
UK). Data was recorded as both median fluorescence intensity (MFI), an average of the 
brightness of each cell labelled with a specific receptor mAb, and as percentages of cell 
surface marker positive monocytes. MFI results are presented as a ratio of the MFI for the 
positively labelled cells, to the MFI of the negative control cells incubated with fluorophore-
labelled isotype controls.  
Colour compensation was set for each group of experiments prior to data analysis, to correct 
for any fluorescence spillover. This occurs when the emission spectra of two fluorophores 
overlaps slightly and hence a band pass filter detecting one may also detect a degree of 
fluorescence emitted by the other fluorophore (conjugated to a different cell surface receptor 
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mAb) and hence cause inaccuracy in the results obtained. The degree of colour compensation 
of each band pass filter in use was determined by running one subject’s samples, labelled 
separately with each flow cytometry mAb and using the MFI values from the two detectors 
for these separate samples to determine an appropriate percentage correction for each filter. 
An example is shown in table 2.8. 
 MFI in PE band pass filter 
(585nm) 
MFI in FITC band pass filter 
(530nm) 
Unstained cells 342*  732* 
Cells labelled with a TNFR2 
mAb (conjugated to FITC) 
1012** 5748 
Correction factor= (1012-342)/(5748-732)=0.134 
The 585nm (PE) band pass filter is corrected by subtracting 13.4% of the total signal 
detected in that filter. 
*due to autofluorescence       **due to unwanted spillover  
  
Table 2-8 An example of colour compensation 
The table shows the MFI values of unstained monocytes and monocytes labelled with a 
TNFR2 mAb conjugated to FITC in band pass filters that detect FITC or PE. Any 
fluorescence detected in the PE band pass filter is as a result of autofluorescence and/or 
spillover. The four values can be used to determine what percentage of the signal must be 
subtracted from the PE filter in future experiments to correct for spillover. 
 
2.8.1 Gating strategy 
For each set of experiments a forward versus side scatter plot was created on a sample of 
unstained cells to identify all events and a gate was placed around the isolated monocyte 
population. Each dot represents an individual event/cell. Most events are complete cells but 
debris is often present and this is identified to the bottom left of the plot, indicating its low 
size and low internal complexity. An example plot is shown in figure 2.13. 
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Figure 2-13 Gating around the monocyte population 
a) A forward scatter (x-axis) versus side scatter (y-axis) plot is shown. The monocyte 
population extracted by negative immunoselection is shown in gate P1 (in this example equals 
10,457 events). b) A forward scatter versus side scatter plot of whole blood from a different 
young healthy control subject is shown for comparison. Monocytes are shown in gate P4. 
 
A pulse-width versus forward scatter area plot was created in order to exclude any doublet 
events, whereby two cells clump and pass through the flow cytometer together rather than in 
succession. This plot works on the principle that the time taken for a light signal to pass 
through two cells clumped together will be longer, i.e. a greater voltage pulse width. Two 
clumped cells may also have a greater diameter and hence higher forward scatter. For this 
reason, as shown in figure 2.14, cells with high pulse width and of a forward scatter equal or 
greater than the majority of cells can be identified and excluded as these are likely to 
represent doublet events (233). 
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Figure 2-14 Pulse width versus forward scatter plot.  
R1 shows a gate around singlet events/cells. Events with high pulse width are shown as blue 
dots above gate R1 and represent excluded doublet events. 
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Next, quadrant scatter plots were created of the previously gated cells, comparing intensity of 
one cell surface receptor of interest on the x-axis against another on the y axis, for example 
TNFR2 against TNFR1, as shown in figure 2.15. Quadrant gate setting is shown in the figure. 
 
Figure 2-15 Further gating of monocytes 
a) Quadrant plot showing autofluorescence of unstained monocytes, detected in the band pass 
filters for TNFR1 (y-axis) and TNFR2 (x-axis). A quadrant gate has been set. b) Quadrant 
plot showing fluorescence emitted from cells from the same experiment incubated with 
fluorophore labelled isotype control Abs (negative control). The quadrant gate has been 
moved to the right to exclude the additional fluorescence from non-specific and Fc-receptor 
binding. This is the final gate for later analysis of cells labelled with the antibodies of interest. 
c) Quadrant plot showing fluorescence emitted from cells labelled with TNFR1 and TNFR2 
flow cytometry mAbs. Some cells have moved beyond the limits of the previously set 
quadrant gate, reflecting genuine receptor-mAb binding. Shown are percentages of monocytes 
that were positive for neither receptor (left lower quadrant), both (upper right quadrant), 
TNFR1 only (upper left quadrant) or TNFR2 only (lower right quadrant). d) Data from the 
same subject as c, shown as a fluorescence histogram for TNFR1 intensity, demonstrating that 
very few cells (pink histogram) had greater fluorescence than the negative control cells (black 
histogram). The red marker is set to delineate positive from negative cells. e) Data from the 
same subject as c, shown as a fluorescence histogram for TNFR2 intensity, demonstrating that 
94 
 
many cells (pink histogram) had greater fluorescence than the negative control cells (black 
histogram). The red marker is set to delineate positive from negative cells. 
 
2.9 Apoptosis assay 
It was observed that in some subjects’ samples, flow cytometry plots for monocytes incubated 
for longer periods showed a reduction in the size (corresponding to less forward scatter) and 
in some cells increased granularity (increased side scatter) also. To investigate if this change 
was due to apoptosis of some of the cells, the PE- Annexin V Apoptosis Detection Kit I (BD 
Biosciences, Oxford, UK) was used to test isolated monocytes from one healthy subject. This 
assays works on the principle that as cells begin the process of early apoptosis the membrane 
phospholipid, phosphatidylserine, is translocated from the inner to the outer aspect of the 
plasma membrane. Annexin V, a calcium dependent phospholipid-binding protein is able to 
bind to this and fluoresce if labelled with PE (234). Cells in the later stages of apoptosis, or 
those undergoing necrosis, lose the impermeability of the cell membrane and hence allow a 
dye, 7-Amino-Actinomycin (7-AAD), to enter the cell. The 7-AAD dye is only visible once 
within a damaged cell when it undergoes a spectral shift once associated with DNA (235). 
The apoptosis assay protocol (236) used does not involve a washing step post addition of the 
annexin V and 7-AAD as any bound 7-AAD would be washed away, therefore some annexin 
V might bind non-specifically at low levels even in the absence of any early apoptosis (direct 
communication with BD Biosciences Scientific Support, March 2013). Product literature 
therefore recommends incorporating a positive control, in which monocytes are induced to 
undergo apoptosis, with which to compare the extent of Annexin V or 7-AAD binding. 
Camptothecin (Sigma-Aldrich Chemicals Ltd, Poole, UK), an inhibitor of DNA replication 
and commonly used inducer of apoptosis (237) was used as per the assay protocol (236). 
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Isolated monocytes from one healthy subject (1 x 105 per condition and in duplicate) were 
treated in the following ways: freshly isolated untreated cells; cells treated with camptothecin 
to a final concentration of 20 µM for 20 hours (as recommended in the assay protocol (236)); 
cells treated with LPS to a final concentration of 100 ng/ml for 20 hours. Monocytes treated 
for 20 hours were incubated at 37 0C and in 5% CO2. 
Cells in culture plates were first gently de-adhered by removing the culture media and 
replacing it for 20 minutes with 750 µl of Accutase® solution (Sigma-Aldrich Chemicals Ltd, 
Poole, UK). Monocytes were washed twice in sterile PBS-1 and re-suspended in 1X binding 
buffer, provided in the commercial assay. 100 µL of the binding buffer, containing 
approximately 1 x 105 monocytes was transferred to each flow cytometry tube. Cells were 
then either left unstained, stained with 5 μl of PE-labelled Annexin V or 5 μl of 7-AAD or 
with both. The flow cytometry tubes were gently vortexed and incubated for 15 min at room 
temperature in the dark, following which 400 μl of 1X binding buffer was added to each tube. 
Fluorescence was recorded using the BD Accuri™ C6 flow cytometer (BD Biosciences, 
Oxford, UK). Excitation of PE and 7-AAD was achieved using an argon laser at 488 nm. 
Fluorescence emitted from each fluorophore was detected through the following band pass 
filters: 585 nm for PE and 670 nm for 7-AAD. A 4.5% correction was applied to the 585 nm 
band pass filter and 19.6% to the 670 nm band pass filter to correct for those percentages of 
spillover into those filters. Flow cytometry data was analysed using BD Accuri C6 software 
(BD Biosciences, Oxford, UK). Gating was applied as previously outlined in 2.8.1. In some 
analyses further gates were applied to exclude debris and this strategy is outlined in detail in 
figure 3.11. 
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2.10 Statistical analysis 
Data is presented as median and range/IQR in chapters 4 and 5, due to small sample sizes, 
with the exception of data presented as percentages which is displayed as means and standard 
deviation (SD). Data is presented as mean and SD or median and range/IQR in chapter 3. 
Non-parametric testing was used throughout. Individual comparisons were made using a 
Wilcoxon signed-rank test for dependent data and a Mann Whitney U test for independent 
data. Friedman’s test was used to detect any overall difference in multiple related medians, 
with post-hoc all pairwise multiple comparisons testing if the Friedman’s test result allowed 
rejection of the null hypothesis of there being no overall difference. SPSS provides adjusted 
significance levels for the post-hoc pairwise comparisons using the Dunn-Bonferroni 
correction, whereby the unadjusted significance values are multiplied by the number of 
comparisons, setting the value to 1 if the product is greater than 1. In some analyses all 
possible comparisons were not relevant, for example time course experiments in which the 
comparisons of interest were each time-point specifically with time zero. In these cases an 
adjusted p-value was determined by multiplying the unadjusted p-value only by the number of 
comparisons of interest. Area-under-the curve (AUC) values were calculated according to the 
trapezium rule. Statistical significance was set at p<0.05 with two-tailed significance if there 
was no prior hypothesis regarding the direction of difference between two groups and one-
tailed significance if the direction of difference was predicted due to previous experiments or 
published data, as suggested (238). Use of one-tailed p-values are specified in the text where 
used. Data was analysed using the SPSS statistical program (version 22.0 Chicago, USA). All 
statistical analyses were discussed with a medical statistician. 
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CHAPTER  3 
 
VALIDATION EXPERIMENTS 
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3 Validation experiments 
3.1 Introduction and aims 
The main aim of this chapter was to describe the initial experiments that were undertaken in 
order to thoroughly prepare for the investigation of the effects of the rs361525 polymorphism 
on monocytes from patients with A1ATD-related COPD in chapter 4. In addition, validation 
results of the various assays and experimental techniques used throughout the thesis are also 
described. Lastly, findings from the PE- Annexin V Apoptosis Detection Kit I (BD 
Biosciences, Oxford, UK) are presented. This assay was used to investigate the hypothesis 
that the change in monocyte size and granularity that was first noted in later stages of the 
thesis was due to apoptosis of monocytes.  
3.2 Results 
3.2.1 Purity of monocyte isolates 
Immunostaining with CD14 and CD16 mAbs and subsequent flow cytometric analysis of 
monocyte isolates from three healthy control subjects was performed to determine the purity 
of isolates obtained using the Dynabeads® Untouched™ Human Monocytes kit (Life 
Technologies Limited, Paisley, UK). Fluorescence spill-over was detected in the 675/25 band 
pass filter and an 18.4 % correction factor applied to compensate for this. 
Figure 3.1 shows a representative plot from one subject, illustrating that the majority of gated 
monocytes were CD14 positive and CD16 negative, although unexpectedly a proportion were 
CD14 and CD16 positive. 
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Figure 3-1 Example flow cytometry plot illustrating CD14/CD16 status. 
Representative quadrant plot and fluorescence overlay histograms from one subject. a) A 
quadrant marker is set around the main body of monocytes incubated with an isotype control 
antibody. b) Monocytes labelled with CD14 and CD16 mAbs. The 2-parameter dot plot is 
split into 4 quadrants: bottom left- CD14 and CD16 negative; top left- CD14 positive only; 
top right- CD14 and CD16 positive; bottom right- CD16 positive only. b) Two histograms are 
shown, with fluorescence intensity in the PerCP channel on the x-axis (logarithmic scale) and 
cell count on the y-axis. The black histogram represents monocytes incubated with a PerCP-
labelled isotype control antibody. The pink histogram represents monocytes labelled with 
PerCP-CD14 mAb. c) The black histogram represents monocytes incubated with an APC-
labelled isotype control antibody. The green histogram represents monocytes labelled with 
APC-CD16 mAb. Red vertical markers are shown on both figures to delineate fluorescence 
due to specific binding of mAbs to the cell surface receptor of interest (to the right of the set 
marker) from that due to non-specific binding of flow cytometry antibodies (to the left of the 
marker).  
 
 
 
100 
 
Table 3.1 shows the percentages of monocytes which were CD14+CD16-, CD14+CD16+, 
CD14-CD16+ and CD14-CD16- in each of the three healthy subjects tested. 
Subject CD14+CD16- CD14+CD16+ CD14-CD16+ CD14-CD16- Total 
One 74.3 14.6 10.9 0.2 100.0% 
Two 63.9 29.9 6.1 0.1 100.0% 
Three 64.6 30.3 5.0 0.1 100.0% 
 
Table 3-1 Purity of monocyte isolates in three healthy subjects 
CD14 and CD16 cell surface marker expression was measured in monocyte isolates from 3 
healthy subjects extracted using the Dynabeads® Untouched™ Human Monocytes kit. 
Positively labelled samples were run in duplicate and the percentages shown are the mean of 2 
results. 
 
3.2.2 Validation of enzyme linked immunosorbent assays 
The precision of an assay is determined by how reproducible a result is within one ELISA 
plate (intra-assay validation) and across multiple ELISA plates (inter-assay validation). Intra-
assay validation of the TNF-α, CXCL8, TNFR1 and TNFR2 ELISA assays was conducted as 
follows and the coefficient of variation percentage (CV%) values are shown in table 3.2: for 
each of the four assays one known concentration of the relevant mediator wa prepared from 
the supplied standard. These solutions were then run in 10 wells for each known concentration 
to allow determination of the intra-assay variability. Each result was determined by 
interpolation from the standard curve using the forecast function in Excel (Microsoft Office 
2010). The mean and SD of the results of the 10 wells was calculated and from this the CV% 
was determined.  
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Assay TNF-α CXCL8 TNFR1 TNFR2 
CV % 5.8 3.2 9.8 9.1 
 
Table 3-2 Intra-assay validation of ELISAs 
The table shows CV% values for the four ELISAs used in this thesis, when a known 
concentration of the relevant mediator was run in 10 wells of the same assay plate.  
 
Multiple TNF-α and CXCL8 ELISA plates were used in the studies for this thesis. It was 
therefore necessary to conduct inter-assay validation of the assays used for these mediators, 
and the CV% values are shown in table 3.3. For both assays one known concentration of the 
relevant mediator was prepared from the supplied standard and then run once on each of ten 
consecutive plates. Each result was determined by interpolation from the standard curve using 
the forecast function in Excel (Microsoft Office 2010). The mean and SD of the results of the 
10 wells was calculated to determine the CV % value.  
Assay TNF-α CXCL8 
CV % 14.8 15.5 
 
Table 3-3 Inter-assay validation of ELISAs 
The table shows CV% values for the two ELISAs used in this thesis where multiple plates 
over time were required. A known concentration of each mediator was run in one well on 
each of ten assay plates.  
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3.2.3 Determining quantity and purity of extracted RNA 
The median 260/280 ratio of 396 RNA samples was 2.1 (IQR 1.8-2.4). The concentration of 
RNA in all samples was less than 10 ng/µl. All samples were used in ongoing experiments 
and the reasons for this are discussed in 3.3.  
3.2.4 Validation of GAPDH as a reference gene 
It is important when choosing a reference gene that the gene is validated for an individual 
experimental model. This means that its expression must be shown to remain unaffected by a 
particular experimental condition and must be the same between subjects, otherwise 
calculated differences in expression of the gene of interest will be inaccurate (239). Ideally, 
each gene of interest should be normalised against multiple reference genes but this is costly 
and impractical in cases where limited RNA/DNA is available (240). Alternatively, experts 
have stated that where an individual reference gene can be shown to be stably expressed in the 
model under study then it is acceptable to use only that one, particularly when any slight 
genuine variability in reference gene expression is outweighed by much greater changes in the 
gene of interest between samples (239, 240). For example, a 10 fold variability in expression 
of the reference gene is less important if changes in the gene of interest are 100 fold (239). 
Dedha et al compared the expression of a panel of commonly used reference genes in whole 
blood and PBMCs under a variety of conditions and subject characteristics. They classified 
stable reference genes as those in which the average fold change of that gene from the mean 
expression was less than 2 and the maximum variability in fold change less than 5 (240).  
The suitability of GAPDH for use as a reference gene in this thesis was tested by performing 
RT-qPCR on samples from five of the COPD patients (three with the rs361525 polymorphism 
and two without), each containing a volume of cDNA in solution equivalent to 0.9 ng of 
starting mRNA. This equated to 64 CT values. Each of the 64 values was an average of a 
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sample run in duplicate. The samples represented a range of experimental conditions 
(unstimulated; stimulated with LPS or PMA; stimulated with LPS in the presence of TNF-α 
mAb) and had been harvested at varying time-points between 0 and 24 hours. The results of 
this validation experiment are shown in table 3.4 and highlight the stability of expression of 
GAPDH across a large number of samples from different patients and under a variety of 
experimental conditions. The results are expressed as a mean fold change from the mean CT 
value. 
Mean (median) CT value for GAPDH in 64 
samples 
27.1 (27.0) cycles 
Standard deviation of the mean CT value 0.8 cycles 
Mean fold change from the mean CT value 1.7 
Standard deviation of fold change from the 
mean CT value 
0.6 
Maximum fold change from the mean CT 4.6 
75th percentile fold change from the mean CT 1.8 
25th percentile fold change from the mean CT 1.2 
 
Table 3-4 Validation of GAPDH as a reference gene 
The table shows the mean (SD) CT value for GAPDH in 64 different samples and the mean 
(SD) fold change from this mean value. This demonstrates the stability of GAPDH across a 
broad range of samples. 
 
3.2.5 Intra-assay and inter-assay validation of the RT-qPCR reaction 
The three most frequently studied genes in this thesis, TNF-α, CXCL8 and GAPDH, were 
chosen to determine an estimate of the intra-assay and inter-assay variation in results obtained 
using TaqMan® gene expression assays.  To determine intra-assay variation RT-qPCR was 
performed using equal quantities of cDNA from one subject in eight wells per gene 
expression assay of one PCR experiment. To determine inter-assay validation RT-qPCR was 
performed using equal quantities of cDNA from one subject in one well per gene expression 
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assay for eight PCR experiments. The results, shown in table 3.5, are expressed as a SD of the 
mean CT value obtained for each of the three assays and CV% values. 
 TNF-α CXCL8 GAPDH 
Intra-
assay 
Inter-
assay 
Intra-
assay 
Inter-
assay 
Intra-
assay 
Inter-
assay 
Mean CT 
value  
30.2 29.6 23.4 23.0 26.7 26.5 
SD of CT 
value 
0.1 0.3 0.06 0.2 0.04 0.2 
CV% 0.3% 1.0% 0.3% 0.9% 0.1% 0.8% 
 
Table 3-5 RT-qPCR intra-assay and inter-assay validation 
The table shows the mean, SD and CV% values of CT values for three genes of interest. Intra-
assay variation was determined by measuring the expression of each gene (expressed as as a 
CT value) using cDNA from one subject in eight replicates per gene during one RT-qPCR 
experiment. Inter-assay variation was determined by measuring the expression of each gene 
using cDNA from one subject in one well per gene for eight separate PCR experiments. 
 
3.2.6 Identifying stimulants of TNF-α secretion by monocytes 
In order to determine if monocytes from A1ATD-related COPD subjects with the rs361525 
polymorphism produced more TNF-α than cells from wild-type subjects it was necessary first 
to identify a mediator which would elicit a TNF-α response, the optimum concentration of 
that mediator to elicit a maximum response and the peak time point of TNF-α secretion at 
which to harvest supernatants in these later experiments. Unless otherwise specified, 0.45 
million monocytes per well were used, each time point or condition was conducted in 
duplicate and a mean result taken. Results for each pre-specified time point or concentration 
of mediator were determined by collecting supernatants from separate wells.  
Time course profiles of sTNF-α were conducted using monocytes cultured in the absence of 
an exogenous stimulant (unstimulated) or in the presence of LPS, IL-1β or MCP-1 (figure 
3.2). Although indirect comparisons between different subjects’ monocytes, LPS elicited the 
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greatest response. Similar time course profiles (not shown) were observed using 1 ng/ml or 10 
ng/ml of the relevant stimulant. All time course profiles demonstrated that the concentration 
of sTNF-α decreased back towards to baseline after 20 hours of culture. 
 
Figure 3-2 Time course profile of sTNF-α in the supernatant of monocytes  
Time course profiles for sTNF-α concentration in response to different stimuli are shown. 
Each datum point is the median value (with range). Friedman’s testing where significant was 
followed by post-hoc pairwise comparisons of each time-point to time zero (unadjusted p-
values were first corrected by multiplying by 4 and where significant are shown on the graphs 
at the relevant time-points). a) No exogenous stimulus: Friedman’s test p<0.01. b) 100 ng/ml 
of LPS: Friedman’s test p<0.01. c) 100 ng/ml of IL-1β: Friedman’s test p=0.01 d) 100 ng/ml 
of MCP-1: Friedman’s test p=0.01. 
 
Monocytes were stimulated for 8 hours with increasing concentrations of each stimulus, up to 
a maximum of 100 ng/ml of the mediator. Figure 3.3 shows that 100 ng/ml of LPS or IL-1β 
increased sTNF-α concentration over that produced by monocytes cultured without an 
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exogenous stimulus. MCP-1 had no effect on sTNF-α concentration at any concentration. 
Higher concentrations of LPS were not tested as these were likely to be supra-physiological 
and hence less clinically relevant (241).  
 
Figure 3-3 sTNF-α production by monocytes stimulated with increasing concentration of 
stimulant 
Monocytes were stimulated for 8 hours with an increasing concentration of each stimulant. 
Individual subject data is shown with median values displayed as bars. Friedman’s testing 
where significant was followed by post-hoc pairwise comparisons of each concentration to 0 
ng/ml of stimulant (unadjusted p-values were first corrected by multiplying by 3 and where 
significant are shown on the graphs at the relevant time-points). a) LPS: Friedman’s test 
p<0.01 b) IL-1β: Friedman’s test: p=0.01 c) MCP-1: Friedman’s test non-significant. 
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3.2.7 Optimal timing for cell supernatant collection 
The monocyte extraction process takes approximately four hours to carry out making detailed 
time course experiments difficult to achieve if conducted on the same day as extraction. 
Further time course experiments were therefore conducted in cells which had been allowed to 
incubate overnight, again using 0.45 million monocytes per well and in duplicate. This 
permitted a greater number of time-points to be tested throughout the course of a day.         
100 ng/ml of LPS was employed as the monocyte stimulant as this had elicited the greatest 
sTNF-α response in concentration response experiments (figure 3.3). After incubating 
overnight the cell culture medium was changed prior to stimulating the monocytes with LPS, 
to remove any cytokines which had been secreted prior to this and which would affect 
subsequent measurements.  
Figure 3.4a shows the time course profile following stimulation with LPS. In a separate time 
course profile it was not possible to detect any sTNF-α at any time-point in the supernatants 
of monocytes which had been incubated overnight and then left without any exogenous 
stimulation.  
The concentration of CXCL8 was also measured in the same samples. Figure 3.4b shows that 
even without the addition of an exogenous stimulus monocytes which have been incubated 
overnight remain able to produce CXCL8 and that this accumulates in the supernatant with 
time, eventually levelling off after approximately 12 hours. In contrast, monocytes incubated 
overnight and then stimulated with LPS continue to secrete CXCL8 into the supernatant at 24 
hours (figure 3.4c). 
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Figure 3-4 Time course profile of sTNF-α and CXCL8 in the supernatant of monocytes 
rested overnight prior to stimulation with 100 ng/ml of LPS 
Time course profiles for sTNF-α and CXCL8 concentration are shown. Each datum point is 
the median value (with range). Friedman’s testing where significant was followed by post-hoc 
pairwise comparisons of each time-point to time zero (unadjusted p-values were first 
corrected by multiplying by 6 and where significant are shown on the graphs at the relevant 
time-points). a) sTNF-α concentration in LPS-stimulated monocytes: Friedman’s test p=0.01 
b) CXCL8 concentration in unstimulated monocytes: Friedman’s test p=0.02 c) CXCL8 
concentration in LPS-stimulated monocytes: Friedman’s test p<0.01. 
 
Despite the comparison of time course profiles between monocytes stimulated immediately 
and those left overnight prior to stimulation being indirect (different healthy subjects donated 
monocytes to each), it was observed that there was a marked reduction  in the concentration of 
sTNF-α detectable at each time-point in response to LPS stimulation in the latter experiment. 
The original experimental design intended for use in the A1ATD patient group had been to 
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extract monocytes on day 1 and stimulate them on day 2 as this would be more practical from 
an organisational perspective. However it became clear that should monocytes produce less 
sTNF-α on day 2 this would not be a feasible strategy. A further experiment was therefore 
designed in which monocytes from 6 subjects were stimulated for 8 hours either immediately 
after the extraction process was completed or the following morning (figure 3.5). This 
demonstrated, as hypothesised, that the concentration of sTNF-α was significantly lower in 
cells which had been allowed to incubate overnight prior to stimulation. It was determined 
therefore that experiments conducted in the A1ATD patient group would need to occur on the 
day of monocyte isolation, immediately following the extraction process. 
 
 
Figure 3-5 Concentration of sTNF-α in the supernatant of monocytes stimulated for 8 
hours with 100 ng/ml of LPS immediately after monocyte extraction (day 1) or after 
incubating overnight (day 2)  
Paired data is shown for monocytes stimulated on day 1 or day 2 after isolation. Differences 
between experimental conditions were tested with a Wilcoxon Signed Ranks test. 
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3.2.8 Effect of experimental replication on coefficient of variation 
In order to determine if increasing the number of replicate samples for each experimental 
condition reduced the variation in results obtained, expressed as a CV% value, the following 
experiment was conducted: 5 replicate preparations of monocytes per subject were stimulated 
for 8 hours with 100 ng/ml of LPS and the concentration of sTNF-α in the supernatant 
measured. Each sample of supernatant was run in duplicate on the ELISA plate as described 
earlier. CV% values were calculated for each subject using sequential results, so that values 
were obtained for variation using 2, 3, 4 and 5 replicates. It was hypothesised that increasing 
the number of replicates would significantly reduce the CV%, however, as this was not the 
case statistical testing was not performed (figure 3.6). A pragmatic approach was therefore 
taken in future experiments in A1ATD patients and 3 replicates of each condition were 
conducted for each experimental condition/time-point. 
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Figure 3-6 Effect of experimental replication on intrasubject variation in results 
obtained for TNF-α concentration in the cell-free culture supernatant 
For each subject four columns are shown. Columns represent the CV% value of TNF-α 
concentration in the cell culture wells of monocytes exposed to 100 ng/ml of LPS for 8 hours, 
using 2, 3, 4 or 5 replicate wells.  
 
3.2.9 Soluble TNF-α stimulates CXCL8 production 
One hypothesis of this thesis was that increased production of TNF-α by monocytes from 
A1ATD-related COPD patients with the rs361525 polymorphism would lead to an enhanced 
effect on those monocytes by the excess TNF-α, specifically, they would produce more of the 
neutrophil chemoattractant CXCL8, and that blocking the TNF-α with a mAb would abrogate 
the effect. It was therefore necessary to show that monocytes can produce CXCL8 in response 
to sTNF-α and that a commercially available anti-TNF-α mAb could reduce this. Monocytes 
from 4 healthy subjects were stimulated in duplicate with increasing concentrations of 
exogenous sTNF-α for 24 hours and the concentration of CXCL8 measured by ELISA (figure 
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3.7a). No difference in CXCL8 concentration compared to unstimulated monocytes was 
observed until 1000 pg/ml of sTNF-α was used. 
It was necessary to determine if the TNF-α mAb used was inhibitory, i.e. its binding to sTNF-
α prevented sTNF-α from activating its receptors, rather than purely preventing its detection 
by a commercial ELISA and also to exclude any non-specific effect of an IgG1 antibody. 
Monocytes from 4 subjects were stimulated in duplicate with 100 pg/ml of sTNF-α alone, 
sTNF-α plus 10 µg/ml of TNF-α mAb (IgG1) or sTNF-α plus 10 µg/ml of IgG1 control 
isotype antibody (figure 3.7b). It was hypothesised that the presence of a TNF-α mAb would 
lead to a reduction in CXCL8 output by the monocytes compared to those stimulated with 
sTNF-α, whereas there would be no change in the presence of an irrelevant antibody. A trend 
was observed for CXCL8 concentration to reduce in the presence of the TNF-α mAb but this 
did not reach statistical significance. However, there was less CXCL8 in the presence of this 
mAb compared to the isotype control antibody (p=0.01) and no significant difference between 
the monocytes incubated with the control antibody and those stimulated with sTNF-α. From 
this it can be inferred that the isotype control antibody was having no clinically relevant effect 
on the interaction of sTNF-α with its receptors, whereas the TNF-α mAb was. 
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Figure 3-7 sTNF-α induces CXCL8 secretion by monocytes and a TNF-α mAb prevents 
this 
a) Monocytes were stimulated with an increasing concentration of sTNF-α for 24 hours.    
Individual subject data is shown with median values displayed as a bar. Friedman’s test 
p=0.01. Significant post hoc pairwise comparisons of stimulating sTNF-α concentrations to 0 
ng/ml sTNF-α are shown on the graph (unadjusted p-values were first corrected by 
multiplying by 4). b) Monocytes were stimulated with 100 pg/ml of sTNF-α, alone or in the 
presence of a TNF-α mAb or an isotype control Ab, for 24 hours. Individual subject data is 
shown with median values displayed as a bar. Friedman’s test p=0.02. Significant post hoc 
pairwise comparisons are shown on the graph (a Dunn-Bonferroni correction was applied to 
unadjusted p-values). 
 
3.2.10 Selecting an optimum concentration of TNF-α mAb 
In order to determine an estimate of the optimum concentration of the TNF-α mAb required to 
block sTNF-α produced by monocytes, an experiment was conducted in which 10 ng/ml of 
sTNF-α was added to each of 14 culture wells, containing 0.45 million monocytes per well, 
from one healthy control. 10 ng/ml was chosen as an appropriate concentration of sTNF-α to 
use as this exceeded the maximum concentration of sTNF-α detected in early validation 
experiments using LPS as a stimulant (approximately 8 ng/ml). Increasing concentrations of 
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the TNF-α mAb, ranging from 0 to 40 µg/ml had first been added to each well and the culture 
plate gently agitated prior to incubation for either 1 or 24 hours. At the end of these pre-
specified time periods, detectable sTNF-α was determined in the cell-free supernatants using 
ELISA. In this way it was possible to determine the concentration of the TNF-α mAb required 
to neutralise the effect of 10 ng/ml of sTNF-α. The time-points of 1 and 24 hours were chosen 
to show that binding of the TNF-α mAb is both rapid and remains in steady state. Figure 3.8 
illustrates that a concentration of 5 µg/ml of TNF-α mAb was sufficient to bind 98.2% of 10 
ng/ml of exogenous sTNF-α (plus any produced by the monocytes themselves). As the output 
of sTNF-α by monocytes from A1ATD-related COPD patients with the rs361525 
polymorphism was at this stage unknown this concentration was doubled to 10 µg/ml for use 
in future experiments. 
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Figure 3-8 Concentration of a TNF-α mAb required to prevent detection of 10 ng/ml of 
sTNF-α  
Each datum point represents the ability of each concentration of the TNF-α mAb to bind 10 
ng of sTNF-α, expressed as a percentage reduction in detectable sTNF-α by ELISA. Cell-free 
supernatants were removed from culture plates at 1 and 24 hours post incubation to illustrate 
that antigen-mAb binding occurs rapidly and remains in steady state. 
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3.2.11 Apoptosis of monocytes 
It was noted that some subjects’ monocytes when incubated for 6 or 24 hours were 
undergoing changes to their size and internal complexity, as shown by changes to forward and 
side scatter respectively. This is illustrated in figures 3.9 and 3.10, whereby freshly isolated 
monocytes appear as a discrete population (figure 3.9a) but after 20 hours of culture in the 
presence of LPS there appears to be two populations of cells (figure 3.10a), one occupying the 
same position as freshly isolated monocytes and the other much smaller. Some cells in both of 
these populations also had greater side scatter than freshly isolated monocytes. 
In order to determine if the population of monocytes which became smaller was undergoing 
apoptosis and hence should be gated out during further analysis of cell surface receptor 
expression (see chapter 5), the PE- Annexin V Apoptosis Detection Kit I (BD Biosciences, 
Oxford, UK) was employed, using monocytes from one healthy subject. Figure 3.9 illustrates 
a sample of freshly isolated unstained monocytes. Annexin V binding was observed in the 
majority of cells, suggesting possible early apoptosis even in freshly isolated monocytes. 
1.6% of monocytes were both Annexin V and 7-AAD positive, indicating late apoptosis/cell 
death. 
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Figure 3-9 The PE-Annexin V Apoptosis Detection Assay in freshly isolated monocytes 
a) Freshly isolated monocytes were gated as shown on the forward-side scatter plot. Doublet 
events were then excluded (not shown). b) Quadrant gates were set from unstained gated 
monocytes. c) The quadrant plot shows that the majority of monocytes were Annexin V 
positive. d) The black histogram represents autofluorescence of gated unstained monocytes 
and the pink histogram, monocytes labelled with PE-Annexin V. The shift in fluorescence to 
the right of the red marker indicates Annexin V binding. e) The black histogram represents 
autofluorescence of gated unstained monocytes and the pink histogram, monocytes incubated 
with 7-AAD. Minimal shift in fluorescence to the right of the marker was observed with only 
1.6% of monocytes staining positive for 7-AAD. 
 
Figure 3.10 shows monocytes which had been stimulated with LPS for 20 hours. When gated 
over the monocytes which remained in approximately the same position on the forward-side 
scatter plot as freshly isolated monocytes it was evident that again the majority of cells were 
Annexin V positive (with a similar MFI to that of freshly isolated monocytes). A minority of 
monocytes were also 7-AAD positive, indicating late apoptosis/cell death. 
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Figure 3-10 The PE-Annexin V Apoptosis Detection Assay in monocytes stimulated with 
LPS for 20 hours (one) 
a) Monocytes cultured for 20 hours with LPS were gated as shown on the forward-side scatter 
plot. Doublet events were then excluded (not shown). b) Quadrant gates were set from 
unstained gated monocytes. c) The quadrant plot shows that the majority of gated monocytes 
were Annexin V positive and 7.8% were Annexin V and 7-AAD positive. d) The black 
histogram represents autofluorescence of unstained monocytes and the pink histogram, 
monocytes labelled with PE-Annexin V. The shift in fluorescence to the right of the red 
marker indicates Annexin V binding. e) The black histogram represents autofluorescence of 
gated unstained monocytes and the pink histogram, monocytes incubated with 7-AAD. Low 
numbers of cells with varying degrees of fluorescence secondary to 7-AAD binding can be 
seen, to the right of the red marker (7.9% of monocytes 7-AAD positive). 
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Figure 3.11 shows the same monocytes stimulated with LPS for 20 hours, but gated over the 
population of cells lying to the left of the forward-side scatter plot. As many of the events in 
this area of the plot represent debris rather than cells, further gates were applied to exclude 
these non-cellular events, as described in the figure legend (gating advised by Mr Yoav 
Altman, director of the Flow Cytometry Shared Resource, Sanford Burnham Prebys Medical 
Discovery Institute, USA, direct communication, 13th November 2015). The majority of these 
monocytes were in late apoptosis and the fluorescence intensity of Annexin V positive cells 
was for most cells greater than in earlier examples. However, it should be noted that some 7-
AAD positive cells had a similar degree of Annexin V binding as freshly isolated monocytes, 
suggesting the Annexin V binding observed in freshly isolated cells may have been a genuine 
phenomenon, indicative of early apoptosis.  
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Figure 3-11 The PE-Annexin V Apoptosis Detection Assay in monocytes stimulated with 
LPS for 20 hours (two) 
a) Monocytes which had been cultured for 20 hours with LPS were gated as shown on the 
forward-side scatter plot. Doublet events were then excluded (not shown). b) Quadrant gates 
were set from unstained gated monocytes. c) A quadrant plot of the gated stained monocytes 
is shown. A further gate (R3) was placed around the double negative population d) R3 events 
are shown on a forward-side scatter plot. These events occupied a position on the plot 
consistent with debris (low forward and side scatter). These events were gated (R4) and 
excluded from further analysis. e) The final quadrant plot shows 68% of monocytes were 
Annexin V and 7-AAD positive and 30% Annexin V positive only f) The black histogram 
represents autofluorescence of gated unstained monocytes and the pink histogram monocytes 
labelled with PE-Annexin V. The shift in fluorescence to the right of the red marker indicates 
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Annexin V binding. f) The black histogram represents autofluorescence of gated unstained 
monocytes and the pink histogram monocytes incubated with 7-AAD. Most cells were 7-
AAD positive. 
 
As a positive control monocytes were induced to undergo apoptosis using camptothecin, an 
inhibitor of DNA replication and commonly used inducer of apoptosis (237) as advised by the 
assay manufacturers (236). Figure 3.12 shows that most of the monocytes had less forward 
scatter than freshly isolated monocytes, consistent with apoptosed cells and were all either 
Annexin V positive or Annexin V and 7-AAD positive, indicating early or late stage 
apoptosis respectively. Gating was conducted as decribed in figure 3.11. Only the salient 
figures are shown in this example. 
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Figure 3-12 The PE-Annexin V Apoptosis Detection Assay in monocytes incubated with 
camptothecin for 20 hours 
a) Monocytes which had been cultured for 20 hours with camptothecin were gated as shown 
on the forward-side scatter plot. Further gating was as described in figure 3.11. b) The 
quadrant plot shows 39% of monocytes were Annexin V and 7-AAD positive and 60% 
Annexin V positive only f) The black histogram represents autofluorescence of gated 
unstained monocytes and the pink histogram monocytes labelled with PE-Annexin V. The 
shift in fluorescence to the right of the red marker indicates Annexin V binding, with two 
populations evident). f) The black histogram represents autofluorescence of gated unstained 
monocytes and the pink histogram monocytes incubated with 7-AAD. The shift in 
fluorescence to the right of the red marker indicates a population of monocytes positive for 7-
AAD. 
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3.3 Discussion 
In the current study the CD14+CD16- purity of monocytes obtained from PBMC 
preparations, using the Dynabeads® Untouched™ Human Monocytes kit (Life Technologies 
Limited, Paisley, UK) varied between 64% and 74%. Product literature supplied by Life 
Technologies Limited states that purity is 94% but this is based purely on categorising 
isolated cells on the presence or absence of CD14 on the cell surface (242). In this respect, the 
isolates obtained in this study were between 89 and 95% pure, close to that specified by the 
commercial data. However, it is clear from data presented here that a percentage of cells 
obtained were also CD16+. This possibly reflects either that not all of the CD16+ cells were 
bound by the anti-CD16 mAbs in the isolation kit or antibody bound cells were not effectively 
cleared by the magnet separation step. The latter is less likely as final cell preparations had no 
brown discolouration visible to the naked eye, suggestive of magnetic bead contamination. It 
is unlikely that the cell preparations were contaminated with significant numbers of other cell 
types such as lymphocytes or CD16+ neutrophils, as the forward-side scatter plots of all 
isolated monocyte preparations showed one distinct population of cells (as illustrated in figure      
3.9). Hence it is most likely that the CD16+ cells were CD14+CD16+ monocytes. In one 
sense it is of no great concern that some CD14+CD16+ monocytes were included in the final 
cell preparations as this thesis aimed to study monocytes in general. However it must be borne 
in mind that it is likely that the two different monocyte subsets react differently to stimulants 
such as LPS or indeed TNF-α (243, 244), and the CD16+ monocytes may or may not have 
had anti-CD16 mAbs bound to them which could have caused inadvertent stimulation. 
Alternatively these findings could be explained by changes to CD14 and CD16 expression 
patterns during the extraction process. Skinner et al demonstrated in whole blood that the 
percentage of CD16+ monocytes doubled from 5 to 10% only two hours following LPS 
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stimulation and that TNF-α stimulation could also drive this change in monocyte phenotype 
(244). It is possible therefore that TNF-α secretion by the monocytes during the extraction 
process may have been causing up-regulation of CD16 and that this was being expressed at 
the cell surface after the negative isolation process had finished. In support of this theory it 
was observed that the CD16+ monocytes had similar intensity of expression of CD14 as that 
of the greater CD16– population, indicative of these cells being intermediate monocytes, with 
far less non-classical CD14– CD16+ non-classical monocytes. As monocyte subsets are 
thought to possibly progress from CD14+CD16– (classical) to CD14+CD16+ (intermediate) 
to CD14–CD16+ (non-classical) (204) it is possible that that process was being observed in 
the isolated monocytes in the current studies.  
Classical monocytes were studied in this thesis for a number of reasons. Firstly, this monocyte 
subset constitutes 90% of circulating monocytes (204) and hence a greater proportion of cells 
could be utilised from donated blood (of which only 10% of blood leukocytes are monocytes 
(196)). Secondly, whilst it is recognised that they may secrete less TNF-α than non-classical 
monocytes they are still able to produce TNF-α (204, 207, 243) (as demonstrated in the 
present experiments) and it was deemed important to isolate the cells using a negative 
selection technique that would ideally avoid inadvertent cell stimulation. An alternative 
method of isolation from whole blood or the Buffy coat layer, such as using a flow cytometry 
cell sorter, could be used in future, although this theoretically might lead to cell activation. 
This would permit study of all monocyte subsets together or separately. In addition each tube 
of cells could be run as a multi-colour experiment, whereby cells are labelled with CD14, 
CD16, CD64, TNFR1 and TNFR2 mAbs. This would allow assessment of TNF-α receptor 
status to be further considered in the context of monocyte subsets.  
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Other improvements to flow cytometry experiments should also be incorporated. A viability 
dye could be included as a marker in each tube to gate out dead cells from analysis, for 
example, 7-AAD. Dead cells are a particular problem as they may exhibit increased 
autofluorescence, reducing the sensitivity of each assay for low levels of cell surface marker 
expression, as gates are adjusted to compensate (245). In addition, multicolour experiments 
are subject to a risk of fluorescence spillover into individual channels as a result of combined 
fluorescence from multiple fluorophores and this is not corrected for by colour compensation 
corrections made when considering only pairs of fluorophores. Employing fluorescence-
minus-one controls, whereby control tubes contain all flow cytometry mAbs, except the mAb 
conjugated to one of the fluorophores, can be used to set more accurate gates and exclude 
events that are due to spillover into a particular channel (246, 247). This is repeated for each 
mAb-fluorophore conjugate used in the experiment. Lastly, some authors argue that 
quantitation beads may be a superior way of expressing cell surface marker numbers per cell 
than comparing MFI ratios (of the MFI of sample labelled with mAb of interest to the MFI of 
sample incubated with its isotype control) (246). Beads labelled with a known quantity of 
fluorophore molecules can be used to calibrate the flow cytometry machine on each run (to 
correct for day to day variation in laser performance for example) and can also be used as a 
standard to calculate and compare the numbers of cell surface markers between subjects and 
experimental conditions. This may be preferable to presenting MFI ratios as the latter relies 
on the assumption that the background level of unwanted Fc-receptor binding is equivalent 
between the specific mAb and its isotype control and that binding of both are affected equally 
by the experimental conditions imposed on the cells (247), which may not be the case. 
The present study confirmed that intra-assay variability of the TNF-α and CXCL8 ELISA 
assays agreed with that quoted by the manufacturers (R and D systems Ltd, Abingdon, UK) at 
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less than 10% (248). However, inter-assay variability of the two assays was slightly higher 
than 10% (table 3.2 and 3.3). Inter-assay variability is unavoidable to a degree as the reagents 
across ELISA kits for the same protein can vary slightly and even slight differences in timing 
of the ELISA stages can have a small effect. As this could have affected conclusions drawn 
regarding differences in TNF-α and CXCL8 output between monocytes from A1ATD-related 
COPD patients with and without the rs361525 polymorphism, in chapter 4 one CXCL8 
ELISA was conducted in which samples from LPS-stimulated monocytes at one time-point 
from all 18 patients with and without the polymorphism were run on the same plate. This 
showed no major difference in the conclusions drawn compared to results that had been 
obtained from a number of CXCL8 ELISA plates (see chapter 4). This issue could also be 
addressed in future studies by running the same low, medium and high standard on each 
ELISA plate and using this as a correction factor if needed. 
The intra-assay variability of the TNFR1 and TNFR2 ELISAs was higher in the current study 
than that quoted by the manufacturer (Invitrogen, UK) (249, 250), said to be between 1.7 and 
6.5% for TNFR1 and 2.1 and 3.7% for TNFR2. However, the intra-assay variability obtained 
for these assays was still 10% or less, in keeping with general ELISA performance and the 
TNF-α and CXCL8 assays studied here and so was deemed acceptable (table 3.2). The R2 
value for the regression equations for the TNF-α, CXCL8 and TNFR1 assays was 0.99 which 
is considered a good fit (251) and for the TNFR2 assay, close to this at 0.98.  
RNA from centrifuged cell pellets was isolated using the Isolate RNA Minikit (Bioline, UK). 
The kit is designed to allow isolation of highly pure RNA, uncontaminated with proteins or 
genomic DNA. Ideally the 260/280 ratio for RNA should be between 1.8 and 2. A ratio lower 
than this may due to contamination of the sample with residual reagents from the extraction 
protocol or due to low concentrations of RNA (less than 10 ng/µl of nucleotide). A ratio 
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higher than 2 is not indicative of a problem (252). The majority of samples obtained in this 
study (82%) had a 260/280 ratio of 1.8 or higher. In the current study a large number of 
experimental conditions had to be carried out using the monocytes isolated from each healthy 
subject or A1ATD patient and a considerable volume of blood was necessary to be able to do 
this (60 ml). The monocyte yield from blood samples is much less than that for other 
leukocytes such as neutrophils because they compromise a smaller proportion of the 
circulating leukocyte pool (196). Therefore a consequence of this limitation is that only 0.25 
million monocytes per culture plate well could be used for mRNA time course experiments 
and hence low final concentrations of total RNA were obtained for each sample (less than 10 
ng/µl of nucleotide). As described, this can lead to an erroneously low 260/280 ratio value. 
For this reason and because there was no clear pattern to samples where ratios were out of the 
desired range (i.e. samples run simultaneously using the same kit did not uniformly have low 
values suggestive of contamination) and because the majority of RNA samples had an 
acceptable 260/280 ratio of greater than 1.8, all RNA samples were included in ongoing RT-
qPCR experiments. To support the assertion that some 260/280 ratios were erroneously low 
rather than because of poor quality it should be noted that the direction of results for mRNA 
expression in chapter 4 matched those of the protein expression obtained by ELISA. 
The CV% values for intra-assay and inter-assay variability of the three most frequently 
studied genes undergoing RT-qPCR were acceptable, having a CT standard deviation value of 
less than or equal to 0.3 in all (table 3.5). Some authors suggest it is preferable to express 
inter-assay variability as a CV% of actual DNA copy number generated for one sample across 
multiple runs (253). This is because CT values will always be subject to a small but 
unavoidable variability between runs whereas differences in copy number of amplicon will 
reflect true inter-assay variability. This technique was not possible in the current studies as 
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use of a DNA amplicon to generate a standard curve for each plate requires preparation of the 
samples under a specialised PCR hood (not available) to prevent inadvertent release of DNA 
template into the laboratory which could contaminate future PCR reactions as they are being 
set up. Despite this, the SDs of the mean CT values across multiple plates for the three sample 
genes were all 0.3 or less and thus deemed acceptable (240). 
A key principle of the relative quantification method is that it relies on the TaqMan® assay 
for both the normalising gene and the gene of interest having equal efficiencies. Efficiency 
refers to the ability of the primer, probe, other PCR reaction components and the PCR thermal 
cycler to allow a doubling in quantity of the DNA template with each thermal cycle. When 
this occurs efficiency is 100%. Differences in efficiency between the assays for the 
normalising gene and gene of interest would introduce error into the relative quantification 
calculation at higher CT values (253). Efficiency can be determined for each assay by 
producing serial dilutions of a chosen sample (5 to 6 log dilution ideally) and then plotting the 
log cDNA concentration against acquired CT values. An expected slope for a dilution series 
of template cDNA is –3.32 if the efficiency is equal to 100%. The major limitation of 
conducting efficiency experiments occurs when the starting copy number of mRNA for the 
studied genes is low, for example as in this study whereby extracted RNA concentration was 
necessarily low due to limits on the number of monocytes which could be isolated from each 
subject. This makes even a 1 to 2 log dilution series difficult and it has been shown that 
without a broad range of concentrations of cDNA, starting with a high concentration, then 
efficiency calculations are extremely inaccurate (253). To this end, the manufacturer of 
TaqMan® assays specifically recommend not testing the efficiencies of their assays as this 
has been conducted extensively in-house and all are stated to have efficiencies close to 100%. 
Of course, it is possible to amplify a cDNA sample generated from a previous RT-qPCR 
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reaction in order to produce enough cDNA to generate a 5 to 6 log series dilution, but this 
carries with it the significant risk of contaminating the laboratory with completed PCR 
product. Therefore, in the current study, equal and near 100% efficiency of all assays was 
assumed and efficiency testing was not carried out. However, it must be noted that the 
example PCR amplification curves shown in figure 2.5 to 2.11 illustrate that although curve 
shape was consistent within assays, the TNF-α, IL-6 and GAPDH PCR curves were shallower 
in comparison to the other assays, suggesting reduced efficiency of the reaction, and did not 
reach plateau phase. Possible reasons for reduced efficiency, real or apparent, include 
differences in fluorescence intensity of different fluorophores (apparent), primer-dimerisation 
when target sequence concentration is low, amplicon length greater than 100 bp possibly 
reducing the likelihood of doubling each cycle, or inadequate concentration of reagents in the 
sample (228). In the current experiments the same fluorophore, FITC, was used for all assays. 
Primer-dimerisation or inadequate reagent concentration are unlikely as other assays, for 
example, IL-6 and IL-10, routinely had later CT values and yet produced classic sigmoidal 
shaped amplification curves. The amplicon length for GAPDH was 122 bp which may have 
adversely affected efficiency but TNF-α amplicon length was only 80 bp. Whilst a simple 
explanation for the disparity in amplification curve shape between assays is not apparent it 
must be considered that there may have been differences in PCR efficiency between assays. 
Non-template controls for each of the assays used were run on each plate. The non-template 
control contained PCR-grade water as a replacement for an RNA sample. These wells 
sometimes produced a CT value of between 35 and 40. A positive non-template control 
suggests possible contamination by and amplification of previous PCR product which has 
been aerosolised into the laboratory. It is likely however that these results are erroneous as 
firstly CT values of 35 and above are at the very limits of the sensitivity of the thermal cycler 
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and hence are suspect (253) and secondly in many cases the shape of the PCR curve was not 
in keeping with a genuine result. Even in the scenario of possible contamination such low 
levels of expression (these CT values are likely to reflect only one to two copies of a gene) are 
unlikely to affect validity of results obtained from other samples where the gene was 
expressed at much higher levels. As such, PCR plates containing positive non-template 
controls with CT values of 35 or above were not rejected. 
It should be highlighted that the GAPDH TaqMan® assay, despite being labelled as spanning 
an exon-exon boundary (denoted by the suffix m1), does in fact sit within an exon of the 
GAPDH gene. (Data regarding assays changes from time to time as more details regarding the 
genome are obtained -clarified via direct communication with Life Technologies, April 10th 
2014). This increases the risk that should any genomic DNA be present in an RNA sample, 
which is unlikely with the RNA extraction kit used in the current study, then it could be 
amplified by the assay during the PCR reaction. This is unlikely to have occurred however as 
table 3.4 details the stability of GAPDH across a wide range of samples, which would have 
been adversely affected should a number of samples have been contaminated with genomic 
DNA containing extra GAPDH. 
Several potential stimulants of TNF-α secretion by monocytes were selected for initial time 
course and concentration-response experiments. IL-1β is an early phase cytokine which 
stimulates the transcription of inflammatory cytokines including TNF-α within monocytes and 
macrophages in COPD (79). MCP-1 is a principally a monocyte chemo-attractant but was 
used here in stimulation experiments to determine if it also has a role in up-regulation of 
TNF-α production (79). LPS is a component of the cell membrane of gram-negative bacteria 
which when bound to the serum factor, LPS binding protein (254), is able to bind to CD14 
(255) on the monocyte/macrophage cell surface and activate toll-like receptor 4 (TLR4), 
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leading to activation of multiple transcription factors and subsequent transcription of pro-
inflammatory genes including the TNF-A gene (256).  The endotoxin is internalised by the 
monocyte/macrophage within 5 minutes (257).  
Whilst most of the transcription factors up-regulated by LPS act at the proximal TNF-A 
promoter (144) studies have demonstrated binding of NFκB members, particularly p65, up-
regulated by LPS, to the distal portion of the promoter where the rs361525 polymorphism lies 
(152, 153, 258) and other authors have shown that LPS can up-regulate reporter gene 
expression in macrophage cell lines expressing the A-allele at position -237 (128). These 
reports support the use of LPS as a stimulant in the current studies. LPS is also a component 
of cigarette smoke, making it a relevant stimulant in COPD subjects (259, 260). 
Although limits to the number of monocytes which could be extracted per individual 
precluded direct comparison, the results of these time course and concentration-response 
experiments suggested that LPS induced the most TNF-α secretion (figure 3.2), with MCP-1 
inducing no response. It was noted that the intersubject variation in TNF-α secretion was 
wide, in keeping with previous studies (261, 262). In order to maximise the possibility of 
seeing a difference in TNF-α secretion by monocytes between A1ATD-related COPD patients 
with and without the rs361525 polymorphism, LPS was therefore selected as the most 
appropriate stimulant to use in ongoing experiments. As the exact properties of LPS are 
known to vary considerably between type and strain of mutant bacteria (255), one batch of 
LPS, reconstituted and divided into aliquots, was used throughout the current study. Deciding 
upon the concentration of LPS was a more challenging decision as it is unclear what the local 
concentrations of inhaled LPS at the lung mucosal surface might be in smokers and hence the 
concentration that monocytes/macrophages are exposed to. LPS is implicated in the 
pathogenesis of COPD and is frequently used in models of lung inflammation (241, 263). 
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Korsgren et al showed that inhaled LPS at a dose of 5 µg and 50 µg elicited a marked increase 
in induced sputum TNF-α concentration and neutrophil cell activity (260). Hasday et al 
demonstrated that the tobacco and filter tip components of light cigarettes contained on 
average 27 µg and 0.7 µg of LPS respectively. The mainstream and side stream smoke 
produced upon mechanical smoking of these cigarettes contained 45 ng and 75 ng of LPS per 
cigarette with an estimated 2400 ng delivered to the lungs after smoking one pack. The 
authors also measured the concentration of circulating LPS in 15 healthy smokers and 16 age-
matched non-smoking controls and found no statistically significant difference in serum 
concentration. Serum concentrations were much lower than that found in inhaled cigarette 
smoke, at approximately 67 pg/ml in each group (259). Even in patients with septic shock, 
circulating LPS concentrations have been found to be only 300 pg/ml on average (264). 
Hence it would seem that the burden of inhaled LPS as a result of cigarette smoking, 
occupational exposure (e.g. cotton textile workers) or even domestic exposure from dust and 
pets is largely dealt with by mechanisms within the lungs (241) and it is probable that 
monocytes/macrophages with their abundance of CD14 expression contribute significantly to 
this. It remains challenging to accurately estimate the concentration of LPS that patrolling 
macrophages in the airways and alveoli of the lung may be exposed to. However it can be 
surmised that it is likely to be higher than that found in the serum. It was decided therefore to 
use 100 ng/ml in further experiments with monocytes as this was shown in the current studies 
to elicit greater TNF-α secretion than 10 ng/ml, whilst not using higher concentrations that 
were unlikely to reflect those present during pathological insults.  
However, in retrospect it may have been preferable to have used the EC80% (effective 
concentration of LPS that elicits 80% of the maximum response) as this would allow one to 
observe TNF-α output on the linear part of a sigmoidal concentration response curve rather 
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than at plateau as occurs with a maximum concentration of stimulant. This is potentially 
important when interpreting experiments presented in chapter 4. If the position of the linear 
phase of a sigmoidal concentration response curve for AG monocytes lies to the left of that of 
GG monocytes they would produce more TNF-α at lower concentrations of stimulant and a 
difference between the two groups would be seen. By using higher concentrations of LPS it is 
possible that any differences between the AG and GG monocytes would have been missed as 
both may have reached (the same) plateau at 100 ng/ml of LPS. However, even using the 
average EC80% is subject to limitations. Specifically, when the LPS concentration-response 
curve (shown in figure 3.3) was considered as individual curves for each of the eight subjects 
(not shown) there was considerable variation in EC80% and ECmax between subjects. 
Therefore, the mean/median EC80% may not actually be the concentration that elicits 80% of 
the maximum response for some subjects’ monocytes. 
This early validation work demonstrated that peak sTNF-α concentration in the cell culture 
supernatant occurred at approximately 8 hours post stimulation with LPS, decreasing 
thereafter (figure 3.2b). It was hypothesised that the decrease in detectable sTNF-α may be 
due to autocrine binding of sTNF-α to its receptors and this was subsequently investigated in 
chapter 5. CXCL8 concentration continued to rise up to 24 hours post LPS stimulation despite 
the latter experiment having been conducted in monocytes rested overnight, which had lost 
their ability to produce TNF-α (figure 3.4). The production of low concentrations of sTNF-α 
by freshly isolated unstimulated monocytes (figure 3.2a) may have been due to a degree of 
activation of the monocytes as a result of their adherence to the culture plate (265).  
From these studies it was determined that cell culture supernatants from monocytes from 
A1ATD-related COPD patients would need to be harvested at approximately 6 to 8 hours and 
at 24 hours post isolation and stimulation to capture maximum sTNF-α and CXCL8 output 
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respectively. It should be noted however that choosing these peak-time points relies upon the 
assumption that time course profiles in monocytes from healthy subjects match those of 
monocytes from A1ATD-related COPD subjects with and without the rs361525 
polymorphism. If they differ then comparing individual time-points could lead to erroneous 
conclusions regarding differences in sTNF-α output by both groups. For this reason full time 
course profiles of both mRNA expression and protein concentration may have been preferable 
(although difficult to practically carry out due to time limitations), with data expressed as 
differences between AUC values. Conversely, AUC calculations are subject to potential error 
as they rely on the inclusion of enough time-points to generate accurate shaped curves. This 
issue is discussed further in chapter 4. 
It must be noted that the apoptosis assay confirmed that some monocytes were undergoing 
apoptosis by 20 hours which may have partly contributed to the reduction in TNF-α secretion 
observed in rested cells (figure 3.4a). Another contributing factor may be that the low level of 
sTNF-α secreted by freshly isolated monocytes in the absence of any stimulant may have 
directly or indirectly exerted a negative feedback effect on the monocytes, preventing 
subsequent sTNF-α secretion in response to LPS, as has been observed in LPS-treated mice 
pre-treated with low concentrations of TNF-α (266). Alternatively, the reduction in response 
may reflect changes to the expression of CD14 and/or TLR4 on the monocyte surface as a 
consequence of overnight incubation in CM without an exogenous stimulus. As CD14 and 
TLR4 form the receptor for LPS (255, 256) any down-regulation of receptors would decrease 
the cellular response to LPS. In keeping with this, Gantner et al demonstrated CD14 
decreased on the surface of monocytes when cultured in human serum for 6 days and that 
twenty times higher concentrations of LPS were required to stimulate TNF-α secretion than in 
freshly isolated monocytes (267).Whilst not directly comparable, for example monocytes in 
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the current studies were incubated with CM containing FBS rather than human serum and 
overnight rather than for six days, these data suggest that changes to CD14 might be occurring 
overnight prior to the addition of LPS. Furthermore, Tsai et al demonstrated that TNF-α can 
down-regulate TLR4 on the surface of human monocytic THP-1 cells (268) and as freshly 
isolated monocytes have been shown here to produce TNF-α in the absence of an exogenous 
stimulus (figure 3.2a) it is possible that this TNF-α was down-regulating TLR4 expression on 
the monocyte surface and hence abrogating the response to LPS the following day. 
Although it was not possible to know the range of concentrations of sTNF-α that would be 
observed in the patient group a suitable concentration of blocking TNF-α mAb was estimated 
from the current studies. The nature of the function of the mAbs used in this thesis and 
subsequent limitations are discussed in full in chapter 5. The experiment presented in figure 
3.7b, whereby the blocking effect of the TNF-α mAb was studied could be improved in future 
by repeating it with a greater number of samples and a negative control well measuring 
CXCL8 secretion in monocytes cultured without any sTNF-α present. This would determine 
whether the addition of the TNF-α mAb prevented all sTNF-α induced CXCL8 secretion, 
back to baseline levels. 
It was necessary to take a pragmatic approach when deciding upon the number of replicate 
culture wells for each experimental condition/time-point to conduct as there was no evidence 
to suggest that using greater than three replicates reduced variation. It is evident from the data 
shown in figure 3.6 that even when using three replicates the results for some individuals 
produced CV% of greater than 9%. It is clear that intrasubject variation can be significant 
even when suspensions of monocytes are inverted several times prior to pipetting equally 
among culture wells, the same concentration of stimulant is employed and the results are 
analysed using the same ELISA assay. Althought suspensions of monocytes were inverted 
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gently to allow equal distribution of cells throughout the CM it is possible that small air 
bubbles in the suspension may have affected final cell numbers in wells of the culture plates 
and this may have contributed to the CV% values observed. How variation between 
experimental replicates might be affected by different stimulants or when considering the 
measurement of cytokines other than TNF-α was not considered here. 
The final studies in this chapter addressed the issue of the changing morphology of the 
isolated monocytes over time, as observed by the change in the forward-side scatter flow 
cytometry plots of the cultured cells compared to those of freshly isolated monocytes. This 
was confirmed to be due to apoptosis of a proportion of the monocytes. It is well recognised 
that monocytes cultured in the absence of serum will undergo apoptosis and that pro-stimulant 
factors such as LPS or TNF-α can induce resistance to programmed cell death (269, 270). 
Despite the presence of serum, LPS and TNF-α in the current experiments, apoptosis still 
occurred to an extent and  it was important to recognise this in order to identify viable cells at 
later time-points for gating purposes. Many cells which stayed approximately the same 
diameter never-the-less displayed increased side-scatter reflective of increased granularity and 
intra-cellular complexity. This may reflect monocytes which were beginning the process of 
differentiating into macrophages (271). 
Surprisingly, Annexin V binding was also observed in freshly isolated monocytes from the 
healthy donor. This may reflect early apoptosis occurring as a result of the extraction process 
and cell handling, despite efforts to minimise cellular activation by keeping the cells on ice 
between steps of the protocol. In support of these findings reflecting genuine early apoptosis 
was the observation that in camptothecin treated 7-AAD positive monocytes the extent of co-
existent Annexin V binding (as expressed by fluorescence intensity) varied considerably. 
Some of the monocytes in this late apoptotic state had similar low degrees of Annexin V 
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binding as that observed in freshly isolated monocytes and yet must have been in apoptosis 
given they were also 7-AAD positive. Similarly, low level Annexin V binding is unlikely to 
be completely explained by possible exposure of PS on the cell surface as a result of removal 
of adherent cells as it was observed in freshly isolated monocytes in suspension as well as 
adherent stimulated monocytes. Whilst Accutase® solution (Sigma-Aldrich Chemicals Ltd, 
Poole, UK) was recommended in the apoptosis assay protocol (236) to gently remove 
adherent cells prior to addition of Annexin V it remains a possibility that de-adherence may 
lead to PS exposure on the cell surface.  
It also remains possible that some of the Annexin V binding may have been non-specific 
(although not via Fc receptor binding as Annexin V is not an antibody). To control for this in 
future a number of experimental modifications could be made. Firstly, as Annexin V binding 
is calcium dependent a control tube with the addition of EDTA to sequester calcium ions, as 
has been described previously (272) could be added. Any Annexin V binding observed in this 
tube would be consistent with non-specific binding (direct communication with Mr Yoav 
Altman, director of the Flow Cytometry Shared Resource, USA, 13th November 2015). 
Secondly, although the assay protocol used in the current experiments did not include a 
washing step, this could be added between the addition of Annexin V and then 7-AAD, using 
the binding buffer to wash (direct communication with Mrs. A. Berasategi, BD Biosciences 
Scientific Support Europe, 12th November 2015). However, non-specific binding, should it 
occur, may not necessarily be affected by washing the cells.  
Conversely, the relative lack of freshly isolated monocytes undergoing late stage apoptosis 
goes against the hypothesis that these monocytes were all undergoing early apoptosis as one 
might expect some of the cells to be in a later stage of the apoptotic process at the point of 
performing the assay. Interestingly, Appelt et al reported that PS is expressed on the surface 
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of non-apoptotic monocytes leading to Annexin V binding, both immediately after isolation 
and after 24 hours of culture and that the degree of Annexin V binding was one to two orders 
of magnitude lower than that on monocytes induced to undergo apoptosis (272). They 
confirmed the viability of those monocytes by determing the absence of caspase activity, the 
presence of an intact mitochondrial membrane potential and lack of nuclear morphological 
changes. These findings would suggest that at least some of the Annexin binding observed in 
freshly isolated monocytes in particular was due to the presence of PS on the cell surface 
membrane in intact viable cells. 
Alternative methods of assessing if apoptosis was occurring in freshly isolated monocytes 
should also be used in future, for example, staining cells with acridine orange and ethidium 
bromide, followed by fluorescence microscopy, as has been previously used in monocytes 
(273). Live cells are shown by the uptake of acridine orange (green fluorescence) and 
exclusion of ethidium bromide (red fluorescence). Apoptotic cells can be discriminated from 
necrotic cells by the perinuclear condensation of chromatin stained by ethidium bromide in 
the former or the generalised cell staining with ethidium bromide in the latter (273). 
3.4 Conclusions 
This chapter has described the initial experiments undertaken in order to optimise studies 
conducted in chapter 4. Validation results of the various assays and experimental techniques 
used throughout the thesis have also been described and any limitations of and challenges 
arising from these techniques addressed. 
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CHAPTER  4 
THE EFFECTS OF THE RS361525 TNF-A 
POLYMORPHISM IN PATIENTS WITH 
A1ATD AND COPD 
 
 
 
 
 
 
 
 
 
 
 
 
 
140 
 
4 The effects of the rs361525 TNF-A polymorphism in patients with A1ATD and 
COPD 
4.1 Brief Introduction 
Previous work from our research group has shown that the presence of the rs361525 
polymorphism, a G to A substitution at position -237 in the promoter region of the TNF-A 
gene, conferred an increased relative risk of having CB, a specific phenotype of COPD, in 
patients with A1ATD (125). In addition, sputum from A1ATD patients with CB and the 
polymorphism (AG heterozygotes) had one hundred times greater TNF-α concentration 
compared to those with the wild type gene (GG homozyogotes) (17), suggesting that presence 
of the polymorphism leads to increased local production of the protein, most likely through 
increased gene transcription given its location in the promoter region. Their sputum also 
contained more CXCL8, suggesting the greater concentration of free TNF-α was exerting an 
exaggerated pro-inflammatory effect on CXCL8 producing cells found in the airway. The 
sputum contained approximately 50% less soluble TNFR1 (although no difference in 
concentration of TNFR1 in the plasma was seen), the reason for which is unknown in the 
context of this polymorphism, but theoretically might relate to a reduction in TNFR1 cleavage 
from cell surfaces by TACE or reduction in receptor production, as a result of greater TNF-α 
in the pericellular environment. If the former were the case this could potentially enhance the 
pro-inflammatory phenotype of the cells from rs361525 subjects even further, as illustrated by 
the uncommon inherited TNF-receptor associated periodic febrile syndrome, in which 
sufferers have excess TNFR1 on the cell surface, thereby making them more susceptible to 
TNF-α-TNFR1 mediated effects (274). 
As Sapey et al found that patients with the polymorphism had a lower BMI (17), suggesting 
that increased TNF-α production was associated with a systemic effect (as observed in other 
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studies (98, 99, 108)), it was concluded that there was a strong rationale for initially studying 
the polymorphism further at a cellular level in blood-derived cells rather than airway derived 
cells. Monocytes as the principal producers of TNF-α (3) and cells which are relatively simple 
to isolate were therefore chosen for study in the first instance.  
Based upon these findings the primary hypotheses of this chapter were: 
Hypothesis one: monocytes from A1ATD patients with COPD and the rs361525 TNF-A 
polymorphism would produce more TNF-α than monocytes from matched A1ATD patients 
with COPD and the wildtype allele. 
Hypothesis two: secreted TNF-α would lead to autocrine up-regulation of pro-inflammatory 
cytokine production and the effects of this would be greater in monocytes with the rs361525 
TNF-A polymorphism as a result of there being more TNF-α secreted into the pericellular 
environment. 
The secondary hypotheses in this chapter were planned to be investigated should the primary 
hypothesis be met and were as follows: 
Hypothesis three: Greater TNF-α production in monocytes with the rs361525 TNF-A 
polymorphism would exert a greater autocrine effect on the monocytes, leading to increased 
pro-inflammatory cytokine output occurring specifically via TNF-α binding to TNFR1.  
Hypothesis four: Increased TNF-α production in the rs361525 monocytes would have an 
autocrine effect on the monocytes affecting other monocyte functions such as ROS production 
and phagocytotic ability (in an unknown direction). 
To investigate the primary hypotheses, the following objectives and strategies to meet those 
objectives were set: 
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 Determine if TNF-α production was greater in monocytes from subjects with A1ATD-
related COPD with the rs361525 polymorphism than in monocytes from matched 
subjects with the wild type gene. This was conducted by using LPS and PMA (or no 
exogenous stimulus) to stimulate TNF-α production and then measuring cytokine 
mRNA expression with RT-qPCR and secreted protein by ELISA. 
 Determine if CXCL8 production was greater in monocytes from subjects with 
A1ATD-related COPD with the rs361525 polymorphism than in monocytes from 
matched subjects with the wild type gene, presumed to be as a result of an enhanced 
TNF-α autocrine feedback loop. This was conducted by using LPS and PMA (or no 
exogenous stimulus) to stimulate TNF-α production and then measuring CXCL8 
mRNA expression with RT-qPCR and secreted protein by ELISA. 
 Determine if the production of CXCL8 was affected by TNF-α autocrine feedback 
loops. This was conducted by using LPS to stimulate TNF-α production, in the 
presence or absence of a TNF-α mAb and then measuring CXCL8 mRNA expression 
with RT-qPCR and secreted protein by ELISA. 
0.45 million cells per ml of CM were used for culture experiments (in triplicate) where cell-
free supernatants were to be collected to measure protein concentration by ELISA. All RNA 
experiments at the culture stage were conducted singly (as a large number of time-points for 
each experimental condition was examined this precluded duplication due to limits to cell 
numbers available) and using 0.25 million cells per ml of CM. Messenger RNA samples from 
each experimental condition underwent RT-qPCR in duplicate and the mean result was taken. 
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4.2 Subject characteristics 
Table 4.1 shows the characteristics of the 18 A1ATD subjects included in the studies for this 
chapter. Patients were matched as closely as possible based upon: presence of COPD, age, 
FEV1, transfer coefficient of carbon monoxide (KCO) and gender. Other clinical 
characteristics were compared after the matching process had taken place. Data from mRNA 
experiments in only eight subjects in each group could be used due to a technical issue 
affecting RNA extraction for one subject’s samples, hence that pair was removed. No 
significant differences were observed between groups, before and after removal of one pair’s 
data. One subject in the rs361525 group was homozygous for the A allele (AA). Hereafter, the 
groups are referred to as AG and GG. All patients with COPD were studied rather than just 
those with CB as although the minor allele was expressed at a clinical level in CB subjects 
(125) (possibly suggesting specific CB-related stimuli are important in-vivo) it was 
hypothesised that the rs361525 polymorphism would exert a pro-TNF-α effect at an 
individual cell level in monocytes from all A1ATD/COPD subjects. This permitted a greater 
number of subjects from our cohort of patients to partake in the studies.  
Blood samples from all patients in our A1ATD cohort had previously undergone genotyping. 
This was carried out using a TaqMan® SNP genotyping assay (Life Technologies, UK) on an 
ABI7900 HT PCR machine. The assay included two allele-specific TaqMan® MGB probes 
conjugated to different fluorescent dyes and a PCR primer pair to detect the SNP targets (the 
A allele and the more common G allele). The plates included appropriate negative controls. 
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  Characteristic rs361525 +ve 
(AG/AA)  
   
rs361525 -ve 
(GG)  
   
P value  
N  9 
(8 AG/1 AA) 
9  
Presence of COPD  9/9 9/9  
Age in years  51 (50-65) 60 (49-61) 0.8 
Male  7 (77.8%) 7 (77.8%)  
A1ATD level (µM)  3.6 (2.9-4.6) 4 (2.8-4.9) 0.9 
BMI  21.2 (21.0-
23.8) 
23.2 (22.0-
26.0) 
0.3 
Smoking hx  Current  1 0  
Ex/never  7/1 8/1  
Pack years  22 (10-28) 22 (9-30) 0.9 
FEV1 (L) 1.5 (1.2-1.7) 1.4 (1.0-1.7) 0.3 
FEV1 % predicted  37.7 (33.4-
43.4) 
33.6 (32.6-
54.6) 
0.9 
FEV1/FVC  32.0 (28.0-
34.0) 
32.2 (23.0-
33.0) 
0.5 
KCO % predicted  52 (44-58) 56 (50-64) 1.0 
Emphysema on HRCT  8/9 9/9  
CB phenotype  4/9 5/9  
Bronchiectasis on HRCT  4/9 5/9  
Inhaled steroids  8/9 9/9  
Average of median exacerbations per 
year per patient 
1.0 (1.0-2.0) 0.5 (0-1.0) 0.3 
 
Table 4-1 Characteristics of study subjects 
The table shows key characteristics of subjects with (AG/AA) and without (GG) the rs361525 
TNF-A polymorphism. Subjects were matched as closely as possible. Data is given as median 
(IQR). A Mann Whitney U test was used to detect any difference between groups.  
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4.3 Results 
4.3.1 TNF-α mRNA expression and protein secretion is not increased by the presence 
of the rs361525 TNF-A polymorphism 
Messenger RNA was extracted from the cell pellets of monocytes freshly isolated from AG 
and GG subjects. Figure 4.1 demonstrates that there was no significant difference in 
constitutive TNF-α mRNA expression observed between the subject groups, although there 
was a trend for greater expression in the AG group. Culture experiments were conducted 
singly for mRNA measurement and in triplicate for protein measurement. 
A
G
G
G
0 .0 0 0
0 .0 0 5
0 .0 1 0
0 .0 1 5
0 .0 2 0

C
T
n = 8
S u b je c t g e n o typ e
 
Figure 4-1 Baseline expression of TNF-α mRNA in unstimulated monocytes from 
patients with and without the rs361525 TNF-A polymorphism 
TNF-α mRNA expression in freshly isolated monocytes from AG and GG subjects is shown. 
Individual data points for each subject are illustrated with median displayed as a horizontal 
line. Differences between subject groups were assessed with a Mann Whitney U test. No 
significant difference was observed. 
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Monocytes were also cultured for increasing time periods over 24 hours, unstimulated or 
stimulated with 100 ng/ml of LPS. TNF-α mRNA expression is displayed as time course 
curves as multiple time-points were measured. However, it should be noted that all AUC 
calculations in this chapter were restricted to data from time 0 to 6 hours. This was done due 
to the long gap between the last two time-points (6 hours and 24 hours), meaning that the 
shape of curves beyond 6 hours should be interpreted with some caution. Figure 4.2 shows 
that in monocytes cultured in the absence of an exogenous stimulus there was no difference in 
TNF-α mRNA expression or protein concentration between the two groups. The median AUC 
for AG monocytes was 5.87 ΔCT.hours (range 1.41 to 18.0) versus 4.16 ΔCT.hours (range 
2.26 to 11.27) in GG monocytes. 
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Figure 4-2 TNF-α mRNA and protein production by unstimulated monocytes from 
patients with and without the rs361525 TNF-A polymorphism 
a) A time course curve is shown of TNF-α mRNA expression over 24 hours. Data points are 
shown as median and range values. No significant difference in AUC (calculated from data up 
to the 6 hour time-point only) between groups was observed. The concentration of TNF-α in 
the CM was measured at 6 hours (b) and 24 hours (c). Individual data points for each subject 
are illustrated with the median displayed as horizontal lines. No significant difference in TNF-
α concentration was observed. Data tested with a Mann Whitney U test. 
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Figure 4.3 illustrates that in monocytes stimulated with LPS there was no significant 
difference in TNF-α mRNA expression between groups. The median AUC (calculated up to 6 
hours post stimulation) for AG monocytes was 13.97 ΔCT.hours (range 4.14 to 20.81) versus 
12.71 ΔCT.hours (range 6.48 to 29.64) in GG monocytes. However it should be highlighted 
here that there was a divergence in the shape of the time course curves for both groups at 6 
hours (and to a lesser extent within the unstimulated monocytes in figure 4.2), with the AG 
monocyte TNF-α mRNA expression time course having reached plateau and decreased back 
towards baseline by 6 hours whereas GG monocyte TNF-α mRNA expression had not reached 
plateau by 6 hours post stimulation. The shape of the curve suggests that GG monocyte TNF-
α mRNA expression may have actually been greater than AG monocyte TNF-α mRNA 
expression, the opposite of the findings observed in the sputum (17), but cannot prove this 
given the need for further time-points between 6 and 24 hours. In keeping with this figure 
4.3c showed that TNF-α concentration in the CM was greater in the GG group at 24 hours 
with a trend for it also to be higher at 6 hours (p=0.07) (figure 4.3b). 
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Figure 4-3 TNF-α mRNA and protein production by LPS-stimulated monocytes from 
patients with and without the rs361525 TNF-A polymorphism 
a) A time course curve is shown of TNF-α mRNA expression over 24 hours. Data points are 
shown as median and range values. No significant difference in AUC (calculated from data up 
to the 6 hour time-point only) between groups was observed. The concentration of TNF-α in 
the CM was measured at 6 hours (b) and 24 hours (c). Individual data points for each subject 
are illustrated with the median displayed as horizontal lines. A higher concentration of TNF-α 
was observed in the GG group at 24 hours. Data tested with a Mann Whitney U test. 
 
In all subjects there was a small excess of monocytes for the number of planned experiments. 
Therefore, monocytes were also stimulated for 6 and 24 hours with 3 ng/ml of the potent 
stimulant PMA. PMA is an activator of protein kinase C and hence of NF-κB which will 
induce TNF-α gene transcription (275). Whilst full time course and concentration response 
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profiles of TNF-α mRNA expression and protein secretion for PMA had not been performed 
in preliminary experiments it was deemed worthwhile to use a second known inducer of TNF-
α, at a concentration known to induce production. Figure 4.4 shows that at 6 and 24 hours post 
stimulation there was no statistically significant difference in TNF-α mRNA expression or 
protein concentration between AG and GG subjects, although there were trends for production 
to be greater in the GG monocytes. 
 
 
Figure 4-4 TNF-α mRNA and protein production by PMA-stimulated monocytes from 
patients with and without the rs361525 TNF-A polymorphism 
Individual data points for each subject are illustrated with the median displayed as horizontal 
lines. TNF-α mRNA expression is shown at 6 hours (a) and 24 hours (b) post stimulation with 
PMA. TNF-α concentration in the CM is shown at 6 hours (c) and 24 hours (d) post 
stimulation with 3 ng/ml of PMA. No significant differences were observed between AG and 
GG groups. Data tested with a Mann Whitney U test. 
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4.3.2 CXCL8 mRNA expression and protein secretion is not increased by the presence 
of the rs361525 TNF-A polymorphism 
Sapey et al demonstrated a 20 times greater concentration of CXCL8 in the sputum of 
A1ATD-related COPD patients with the rs361525 polymorphism, likely as a result of more 
free TNF-α acting on local cells in the airway, such as epithelial cells and macrophages, to up-
regulate production of the chemokine (17). It was hypothesised that this would also be 
observed in the monocytes from AG subjects and that this would be as result of greater TNF-α 
autocrine feedback up-regulating CXCL8 production. 
In freshly isolated monocytes there was no difference in CXCL8 mRNA expression between 
the two groups, although there was a trend for greater CXCL8 expression in the AG group 
(figure 4.5).  
 
Figure 4-5 Baseline expression of CXCL8 mRNA in unstimulated monocytes from 
patients with and without the rs361525 TNF-A polymorphism 
CXCL8 mRNA expression in freshly isolated monocytes from AG and GG subjects is shown. 
Individual data points for each subject are illustrated with median values displayed as 
horizontal lines. No significant difference in CXCL8 mRNA expression was observed, 
assessed with a Mann Whitney U test. 
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In unstimulated monocytes no significant differences in CXCL8 output at mRNA or protein 
level were observed between the two groups over time (figure 4.6). However, there was a 
trend for CXCL8 mRNA expression as measured by AUC to be greater in the GG monocytes. 
Median AUC for GG monocytes was 99.57 ΔCT.hours (range 44.37 to 138.12) versus 80.83 
ΔCT.hours (range 26.63 to 209.03) for AG monocytes (p=0.75). Similarly there were trends 
for CXCL8 protein concentration at both time points to be greater in the GG group. 
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Figure 4-6 CXCL8 mRNA and protein production by unstimulated monocytes from 
patients with and without the rs361525 TNF-A polymorphism 
a) A time course curve is shown of CXCL8 mRNA expression over 24 hours. Data points are 
shown as median and range values. No significant difference in AUC (calculated from data up 
to the 6 hour time-point only) between groups was observed. The concentration of CXCL8 in 
the CM was measured at 6 hours (b) and 24 hours (c). Individual data points for each subject 
are illustrated with median values displayed as horizontal lines. No significant difference in 
CXCL8 concentration was observed. Data tested with a Mann Whitney U test. 
 
In LPS-stimulated monocytes there was a trend for the AUC for GG monocyte CXCL8 
mRNA expression to be greater than that for AG monocytes (figure 4.7). Median AUC for the 
GG monocytes was 292.39 ΔCT.hours (range 147.77 to 367.54) versus 190.89 ΔCT.hours 
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(range 98.49 to 261.82) in the AG monocytes (p=0.05). CXCL8 protein concentration was 
significantly higher at 24 hours post stimulation in the GG monocyte supernatant. 
 
 
Figure 4-7 CXCL8 mRNA and protein production by LPS-stimulated monocytes from 
patients with and without the rs361525 TNF-A polymorphism 
a) A time course curve is shown of CXCL8 mRNA expression over 24 hours. Data points are 
shown as median and range values. No significant difference in AUC (calculated from data up 
to the 6 hour time-point only) between groups was observed. The concentration of CXCL8 in 
the CM was measured at 6 hours (b) and 24 hours (c). Individual data points for each subject 
are illustrated with median values displayed as horizontal lines. Higher CXCL8 concentration 
in the GG monocytes at 24 hours post stimulation was observed. Differences between subject 
groups were assessed with a Mann Whitney U test. 
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In PMA stimulated monocytes there was a trend at both time-points for both CXCL8 mRNA 
expression and protein concentration to be greater in the GG monocytes with a statistically 
significant difference in the protein concentration at 6 hours (figure 4.8). 
 
Figure 4-8 CXCL8 mRNA and protein production by PMA-stimulated monocytes from 
patients with and without the rs361525 TNF-A polymorphism 
Individual data points for each subject are illustrated with median values displayed as 
horizontal lines. CXCL8 mRNA expression is shown at 6 hours (a) and 24 hours (b) post 
stimulation with PMA. CXCL8 concentration in the CM is shown at 6 hours (c) and 24 hours 
(d) post stimulation with PMA. Higher concentration of CXCL8 was observed in the GG 
monocyte CM at 6 hours post stimulation. Data tested with a Mann Whitney U test. 
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A large number of samples were collected during the course of these experiments resulting in 
the use of many ELISA plates. As the CV% for inter-assay variation had been shown to be 
greater than 10% (chapter 3) it was necessary to determine if inter-assay variation had any 
effect on the results obtained. Therefore, samples collected at 24 hours post LPS stimulation 
hours from both subject groups were re-run on one CXCL8 ELISA plate (figure 4.9). A 
similar absolute result to that shown in figure 4.7 was obtained. Ideally, samples for 
individual time points and experimental conditions from the two subject groups would have 
been tested on one ELISA plate, however this was not feasible as on many occasions samples 
had to be re-run with different dilution factors and overall many more ELISA plates would 
have been required. 
 
 
 
Figure 4-9 Concentration of CXCL8 in the supernatant of LPS-stimulated monocytes in 
patients with and without the rs361525 TNF-A polymorphism at 24 hours 
The concentration of CXCL8 in the CM was measured at 24 hours. Individual data points for 
each subject are illustrated with median values displayed as horizontal lines. Higher CXCL8 
concentration in the GG monocytes at 24 hours post stimulation was observed, assessed with 
a Mann Whitney U test. All samples of supernatant were tested using the same ELISA plate 
to eliminate the effect of inter-assay variation. 
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4.3.3 The autocrine effect of TNF-α 
To investigate whether TNF-α was involved in an autocrine feedback loop to up-regulate 
CXCL8 production, monocytes stimulated with LPS for 6 and 24 hours were also incubated 
with 10 µg/ml of TNF-α mAb. Cell-free supernatants were collected for analysis of protein 
content and the cells de-adhered for RNA extraction. Data from both subject groups were 
combined. 
Figure 4.10 shows that blockade of TNF-α had no effect on its own expression in this model 
at 6 hours post LPS-stimulation, but there was a significant increase in TNF-α mRNA 
expression at 24 hours in the monocytes incubated with TNF-α mAb. The absolute difference 
was small however, as shown in the table in figure 4.10. 
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Time (hours) LPS- median ΔCT (range) LPS and anti-TNF-α mAb- median ΔCT (range) P value 
6 1.48 (0.19-9.58) 1.29 (0.03-8.82)  
24 0.013 (0.004-0.07) 0.014 (0.004-0.09) p=0.04 
 
Figure 4-10 TNF-α mRNA expression in monocytes stimulated with LPS in the presence 
or absence of a TNF-α mAb 
Paired data is shown for TNF-α mRNA expression at a) 6 hours and b) 24 hours. Each pair of 
data is connected by a line and shows mRNA expression for that subject’s monocytes in the 
presence or absence of a TNF-α mAb. Results from AG and GG subjects were combined. 
Median data is shown in the table. Differences were tested with a Wilcoxon Signed Ranks test 
and p values where significant are shown in the table/figure. 
 
 
Figure 4.11 shows that CXCL8 mRNA expression and protein concentration in the 
supernatant were decreased at 24 hours in the presence of a TNF-α mAb. Messenger RNA 
expression had almost halved at 24 hours but the absolute difference was slight in the protein 
concentration, suggesting a later time-point would need to have been tested to see this 
translate through to the protein level. 
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Time 
(hours) 
LPS- median ΔCT (range) LPS and anti-TNF-α mAb- median ΔCT 
(range) 
P 
value 
6 68.42 (10.56-161.5) 70.35 (10.85-207.2)  
24 21.08 (7.84-44.32) 12.0 (5.13-30.80) p<0.01 
Time 
(hours) 
LPS- median concentration 
ng/ml (range) 
LPS and anti-TNF-α mAb- median 
concentration ng/ml (range) 
P 
value 
6 42.71 (16.78-61.33) 43.41 (15.44-60.06)  
24 196.1 (120.1-414.1) 176.4 (114.7-321.0) p=0.01 
 
Figure 4-11 CXCL8 mRNA expression in monocytes stimulated with LPS in the presence 
or absence of a TNF-α mAb 
Paired data is shown for CXCL8 mRNA expression at a) 6 hours and b) 24 hours and for 
protein concentration in the CM at c) 6 hours and d) 24 hours. Each pair of data is connected 
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by a line and shows mRNA expression/protein concentration for that subject’s monocytes in 
the presence or absence of a TNF-α mAb. Results from AG and GG subjects were combined. 
Median data is shown in the table. Differences were tested with a Wilcoxon Signed Ranks test 
and p values where significant are shown in the table/figure.  
 
The median concentration of detectable TNF-α in the supernatant of LPS-stimulated 
monocytes at 6 hours was significantly higher than that in the supernatant of monocytes 
stimulated with LPS in the presence of a TNF-α mAb (6080.0 pg/ml versus 42.7 pg/ml in the 
AG group (p<0.01) and 7157.3 pg/ml versus 58.7 pg/ml in the GG group (p<0.01)), indicating 
that almost all of the secreted TNF-α had been successfully bound by the mAb. 
 
4.3.4 Intrasubject variation in TNF-α secretion over time 
It was hypothesised that one possible cause for not having confirmed greater TNF-α mRNA 
expression and protein secretion at a cellular level in AG subjects was that TNF-α production 
by monocytes might vary significantly over time, making comparisons between single 
measurements unreliable. To test this monocytes from 3 healthy subjects were isolated twice 
weekly (3-4 days apart) for 3 weeks, stimulating them in duplicate with 100 ng/ml of LPS and 
measuring sTNF-α concentration in the cell-free supernatant at 3 hours. Figure 4.12 shows the 
values over time for each subject. CV% values for subjects one to three were 26.9%, 48.4% 
and 17.7%. 
 
 
 
 
161 
 
 
Figure 4-12 TNF-α secretion by LPS-stimulated monocytes over three weeks 
Monocytes from 3 healthy subjects (2 female) were isolated twice weekly for 3 weeks and 
stimulated in duplicate with 100 ng/ml of LPS for 3 hours. TNF-α concentration in the cell-
free supernatant was measured using ELISA. 
 
With the assistance of a medical statistician these data were used to estimate the numbers of 
patients in each of the AG and GG groups that would be needed to demonstrate a true 20% 
difference in sTNF-α concentration in the monocyte-free supernatants with varying levels of 
power. For the 6 hour data with a sample size of 40 per group the achieved power would be 
83%. For the 24 hour data with a sample size of 140 per group the achieved power would be 
only 62%.  
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4.4 Discussion 
The results from this study did not support the primary hypothesis that monocytes with the 
rs361525 polymorphism express more TNF-α mRNA or secrete more sTNF-α protein than 
monocytes with the wild type gene. In fact, when cells were stimulated with LPS it was the 
monocytes from GG subjects that produced more TNF-α protein at later time points (figure 
4.3). This was an unexpected finding given the 100 times greater concentration of TNF-α 
protein detected in the sputum of AG subjects compared to GG subjects in Sapey et al’s work 
(17), studying COPD patients from the same A1ATD cohort. The second hypothesis, that a 
TNF-α autocrine feedback loop would exist, leading to greater CXCL8 production above that 
due to LPS stimulation alone was found to be partially true, in that blocking the TNF-α 
produced by monocytes with a commercial mAb had a negative effect on CXCL8 output 
(figure 4.11). However, the greater CXCL8 output was observed in the GG rather than AG 
monocytes (figure 4.7), likely to be in keeping with those monocytes having produced more 
TNF-α when stimulated with LPS, leading to a more pronounced autocrine effect. A very 
small but significant increase in TNF-α mRNA was observed in the presence of the TNF-α 
mAb (figure 4.10) suggesting that TNF-α autocrine feedback negatively affects its own 
production. However, the same finding was not observed in TNF-α time course profiles in 
figure 5.9 in chapter 5. 
As the primary hypothesis was not found to be true, further investigation of the other 
hypotheses, investigating the possible effects of the polymorphism on other monocyte 
functions and the role of TNFR1 in the autocrine feedback loop were not studied. 
The current studies raise interesting questions regarding the significance of this SNP. 
Specifically, can it be concluded that monocytes from subjects with the rs361525 TNF-A 
polymorphism do not produce more TNF-α under any circumstance than those from subjects 
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without the polymorphism and in fact do monocytes from the latter produce more TNF-α than 
those with the polymorphism? The answer is probably not a simple yes or no and the results 
obtained here likely reflect both limitations of the studies and the inherent complexity of the 
effect of SNPs within different cell types and diseases and in response to different stimuli. 
These issues are considered below. 
4.4.1 Patient factors 
The subjects in the two groups were matched as closely into pairs, based on as many relevant 
criteria as possible (age, gender, FEV1, KCO and diagnosis of COPD) and no statistically 
significant differences between the two groups were found when comparing other 
characteristics after matching. However, several limitations may have had a bearing on the 
results. Firstly, although overall the number of patients with the phenotype of CB was similar 
in the two groups it was difficult to match each individual pair for this particular criterion, 
whilst still meeting as many other matching criteria as possible, as only 40% of patients in our 
A1ATD cohort have CB. This may have affected the results obtained in the current studies as 
Wood et al found an association of the polymorphism specifically with the CB phenotype of 
COPD (125) and Sapey et al’s findings in the sputum were obtained solely from patients with 
CB (17). Interestingly Sapey et al also noted that after matching their A1ATD/CB patients on 
a number of criteria, the BMI of patients was significantly lower in the rs361525 
polymorphism group (18 versus 24 kg/m2) (17). In conjunction with a faster decline in FEV1 
over 3 years this led the authors to propose that the excess TNF-α in this group was associated 
with a more aggressive disease phenotype. The current studies focussed on cellular work 
rather than clinical features but it is important to note that this finding was not replicated in 
the current studies as there was no significant difference in BMI between the two groups (AG- 
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21 and GG- 23 kg/m2). This may again relate to the fact that not all patients studied had CB 
and that individual subject pairs could not always be matched for this.  
In addition, there was a non-statistically significant but potentially clinically relevant 
difference in age between the AG and GG subjects, as the AG subjects were on average ten 
years younger. Whether age affects in-vitro production of TNF-α specifically by monocytes is 
unclear as a review of studies addressing this question described conflicting results (276), but 
this is certainly a possibility.  
One AG subject was a current smoker and the rest of the subjects were mostly ex-smokers in 
equal proportions. Airway inflammation is known to persist in ex-smokers (277) but all of the 
patients studied by Sapey et al’ (17) were also ex-smokers so this should not have been a 
confounding factor in the current studies, although with only 9 subjects per group it is 
possible that the one current smoker may have affected the results obtained from peripheral 
blood monocytes. As smoking is recognised to accelerate the onset and progression of COPD 
in individuals with A1ATD (42) and hence increase the likelihood of presentation to a 
specialist A1ATD clinic it is unsurprising that most of the subjects studied here were ex-
smokers. Although our cohort also includes non-index cases these are fewer and usually have 
better preserved lung function meaning that separating groups by current or previous smoking 
status and then matching for the rs361525 polymorphism and lung function was not feasible. 
To address this in part a further set of initial TNF-α time course experiments could have been 
conducted in healthy control smokers in order to determine whether smoking status affects 
TNF-α output by monocytes. 
 All of the patients in the original study (17) were taking inhaled steroids (which might 
modulate monocyte function even in the circulation) as were all of the subjects in the current 
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study with the exception of one patient in the AG group, which potentially may have a 
confounding effect on the results. 
Despite these possible limitations matching was carried out as closely as possible. Although 
other authors have found that the GG group in their studies produced more TNF-α than the 
AG group or vice versa (table 1.2), the subjects in those experiments were not individually 
matched and hence it is difficult to exclude another cause for differences observed between 
groups in those studies (133, 135). 
Linkage disequilibrium, whilst a potential issue when combining the results of the effects of a 
SNP on disease expression in case-control studies from different populations, is unlikely to 
explain the discordance between results presented here and those seen in sputum (17) as our 
patient samples were all Northern European and taken from the same cohort. 
4.4.2 Stimulant factors 
Extensive validation experiments were first conducted in monocytes from healthy subjects 
prior to recruiting patients with the rs361525 TNF-A polymorphism, as presented in chapter 
3. LPS was identified as the most potent inducer of TNF-α, of the stimulants tested and peak 
time-points for measuring TNF-α (6-8 hours) and CXCL8 (24 hours) were chosen.  
Ideally it would have been preferable to perform more detailed time course experiments for 
mRNA work and also for protein measurement by ELISA in the A1ATD patients, as this 
would have allowed calculation of AUC values in every case rather than comparing one-off 
time-points, providing a more detailed picture of TNF-α/CXCL8 production over time. 
However, comparing AUC values is also subject to limitations too, namely the need for close 
time-points in order to produce as accurate curves as possible. In this chapter, AUC values 
were only calculated for mRNA time course curves up to and including 6 hours as the gap 
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between this and the final time-point of 24 hours was too long to produce a meaningful curve 
beyond 6 hours. The practicalities of performing a detailed 24 hour time course experiment in 
each case would have been challenging as patients in our cohort live throughout the UK rather 
than locally, meaning that blood sampling, monocyte extraction and the start time of 
experiments varied greatly. 
Lack of prior determination of peak-time-points and concentration response experiments is a 
clear limitation with respect to the data gathered from PMA-stimulated monocytes, in which 
studies suggested trends for slightly greater TNF-α production by GG monocytes, but with no 
statistically significant difference between the two groups. Never-the-less as all subjects had a 
small number of excess monocytes it was determined that using a second stimulant was 
worthwhile.  
PMA is a plant phorbol ester which replicates the action of diacylglycerol, a membrane bound 
secondary messenger found in human cells, which in conjunction with calcium ions activates 
the intracellular messenger protein kinase C (278). In-vivo, diacylglycerol is formed as a 
result of hydrolysis of phosphatidylinositol 4,5-bisphosphate following ligand binding to G-
protein coupled receptors on the cell surface (279). PMA is able to bypass this by passing 
across cell membranes and directly activating protein kinase C. Protein kinase C, of which 
there exists several isoenzymes, is then able to up-regulate TNF-α production in monocytes 
through divergent downstream signalling pathways that activate NFκB transcription factors 
and via ERK (a MAP kinase), the transcription factor AP-1 (279, 280). As the opportunity to 
perform concentration response experiments was not available for PMA the concentration of 
3 ng/ml (equivalent to 5 nM) was chosen based upon experience of using this stimulant in 
monocytes in our laboratory (direct communication with Dr Gillian McNab, ADAPT Project). 
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PMA has been shown to induce TNF-α by cells in whole blood up to a maximum 
concentration of 50 ng/ml (281). 
LPS acts on monocytes by binding to TLR4 and CD14 on the cell surface, along with lipid 
binding protein. This switches on multiple intracellular signalling pathways that lead to the 
rapid up-regulation of numerous transcription factors responsible for pro-inflammatory 
cytokine gene transcription, such as NFκB, AP-1 and members of the interferon regulatory 
factor family of transcription factors, among others (282). The transcription factors that 
switch on TNF-α in monocytes and macrophages in response to LPS have been outlined in 
detail in 1.8.1. Of relevance to the rs361525 TNF-A polymorphism is work suggesting that 
NFκB family members, in particular p65, bind to the distal portion of the promoter of the 
TNF-A gene including the region in which the SNP lies (152, 258). Therefore LPS and PMA 
are both potentially relevant stimuli as they up-regulate NFκB family members and hence 
could allow any differential effects of binding of these transcription factors to this area of the 
promoter in AG and GG monocytes. 
However, whilst LPS-induced TNF-α induction has been shown to occur independently of the 
protein kinase C pathway (283) both LPS and PMA induce intra-cellular signalling pathways 
that will subsequently activate some of the same transcription factors, meaning that using both 
these stimuli may offer no benefit in the current studies over using one or the other. In support 
of this, the differences observed for PMA and LPS-stimulated monocytes were similar, 
whether trends or statistically significant. In addition, a further negative aspect of using LPS 
and PMA is their ability to induce a wide variety of transcription factors which might be a 
disadvantage should those acting at the proximal promoter predominate with respect to 
affecting TNF-A transcription and thus dilute any effects of differential transcription factor 
binding in the distal promoter at position -237 between AG and GG monocytes. Never-the-
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less as another study using DNA constructs with either the A or G allele and a luciferase 
reporter assay transfected into RAW 264.7 murine macrophage-like cells showed that LPS 
up-regulated reporter gene ouput (128) it was still reasonable to use LPS as the primary 
stimulus. In addition, even if the functional effect of the polymorphism is dependent on 
binding of one specific transcription factor, the effects of the polymorphism observed in 
airway secretions would argue against any significant dilutional effect of other transcription 
factors as multiple potential stimuli will be present in the lungs of a patient with COPD (284) 
and yet a 100 fold difference in TNF-α between groups was still observed (17). 
As the cytokine milieu within the airways of COPD subjects is complex (79) it may be other, 
multiple exogenous and/or endogenous stimulants which drove the differences observed by 
Sapey et al (17). In keeping with this, a recent study by Kiss-Toth et al (128) showed that 
expression of a reporter gene encoding for the AG variant of the TNF-α promoter in murine 
macrophages led to increased gene activity in response to LPS and interestingly this was 
potentiated by binding of thyroid hormone receptor to the A allele but not the G allele. This 
indicates that there are multiple steps which may affect the functionality of a SNP and it may 
be that in the airways other co-factors or epigenetic mechanisms were present which led to 
100 times greater TNF-α concentration in the sputum from the polymorphism group (17). 
Although LPS is found in cigarette smoke and dust and has been shown to induce neutrophilic 
airways inflammation (241, 285), this may not have been the optimum stimulant, particularly 
in A1ATD patients who are more likely to have ceased smoking.  
The concentration of LPS chosen for use in the experiments was 100 ng/ml, based upon this 
eliciting the greatest TNF-α response of the concentrations tested, by monocytes from healthy 
subjects. However, as previously discussed in chapter 3 it may have been preferable to have 
used the EC80%. If the position of the linear phase of a sigmoidal concentration response 
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curve for AG monocytes lies to the left of that of GG monocytes they would produce more 
TNF-α at lower concentrations of stimulant and a difference between the two groups would be 
seen. By using higher concentrations of LPS it is possible that any differences between the 
AG and GG monocytes were missed as both may have reached plateau at 100 ng/ml of LPS. 
4.4.3 Cellular factors 
There are other possible reasons why the results obtained did not support those of Sapey et al 
(17). The primary objective of this thesis was to study the effects of the rs361525 
polymorphism at a cellular level. The monocyte was chosen as the cell of interest for several 
reasons: it is simple to isolate in comparison to airway macrophages or epithelial cells, is the 
principal producer of TNF-α and as a cell found predominantly in the circulation may have 
played a role in the possible systemic effect of the polymorphism (3), whereby AG subjects 
had a lower BMI (17). The objective was to show that in this particular patient population the 
polymorphism is associated with increased TNF-α production at a cellular level. Although 
this technique could not prove actual functionality of the SNP this is of less importance as 
even if the polymorphism is only a marker of increased TNF-α production it could still be 
used to identify patients who might have have a more aggressive disease phenotype. Despite 
sound reasons for choosing this cell type there are limitations. It is possible that the 
polymorphism is only active in other cell types relevant to the airways and alveoli of COPD 
patients, for example, bronchial epithelial cells or macrophages and indeed Sapey et al 
observed no difference in TNF-α concentration in the plasma between the two groups 
suggesting blood monocytes may not be the relevant cell type (17). Alternatively the 
monocyte subset studied may have affected the conclusions reached from the current studies. 
Whilst results presented in chapter 3 demonstrate that cell preparations inadvertently 
contained some CD14+CD16+ monocytes, either through experimental limitations or changes 
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to monocytes during the extraction process, very few CD14-CD16+ monocytes were present. 
Although this subset is in the minority of circulating monocytes they are believed to be the 
more pro-inflammatory type (208) and hence may have been the more relevant monocyte to 
study. 
An interesting explanation for the findings might be related to reduction in the cleavage of 
pro-TNF-α in an in-vitro system. Regulation of TACE, the cell bound enzyme which cleaves 
both TNF-α and TNFR1 from the cell surface is incompletely understood (286). It is possible 
that in the airways of A1ATD-related COPD patients there exists a number of mediators that 
increase TACE activity, leading to the increased concentration of sTNF-α observed in 
bronchial secretions, and that these mediators might not be present in a culture system 
containing only monocytes, LPS and CM. If that were the case the supernatant of the AG 
monocytes may not contain higher concentrations of sTNF-α but there may still be greater 
production of TNF-α as a result of the rs361525 polymorphism in the form of greater numbers 
of mTNF-α per cell. Arguing against this theory is the lack of difference in TNF-α expression 
at the mRNA level. This could be addressed in future studies using flow cytometry. 
Lastly, with respect to cell factors is the issue of cell viability. Studies performed later in this 
thesis and described in chapters 3 and 5 identified that a degree of monocyte apoptosis was 
occurring over time, particularly in unstimulated cells. The possible effects of this on the 
results presented here are largely unknown. In some circumstances TNF-α can induce 
apoptosis, via TNFR1 (287-289), so it is possible that the rs361525 monocytes did produce 
more TNF-α but conversely were undergoing more extensive and rapid apoptosis as a result. 
Loss of a greater number of cells to apoptosis, in the absence of in-vivo factors that might 
maintain their viability, would then mean there were less live cells to contribute to further 
TNF-α production, giving the appearance that AG monocytes produced less TNF-α. Of note, 
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GAPDH expression was stable at all time-points, as discussed in chapter 3 and can therefore 
be assumed not to be affected by early and late stages of apoptosis.  
Other factors related to apoptosis might also be relevant. For example, when surrounding 
phagocytes (in this case live monocytes within the culture wells) are overwhelmed by the 
number of apoptotic cells and fail to effectively clear them via phagocytosis a process known 
as programmed necrosis may occur. The apoptotic cell membrane loses its integrity and 
intracellular contents such as DNA are released into the peri-cellular environment (287). 
These mediators can elicit pro-inflammatory effects. If this was occurring in the LPS-
stimulated monocytes and to varying degrees between subjects’ samples then these pro-
inflammatory mediators may have affected the outcomes obtained by influencing 
inflammatory pathways within live monocytes. Lastly, as monocytes themselves act as 
phagoctyes (290, 291) it is likely that some of the live monocytes were phagocytosing the 
apoptotic monocytes which may also have activated them and altered their function, 
influencing the results obtained. 
4.4.4 Factors relating to study power 
A further possible explanation for the unexpected results obtained in the current study is the 
intrasubject variation in TNF-α production observed over time. The data obtained from 
studies over three weeks in healthy subjects clearly showed that monocytes vary in their TNF-
α secretion over time, the reasons for which are beyond the scope of this thesis. This 
phenomenon may be less of a concern when sampling secretions from the lungs as the protein 
content of sputum should reflect the accumulation of cytokine over more than one day and 
from large cell numbers and cell types. Subsequent statistical analysis demonstrated that large 
numbers of patients would be required to show a true 20% difference in TNF-α protein 
production between AG and GG groups using a one-off monocyte study with sufficient 
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power. To recruit eighty or more patients from our cohort, or alternatively to perform multiple 
replicate experiments over time in a smaller sample, is unlikely to be feasible. It was 
challenging to recruit eighteen subjects as patients reside throughout the UK and often find it 
difficult and time consuming to attend, particularly if they are limited by their disease. In 
addition, these power calculations were based on results from healthy subjects. The 
intrasubject variation in monocyte TNF-α protein production in COPD subjects may be even 
greater and hence much larger numbers of patients could be needed than estimated.  
There was a trend for greater TNF-α mRNA expression in freshly isolated monocytes (figure 
4.1) and hence one might argue that with greater sample sizes this may have become 
statistically significant. However, in light of the subsequent finding of intrasubject variation 
over time, even should this be the case, it would remain unwise to conclude from one-off 
studies that monocytes from AG subjects do in fact secrete more TNF-α under certain 
circumstances. This may be a major limitation of many of the in-vitro monocyte studies 
described in table 1.2. 
4.4.5 TNF-α autocrine feedback loop 
The experiments presented in this chapter have shown that TNF-α was involved in an 
autocrine feedback loop to increase production of CXCL8. By 24 hours after LPS stimulation, 
monocytes co-incubated with a TNF-α mAb had significantly reduced CXCL8 mRNA 
expression (by almost half). A small but significant reduction in CXCL8 protein was also 
observed at 24 hours (figure 4.11). It is likely that if the time-points were extended beyond 24 
hours for protein measurement then a greater absolute reduction in CXCL8 protein 
concentration would be observed. The presence of an autocrine feedback loop also likely 
explains why greater CXCL8 mRNA expression and protein secretion was seen in the 
stimulated GG group monocytes, as this group produced more TNF-α in response to LPS. 
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One limitation of these particular experiments was the lack of control wells whereby LPS-
stimulated monocytes should have been incubated with a matched isotype control antibody at 
the same concentration as the TNF-α mAb. This would have ruled out a non-specific effect of 
the TNF-α mAb unrelated to its blocking effect of the TNF-α molecule due to specific epitope 
binding, such as binding of the immunoglobulin Fc portion to Fc receptors on the monocyte. 
4.4.6 Refining study methodology 
The main implications of this work are that either the rs361525 polymorphism is not relevant 
in monocytes from the systemic circulation or that methodological factors have influenced the 
results. In some respects it is not surprising that the results did not agree with those found in 
the airways as the studies outlined in table 1.2 show the available evidence for functionality of 
this polymorphism at a cellular level is conflicting. 
A number of further experiments could be conducted to expand upon the findings (discussed 
in detail in chapter 6), however it would first be important to repeat the current experiments 
using a refined methodology to address some of the issues that arose during this work.  
All cell culture experiments should have included the use of a viability assay to measure the 
degree of cell loss between the AG and GG monocytes, time-points and experimental 
conditions. Several different viability assays are available for this purpose (292). The 
adenosine triphosphate (ATP) assay works on the principle that only viable cells contain ATP 
(in dead cells ATP is no longer synthesised and any existing ATP is rapidly degraded). In the 
presence of the luciferase enzyme ATP will react with luciferin to generate luminescence 
which can be quantified with a plate reader. ATP assays contain a detergent to lyse the cells 
so this assay can only be used after the cell supernatant has been removed for ELISA and not 
for cells which are being harvested for later RT-qPCR. The benefit of this assay is that is does 
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not require a long period to allow colour change to occur (292). Alternatively a protease 
viability marker assay could be used, such as the CellTiter-Fluor™ Cell Viability Assay 
(Promega, Wisconsin, United States). Glycylphenylalanyl-aminofluorocoumarin, a cell 
permeable fluorogenic protease substrate is added to culture wells and only live cells will 
possess protease activity able to catalyse conversion of the substrate to fluorescent 
aminofluorocoumarin. The degree of fluorescence is proportional to the number of live cells 
(292). The strengths of this assay are that cells do not undergo lysis and further assays can be 
conducted afterwards, such as removing the supernatant for ELISA or harvesting the adherent 
cells for RNA extraction. Validation experiments would need to be conducted to ensure that 
the protease viability assay did not affect the results of ELISA and RT-qPCR experiments. 
Standard curves for both assays can be generated using values from serial dilutions of viable 
cells or alternatively results can be expressed as a percent change in 
luminescence/fluorescence relative to an experimental control. The benefit of these assays is 
that they allow normalisation of results relative to the number of live cells in each culture 
well. 
To overcome intrasubject variation greater numbers of patients would be required (or a 
similar number of subjects but giving blood on multiple days to allow experiments to be 
repeated). Monocytes could be extracted from whole blood using a flow cytometer to sort 
cells for culture experiments. This would allow monocytes to be further sorted on the basis of 
CD14/CD16 status. The expression of mTNF-α at baseline and over time in response to 
stimuli could also be measured in the AG and GG monocytes. A flow cytometry viability 
marker such as 7-AAD should also be used routinely to gate out non-viable cells. 
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Lastly, a wider range of stimuli could be used to induce TNF-α production, following 
validation experiments to determine EC80% values and both mRNA and protein time courses 
could be conducted, using unstimulated cells cultured in CM as an appropriate negative 
control. 
4.5 Conclusions 
In the current studies the presence of the rs361525 TNF-A SNP in A1ATD patients with 
COPD was not found to be associated with greater TNF-α production by monocytes and this 
may have been due to factors such as the high intrinsic intrasubject variation in TNF-α 
secretion. Alternatively it may be the cell type or specific A1ATD/COPD phenotype (i.e. CB) 
studied or the interplay of complex patterns of inflammation on many downstream pathways 
that results in a positive relationship between the rs361525 polymorphism and TNF-α 
expression. TNF-α was demonstrated to up-regulate production of the chemokine CXCL8 via 
an autocrine feedback loop. Given the practical limitations of recruiting enough subjects in 
each group to overcome the issue of intrasubject variation in TNF-α production over time, a 
decision was reached to focus further studies in this thesis on TNF-α autocrine feedback loops 
in monocytes from healthy subjects. 
 
 
 
 
 
 
176 
 
CHAPTER  5 
 
THE AUTOCRINE EFFECTS OF TNF-α 
ON MONOCYTES FROM HEALTHY 
SUBJECTS 
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5 The autocrine effects of TNF-α on monocytes in healthy subjects 
5.1 Brief Introduction 
Monocytes are the principal producers of TNF-α and yet surprisingly little is known about the 
autocrine or paracrine effects of TNF-α on this cell type in humans (hereafter referred to as 
autocrine only for simplicity) and the differential roles of its two receptors. Monocytes are 
believed to be central in many diseases, including IBD, inflammatory arthropathies and septic 
shock (3, 9). Monocytes are also one of the few cells that express both TNF-α receptors; 
TNFR1 is expressed on most human cells whereas TNFR2 is found only on immune cells and 
vascular endothelial cells (4). TNFR2 has clearly been shown to play a predominantly anti-
inflammatory role in another important human immune cell, the CD4+FoxP3+ T-reg cell, as 
these cells preferentially express TNFR2 compared to effector T-cells and their suppressive 
function is enhanced by mTNF-α binding to TNFR2 (170). The role of TNFR2 in human 
monocytes has not yet been established. 
The importance of characterising the respective roles TNFR1 and TNFR2 is being 
increasingly recognised. If TNFR1, ubiquitously expressed on almost all cell types, is the 
“pro-inflammatory” receptor, with TNFR2 responsible for a more immunomodulatory role 
this could make selective TNFR1 blockade a more beneficial concept. Indeed, a phase one 
study of Atrosab, a humanized mAb that specifically blocks TNFR1 has demonstrated an 
acceptable safety profile and phase two proof-of-concept trials in rheumatoid arthritis and 
psoriasis are planned for 2016 (293). In addition, another mAb targeting the TNFR1 receptor, 
GSK1995057, has been tested in healthy volunteers with an associated reduction in pro-
inflammatory mediators in BAL fluid in response to LPS (to simulate acute lung injury) 
(294).  
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The work carried out for this thesis investigating the effects of the rs361525 TNF-A 
polymorphism in A1ATD patients, as described in chapter 4, revealed a TNF-α autocrine 
feedback loop, shown by the addition of the TNF-α mAb to LPS-stimulated monocytes 
attenuating the production of CXCL8. Characterising these autocrine effects further and the 
differential roles of the two receptors in monocytes from healthy subjects was therefore felt to 
be important. Several hypotheses were formed relating to the role of TNF-α autocrine 
feedback loops in monocytes and are shown below. All experiments presented in this chapter 
were conducted using monocytes from healthy control subjects (23 subjects, median age- 31 
years, IQR- 25 to 32.5 years; range- 21 to 45 years; 13 males)) rather than A1ATD patients 
with the rs361525 polymorphism.  
Hypothesis one: TNF-α produced by monocytes is involved in autocrine feedback loops to 
up-regulate both pro and anti-inflammatory cytokine production. 
Hypothesis two: TNF-α autocrine feedback loops in monocytes occur via TNFR1 for pro-
inflammatory cytokine production and via TNFR2 for anti-inflammatory cytokine production. 
Hypothesis three: the decrease in measurable sTNF-α over time in the supernatant of 
monocytes in culture (as observed in figure 3.2) is due to autocrine binding to one or both of 
its receptors. 
Hypothesis four: TNF-α autocrine feedback loops in monocytes play a role in influencing the 
expression of the two TNF-α receptors, TNFR1 and TNFR2. 
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To investigate these hypotheses the following objectives and strategies to meet these 
objectives were set: 
 Determine if the production of other pro-inflammatory and anti-inflammatory 
cytokines in addition to CXCL8 was affected by TNF-α autocrine feedback loops. This 
was conducted by using LPS to stimulate TNF-α production, in the presence or 
absence of a TNF-α mAb and then measuring cytokine mRNA expression with RT-
qPCR and secreted protein by ELISA. 
 Examine the relative involvement of the two TNF-α receptors in autocrine feedback 
loops influencing cytokine production. This was conducted by using LPS to stimulate 
TNF-α production in the presence or absence of TNFR1 mAb or TNFR2 mAb or both 
receptor mAbs and then measuring cytokine mRNA expression with RT-qPCR. 
 Measure sTNF-α in the supernatant of LPS-stimulated monocytes incubated in the 
presence or absence of TNFR1 mAb or TNFR2 mAb or both mAbs to determine if 
receptor blockade increases sTNF-α concentration. 
 Characterise the expression pattern of the TNF-α receptors on the surface of 
monocytes at baseline and over time and determine if change in receptor density was 
due in any part to TNF-α autocrine feedback loops. This was done by measuring 
TNFR1/TNFR2 expression on LPS-stimulated monocytes incubated in the presence or 
absence of a TNF-α mAb or TNFR1/TNFR2 mAbs.  
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5.2 Results 
5.2.1 LPS induces cytokine mRNA expression by monocytes 
Prior to investigating the autocrine effects of TNF-α it was necessary to determine the time 
course profiles of pro and anti-inflammatory cytokines in response to LPS. As it was 
previously accepted that LPS induces cytokine secretion (295) one-tailed testing was used to 
test the hypothesis that LPS induced greater production of TNF-α, IL-6, CXCL8, IL-1β, TGF-
β and IL-10 over time than that by unstimulated monocytes. 
Monocytes at a concentration of 0.25 million per ml of CM were cultured in the presence or 
absence of 100 ng/ml of LPS for pre-specified time periods over 48 hours and the RNA 
extracted from harvested cell pellets. Culture experiments were conducted singly. Messenger 
RNA samples from each experimental condition underwent RT-qPCR in duplicate. 
Comparison of AUC values for time course curves demonstrated that stimulating healthy 
monocytes with LPS induced expression of a number of pro-inflammatory cytokines, greater 
than that observed in unstimulated monocytes (figure 5.1 to 5.4). This data is in keeping with 
established knowledge regarding the effect of LPS on pro-inflammatory cytokine mRNA 
transcription (295, 296).  
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ΔCT 
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(p<0.01) 
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(p=0.03) 
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0.01 4.01 
(p=0.01) 
2.18 
(p=0.03) 
17.55 
(p<0.01) 
0.11 0.03 0.03 159.34 (85.58-
232.56) 
 
Figure 5-1 Effect of LPS on TNF-α mRNA expression by monocytes over 48 hours 
Data points are shown for unstimulated and LPS-stimulated monocytes. Data points represent 
median values (with range), also supplied in the table. Friedman’s testing was conducted for 
individual time course experiments and post-hoc pairwise comparison p-values of each time-
point to time zero are shown in the table, where significant (unadjusted p-values were first 
corrected by multiplying by 6). AUC was calculated for each time course curve and the two 
values compared with a Wilcoxon Signed Ranks test (one-tailed p=0.04). 
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21.98 12.07 3049.63 
(2169.80- 
3696.88) 
 
Figure 5-2 Effect of LPS on CXCL8 mRNA expression by monocytes over 48 hours  
Data points are shown for unstimulated and LPS-stimulated monocytes. Data points represent 
median values (with range), also supplied in the table. Friedman’s testing was conducted for 
individual time course experiments and post-hoc pairwise comparison p-values of each time-
point to time zero are shown in the table, where significant (unadjusted p-values were first 
corrected by multiplying by 6). AUC was calculated for each time course curve and the two 
values compared with a Wilcoxon Signed Ranks test (one-tailed p=0.04). 
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Figure 5-3 Effect of LPS on IL-1β mRNA expression by monocytes over 48 hours  
Data points are shown for unstimulated and LPS-stimulated monocytes. Data points represent 
median values (with range), also supplied in the table. Friedman’s testing was conducted for 
individual time course experiments and post-hoc pairwise comparison p-values of each time-
point to time zero are shown in the table, where significant (unadjusted p-values were first 
corrected by multiplying by 6). AUC was calculated for each time course curve and the two 
values compared with a Wilcoxon Signed Ranks test (one-tailed p=0.04). 
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Figure 5-4 Effect of LPS on IL-6 mRNA expression by monocytes over 48 hours  
Data points are shown for unstimulated and LPS-stimulated monocytes. Data points represent 
median values (with range), also supplied in the table. Friedman’s testing was conducted for 
individual time course experiments and post-hoc pairwise comparison p-values of each time-
point to time zero are shown in the table, where significant (unadjusted p-values were first 
corrected by multiplying by 6). AUC was calculated for each time course curve and the two 
values compared with a Wilcoxon Signed Ranks test (one-tailed p=0.04). 
 
The expression of mRNA of two predominantly anti-inflammatory cytokines, IL-10 and TGF-
β (297) over 48 hours, was also measured in response to LPS and in unstimulated cells. LPS 
induced significantly greater IL-10 mRNA expression than unstimulated monocytes (figure 
5.5). In contrast, there was no difference in TGF-β expression in LPS-stimulated monocytes 
compared to unstimulated cells (figure 5.6).  
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Figure 5-5 Effect of LPS on IL-10 mRNA expression by monocytes over 48 hours  
Data points are shown for unstimulated and LPS-stimulated monocytes. Data points represent 
median values (with range), also supplied in the table. Friedman’s testing was conducted for 
individual time course experiments and post-hoc pairwise comparison p-values of each time-
point to time zero are shown in the table, where significant (unadjusted p-values were first 
corrected by multiplying by 6). AUC was calculated for each time course curve and the two 
values compared with a Wilcoxon Signed Ranks test (one-tailed p=0.04). 
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Figure 5-6 Effect of LPS on TGF-β mRNA expression by monocytes over 48 hours 
Data points are shown for unstimulated and LPS-stimulated monocytes. Data points represent 
median values (with range), also supplied in the table. No significant post-hoc pairwise 
comparison of each time-point to time zero were found. AUC was calculated for each time 
course curve and the two values compared with a Wilcoxon Signed Ranks test (non-
significant). 
 
5.2.2 Autocrine binding of soluble TNF-α may occur predominantly via TNFR2 in 
monocytes cultured in isolation 
Cell free supernatants were collected from monocytes cultured in the presence of LPS over a 
20 hour period (figure 5.7a), at a concentration of 0.45 million cells per well/ml. An increase 
in sTNF-α was observed until 8 hours post LPS stimulation, following which the 
concentration of detectable sTNF-α decreased.  
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The TNF-α ELISA used detects both free and soluble receptor-bound cytokine indicating that 
the fall in detectable sTNF-α was not due to binding to its soluble receptors but could instead 
be due to degradation of the protein or binding to one or both of its cell surface receptors, 
excluding the cytokine from the supernatants collected. To test the latter hypothesis 
monocytes from 7 individuals were stimulated in duplicate, with LPS, for 20 hours in the 
presence or absence of a mAb to one or both TNF-α receptors (10 µg/ml). Soluble TNF-α in 
the cell free supernatant was subsequently measured (figure 5.7b). Blockade of TNFR2 led to 
a significant increase in detectable sTNF-α with a trend for a small increase in the presence of 
TNFR1 blockade. This suggests that a significant proportion of the decrease in sTNF-α in the 
cell culture supernatant by 20 hours was due to binding to TNFR2.  
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Figure 5-7 Autocrine binding of sTNF-α secreted by LPS-stimulated monocytes  
a) A time course profile for sTNF-α concentration in response to LPS stimulation is shown. 
Each datum point is the median value (with range). Friedman’s testing was significant 
(p<0.01) and post-hoc pairwise comparison p-values of each time-point to time zero are 
shown on the figure where significant (unadjusted p-values were first corrected by 
multiplying by 4).    b) Monocytes were cultured with LPS for 20 hours, with or without the 
addition of 10 µg/ml of TNF-α R1 mAb or TNF-α R2 mAb or both mAbs. Each experimental 
condition shows individual data points with median values displayed as horizontal lines. 
Overall differences between experimental conditions were assessed with a Friedman’s test 
(p<0.001). Post hoc Dunn-Bonferroni adjusted pairwise comparisons where significant are 
shown on the figure. 
 
A further experiment was conducted to determine if sufficient concentration of each receptor 
antibody had been used to block TNFR1 and TNFR2 on the monocyte surface. Monocytes 
from one subject were cultured (0.45 million cells per well) under four conditions: stimulated 
with LPS, stimulated with LPS in the presence of increasing concentration of either TNFR1 
mAb, TNFR2 mAb or both receptor mAbs. Cells were incubated with the relevant mAbs for 
30 minutes, with gentle agitation, prior to addition of LPS. This was done to ensure blockade 
of cell surface receptors prior to the release of TNF-α by the monocytes in response to LPS. 
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The concentration of receptor mAb ranged from 1 ng/ml (log 0) to 10 μg/ml (log 4). After 24 
hours the concentration of sTNF-α in the cell free supernatants was measured by ELISA. The 
concentration of sTNF-α at 24 hours in control cells stimulated with LPS in the absence of 
either mAb was 1842.5 pg/ml. Figure 5.8 illustrates that as the concentration of TNFR2 mAb 
increased logarithmically there was a steady increase in the concentration of sTNF-α in the 
supernatant, suggesting that an increasing number of TNFR2 receptors on the cell surface 
were being prevented from binding any sTNF-α, thereby displacing it into the supernatant to 
be detected by the ELISA. The concentration response curve indicated that 1 μg /ml of 
TNFR2 mAb was sufficient to block the cell surface receptors on 0.45 million monocytes. 
However, to be sure this was the case an excess of TNFR2 mAb was used in further 
experiments, at a concentration of 10 μg/ml.  
In contrast, no detectable increase in sTNF-α was observed with increasing concentrations of 
TNFR1 mAb. This was unlikely to be due to insufficient concentration of the receptor mAb. 
Product datasheets for the antibodies outline that the concentration of TNFR1 mAb required 
to prevent 50% of sTNF-α induced cytotoxicity in mouse fibroblasts is at most two to four 
times greater than for TNFR2 mAb (298, 299). As TNFR2 ligation by mAb was beginning to 
occur with concentrations as low as 100 ng/ml of mAb, displacing sTNF-α, then it is 
impossible based on product characteristics that concentrations of TNFR1 mAb two orders of 
magnitude greater would not be ligating TNFR1. The same concentration of TNFR1 mAb (10 
μg/ml) was therefore chosen for all future experiments. An alternative method to determine 
optimum concentrations of receptor mAbs required to block receptors such as using flow 
cytometry was not used. This was because the location of binding of fluorophore labelled 
flow cytometry antibodies to the receptors could not be confirmed with the manufacturers as 
epitope locations for mAb binding are not characterised in detail (direct communication with 
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Dr E. Fioravanti, R and D Systems, 27th November 2015). If the flow cytometry TNFR mAbs 
bind at an alternate epitope of the receptor to the functional blocking mAbs then using this 
method to assess optimal concentration would be not be accurate in determining the 
proportion of TNF-α receptors blocked by mAb. 
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Figure 5-8 Determining the concentration of TNFR1 and TNFR2 mAb needed to 
prevent TNF-α binding to its cell surface receptors 
The graph shows monocytes from one subject stimulated for 24 hours with LPS in the 
presence of increasing concentrations of either TNFR1 mAb, TNFR2 mAb or both. The 
concentration of mAbs required to occupy all of either of the receptors was estimated 
indirectly by measuring the concentration of secreted sTNF-α prevented from binding to its 
receptor and hence detectable by ELISA. A concentration-response curve was observed for 
TNFR2 mAb but not TNFR1 mAb. Starting concentration of TNFR1/TNFR2 mAb= 1 ng/ml 
(0 on logarithmic x-axis). The concentration of sTNF-α at 24 hours in cells stimulated with 
LPS in the absence of either mAb was 1842.5 pg/ml.  
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5.2.3 TNF-α induces cytokine mRNA expression in monocytes via a positive feedback 
loop 
To determine whether autocrine binding of TNF-α has a positive feedback effect, cells from 4 
subjects were stimulated with LPS in the presence or absence of TNF-α mAb and the 
supernatants and monocytes were collected separately at 0, 2, 4, 8, 20, 32 and 48 hours post 
stimulation (0.25 million cells per well). As experiments presented in chapter 4 had already 
demonstrated an autocrine feedback loop leading to reduction in CXCL8 output (figure 4.11) 
the following statistical tests were applied as one-tailed tests.  
Messenger RNA expression of TNF-α, CXCL8, IL-1β, IL-6, IL-10 and TGF-β was quantified 
at each time point and presented as time course curves with calculated AUC values (figure 
5.9). TNF-α mRNA expression was not affected by blockade of secreted TNF-α, however 
CXCL8, IL-1β, IL-6 and IL-10 expression was reduced in the presence of TNF-α mAb. TGF-
β mRNA was not affected by the blockade of secreted TNF-α, indicating that TNF-α did not 
affect its regulation as it has been shown to do in other cell types (300). TGF-β is 
constitutively expressed in human tissues (301) and the data in figure 5.6 suggested that LPS 
may actually down-regulate its expression by human monocytes over time. Using LPS as a 
model of natural TNF-α secretion was therefore determined not to be useful in assessing the 
effect of TNF-α on TGF-β mRNA expression by monocytes. TGF-β as an example of an anti-
inflammatory cytokine was therefore not studied further in this thesis. 
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Figure 5-9 Effect of the TNF-α mAb on pro- and anti-inflammatory cytokine mRNA 
expression in LPS-stimulated monocytes  
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 TNF-α CXCL8 IL-1β  IL-6 IL-10 TGF-β 
LPS- median 
(range) AUC 
(ΔCT.hours) 
159.34 
(85.58-
232.56) 
3049.63 
(2169.80-
3696.88) 
1571.21 
(1436.36-
1890.55) 
241.73 
(120.37-
1021.56) 
10.85  
(8.28-12.53) 
32.57 
(21.28-
50.13) 
LPS/anti-TNF-α 
mAb- median 
(range) AUC 
(ΔCT.hours) 
152.11 
(54.26-
197.02) 
2247.92 
(1678.88-
2988.08) 
940.22 
(885.30-
1394.20) 
144.08 
(92.66-
234.90) 
5.78  
(3.84-9.64) 
29.09 
(18.40-
48.81) 
One-tailed  
p-values 
 p=0.03 p=0.03 p=0.03 p=0.03  
 
Each figure illustrates a time course experiment showing cytokine mRNA expression by 
monocytes stimulated with LPS, in the presence or absence of the TNF-α mAb. Data points 
are expressed as median (range). AUC was calculated for each subject’s time course profiles 
and the two values compared using the Wilcoxon Signed Rank Test as shown in the table. P-
values are one-tailed.  
 
To confirm that TNF-α blockade would also influence the secreted protein, the concentration 
of one of the cytokines, CXCL8, was determined in the cell-free supernatants at each time 
point by ELISA (each condition was run in duplicate). This is illustrated in figure 5.10. 
Significantly less CXCL8 was secreted in the presence of TNF-α mAb, however the absolute 
differences were small. 
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Figure 5-10 Effect of TNF-α mAb on CXCL8 in the cell-free supernatant of LPS-
stimulated monocytes.  
The figure illustrates a time course experiment showing CXCL8 protein secreted by 
monocytes stimulated with LPS, in the presence or absence of TNF-α mAb. Data points are 
expressed as median (range). AUC was calculated for each subject’s time course profiles and 
AUC values compared using the Wilcoxon Signed Rank Test. P-values are one-tailed. A 
significantly lower AUC value in the presence of TNF-α mAb was observed (5222.21 
ng.hour.ml-1 versus 5771.49 ng.hour.ml-1 ;one tailed p=0.03). 
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5.2.4 TNF-α induced pro-inflammatory cytokine expression may be induced via 
TNFR1 and anti-inflammatory cytokine expression via both TNFR1 and TNFR2 
To determine the role of individual TNF-α receptors following autocrine binding of TNF-α, 
monocytes from 7 subjects (0.25 million cells per well) were cultured for 20 hours following 
stimulation with 100 ng/ml of LPS in the presence or absence of 10 μg/ml of TNF-α R1 mAb 
or TNF-α R2 mAb or both. Figure 5.11 shows that significant reductions in expression of IL-
1β and IL-10 mRNA were observed when both receptors were blocked. A trend was observed 
across all the cytokines (with the exception of TNF-α) for TNFR1 blockade to reduce 
cytokine mRNA expression. For IL-1β and IL-10 this fell just short of reaching statistical 
significance (both p=0.05). A trend was also observed for TNFR2 blockade to reduce IL-10 
mRNA expression (p=0.09). This suggests but does not prove that TNF-α induced pro-
inflammatory cytokine expression may be induced via TNFR1 and anti-inflammatory 
cytokine expression via both TNFR1 and TNFR2. As expected from the studies using TNF-α 
blockade with a TNF-α mAb (figure 5.9), there was also no significant effect of blocking 
either receptor on TNF-α mRNA in this experimental system. 
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Figure 5-11 Effect of selective TNF-α receptor blockade on cytokine mRNA expression 
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Monocytes were stimulated with LPS (positive control) for 20 hours, alone or in the presence 
of TNFR1 or TNFR2 mAb or both, and cytokine mRNA expression measured. Each 
experimental condition shows individual data points with median values shown as bars. 
Overall differences between experimental conditions for each cytokine were assessed with a 
Friedman’s test and post hoc pairwise comparisons with the positive control conducted if 
appropriate (unadjusted p-values were first corrected by multiplying by 3 and are shown on 
the figures where significant) a) TNF-α: Friedman’s test non-significant b) CXCL8: 
Friedman’s test p=0.03. c) IL-1β: Friedman’s test p<0.01 d) IL-6: Friedman’s test non-
significant e) IL-10: Friedman’s test p<0.01. 
 
5.2.5 TNFR1 and TNFR2 surface expression on monocytes and in response to LPS 
Next the expression of TNFR1 and TNFR2 was examined on the monocyte surface. Flow 
cytometry was conducted as described in 2.8. Fluorescence spillover was detected in both 
band pass filters. 13.4% and 3.7% of signal was deducted from the PE (TNFR1) filter and the 
FITC (TNFR2) filter respectively to compensate for spillover into these channels.  
Figure 5.12 shows the distribution of the pattern of receptor expression on freshly isolated 
monocytes (time zero) and monocytes stimulated with LPS for 22 hours. Monocytes differed 
in their cell surface expression of the receptors, some expressing TNFR1 alone, TNFR2 alone, 
both receptors, or neither receptor. Experimental conditions were conducted in duplicate from 
time 3 onwards. Unfortunately because of intersubject variation encountered in the number of 
monocytes isolated from the same extracted volumes of blood, four subjects whose samples 
were taken on the same day did not have enough monocytes to conduct each time point in 
duplicate. A decision was reached to run time zero experiments (in which the issue of cell loss 
due to apoptosis reducing viable gated events would not be an issue) only once in order that 
later time points could be conducted in duplicate. Example overlay histograms are shown in 
figure 5.13. 
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Figure 5-12 Pattern of TNF-α receptor expression on monocytes 
Each column shows the mean percentage of monocytes (with SD bars) expressing each of the 
four possible cell surface receptor combinations from 6 subjects. Differences between 
experimental conditions for each cytokine were assessed with a Friedman’s test and post hoc 
pairwise comparisons conducted if appropriate (a Dunn-Bonferroni correction was applied to 
unadjusted p-values). Significant differences are shown as horizontal lines. a) Freshly isolated 
unstimulated monocytes. Friedman’s test non-significant (p=0.09). b) Monocytes stimulated 
for 22 hours with LPS. Friedman’s test p=0.02. The table shows the raw data for freshly 
isolated monocytes for each of the six subjects. 
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Figure 5-13 TNF-α receptor expression on freshly isolated monocytes- an example of 
overlay histograms 
Overlay histograms are shown for gated monocytes from one subject. a) Two histograms are 
shown with fluorescence intensity in the PE channel on the x-axis (logarithmic scale) and cell 
count on the y-axis. The black histogram represents monocytes incubated with a PE-labelled 
isotype control antibody. The pink histogram represents monocytes labelled with PE-TNFR1 
mAb. b) The black histogram represents monocytes incubated with a FITC-labelled isotype 
control antibody. The pink histogram represents monocytes labelled with FITC-TNFR2 mAb. 
Red vertical markers are shown on both figures to delineate fluorescence due to specific 
binding of mAbs to the cell surface receptor of interest (to the right of the set marker) from 
that due to non-specific binding of flow cytometry antibodies and autofluorescence (to the left 
of the marker).  
 
Next the expression of TNFR1 and TNFR2 on LPS-stimulated monocytes was examined over 
time. MFI results are expressed as a ratio of the positively labelled monocytes to the MFI of 
monocyte samples incubated with the immunoglobulin isotype control Ab. Figure 5.14 shows 
that TNFR1 expression reduced by 6 hours post LPS stimulation with a trend for a subsequent 
increase by 22 hours post stimulation back to baseline expression. No post-hoc significant 
differences in TNFR2 expression were observed over time when comparing with time zero, 
although there was a trend for expression to increase by 22 hours post stimulation. Example 
quadrant dot plots and overlay histograms are shown in figure 5.15. 
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Figure 5-14 Changes to TNF-α receptor cell surface expression over time 
Each time-point shows individual subjects’ MFI ratios, of the MFI of monocytes labelled with 
TNFR1/TNFR2 flow cytometry mAbs to the MFI of monocytes labelled with isotype control 
Ab. Median values are displayed as horizontal lines. Differences between time-points were 
assessed with a Friedman’s test with post hoc pairwise comparisons as appropriate, 
comparing to time 0 (unadjusted p-values were first corrected by multiplying by 3 and are 
shown on the figure where significant). a) TNFR1 expression: Friedman’s test (p<0.01) b) 
TNFR2 expression: Friedman’s test (p<0.01). 
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Figure 5-15 Changes to TNF-α receptor cell surface expression over time- an example of 
quadrant plots and overlay histograms 
An example quadrant dot plot and overlay histograms are shown for gated monocytes from 
one subject. a) The dot plot illustrates freshly isolated (time 0) monocytes incubated with an 
isotype control flow cytometry Ab. A quadrant gate is set from these cells as shown by the red 
markers. b) The dot plot shows the percentage breakdown of freshly isolated monocytes by 
TNFR1 and TNFR2 status: TNFR1 only (upper left quadrant), TNFR2 only (lower right 
quadrant), both receptors (upper right quadrant) and neither receptor (lower left quadrant). c) 
Two histograms are shown, with fluorescence intensity in the FITC channel on the x-axis 
(logarithmic scale) and cell count on the y-axis. The black histogram represents freshly 
isolated monocytes incubated with a FITC-labelled isotype control Ab. The pink histogram 
represents monocytes labelled with FITC-TNFR2 mAb. d) The black histogram represents 
monocytes which had been stimulated for 3 hours with LPS, incubated with a FITC-labelled 
isotype control Ab. The pink histogram represents monocytes labelled with FITC-TNFR2 
mAb. Red vertical markers are shown on both figures to delineate fluorescence due to specific 
binding of mAbs to the cell surface receptor of interest (to the right of the set marker) from 
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that due to non-specific binding of flow cytometry antibodies and autofluorescence (to the left 
of the marker). Note the slight shift in fluorescence of control Ab labelled cells to the right 
(comparing black histograms in c and d) suggesting greater non-specific binding occurring at 
this later time-point, which illustrates the importance of presenting MFI ratios. 
 
5.2.6 The autocrine effect of TNF-α on cell surface TNFR1 and TNFR2 
Further experiments investigated the hypothesis that changes to TNFR1 and/or TNFR2 
expression over time were in part mediated by autocrine feedback loops. Monocytes from 6 
subjects (0.25 million cells per condition, in duplicate) were stimulated with LPS for 20 hours 
with and without an excess of TNF-α mAb (to attempt to ensure that all sTNF-α and mTNF-α 
was blocked). Twenty five μg/ml of TNF-α mAb was used. Figure 5.16 shows that blockade 
of sTNF-α/mTNF-α led to a trend for a decrease in the expression per cell of TNFR1 (non-
significant p=0.05). A trend for reduction was also observed if TNFR2 specifically was 
blocked rather than the TNF-α molecule itself  (non-significant p=0.05), suggesting that 
TNFR1 expression is in part driven by TNF-α signalling via TNFR2. Conversely, a slight 
increase in TNFR2 expression was observed when TNF-α was blocked (median MFI ratio 
7.41, range 4.05 to 10.26 compared to 7.70, range 4.82 to 11.54; p=0.03). No difference was 
observed when TNFR1 was blocked rather than the TNF-α molecule itself. Figure 5.17 shows 
an example of flow cytometry histograms from one subject.  
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Figure 5-16 Effect of TNF-α blockade on TNF-α receptor cell surface expression 
 
TNFR1 median MFI 
ratio (range) 
LPS LPS and anti-TNF-α 
mAb 
LPS and anti-
TNFR2 mAb 
P 
value 
 4.41 (1.12-6.72) 3.22 (1.24- 4.86)  p=0.05 (non-
significant) 
 4.41 (1.12-6.72)  2.18 (1.20-2.80) p=0.05 (non-
significant) 
TNFR2 median MFI 
ratio (range) 
LPS LPS and anti-TNF-α 
mAb 
LPS and anti-
TNFR1 mAb 
P value 
 7.41 (4.05- 10.26) 7.70 (4.82- 11.54)  p=0.03 
 7.41 (4.05- 10.26)  7.47 (4.95- 11.68) p=0.17 (non-
significant) 
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Each figure shows individual subjects’ paired MFI ratios (of the MFI of positively labelled 
samples to the MFI of cells labelled with isotype control flow cytometry Ab). Differences 
between LPS stimulated cells and other experimental conditions were assessed using a 
Wilcoxon Signed ranks test. Significant differences are shown with horizontal lines. a) The 
effect of global TNF-α blockade on TNFR1 expression. b) The effect of selective TNFR2 
blockade on TNFR1 expression. c) The effect of global TNF-α blockade on TNFR2 
expression. d) The effect of selective TNFR1 blockade on TNFR2 expression. Monocytes 
were stimulated for 20 hours. Median and range values are supplied in the table. 
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Figure 5-17 Effect of TNF-α blockade on TNF-α receptor cell surface expression- an 
example of overlay histograms 
Overlay histograms are shown for gated monocytes from one subject. a) Four histograms are 
shown, with fluorescence intensity in the PE channel on the x-axis (logarithmic scale) and cell 
count on the y-axis. The black histogram represents LPS-stimulated monocytes incubated 
with a PE-labelled isotype control Ab. The red histogram represents monocytes stimulated 
with LPS and labelled with PE-TNFR1 mAb. Green and pink histograms represent LPS-
stimulated monocytes incubated in the presence of TNF-α mAb or TNFR2 mAb respectively 
and then labelled with PE-TNFR1 mAb. b) Four histograms are shown, with fluorescence 
intensity in the FITC channel on the x-axis and cell count on the y-axis. The black histogram 
represents LPS-stimulated monocytes incubated with a FITC-labelled isotype control 
antibody. The red histogram represents monocytes stimulated with LPS and labelled with 
FITC-TNFR2 mAb. Green and pink histograms represent LPS-stimulated monocytes 
incubated in the presence of TNF-α mAb or TNFR1 mAb respectively and then labelled with 
FITC-TNFR2 mAb (in this example none of the experimental conditions had an effect on 
TNFR2 expression). Each of the three experimental conditions were conducted alongside 
samples subjected to the same conditions but incubated with an isotype control flow 
cytometry antibody. As all isotype control histograms overlaid each other only one of three is 
shown in each figure for ease of visualisation. 
 
Next it was determined if the addition of a TNF-α mAb to LPS-stimulated monocytes had any 
effect on the concentration of soluble TNFR1 or TNFR2, in particular to investigate whether 
the reduction in cell surface TNFR1 was due to increased shedding of the receptor into the 
peri-cellular environment, rather than an alternative mechanism such as decreased intra-
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cellular manufacture and expression at the cell surface. The cell free supernatants from 
previously outlined experiments whereby monocytes were stimulated with LPS with and 
without a TNF-α mAb present for 22 hours were harvested to detect any TNFR1/TNFR2 
shedding, using ELISAs able to detect both free and TNF-α-bound receptors. Blockade of 
TNF-α using TNF-α mAb showed trends only for a small increase in soluble TNFR1 and 
TNFR2 in the supernatant (figure 5.18).  
 
 LPS LPS and TNF-α mAb P-values 
Soluble TNFR1 (pg/ml) 100.08 (93.11- 115.16) 107.95 (91.58- 118.43) p=0.05 (non-significant) 
Soluble TNFR2 (pg/ml) 395.16 (313.16- 705.58) 426.20 (294.24- 809.11) p=0.08 (non-significant) 
 
Figure 5-18 Effect of TNF-α blockade on the concentration of soluble TNFR1 and 
TNFR2 in the supernatant of LPS-stimulated monocytes  
The figures show paired data for each subject. Differences between LPS stimulated 
monocytes and monocytes co-incubated with TNF-α mAb were assessed using a Wilcoxon 
Signed Ranks test. Median and range values are shown in the table. Monocytes were 
stimulated for 22 hours. 
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5.3 Discussion 
Although it is well recognised that TNF-α can signal in an autocrine fashion (3, 166, 302), 
relatively little is known about the autocrine effect of this cytokine specifically on its major 
source, monocytes. The studies in this chapter provide evidence to support some of the stated 
hypotheses and further understanding of TNF-α autocrine feedback loops and the roles of 
TNR1 and TNFR2 in human monocytes. 
Firstly, time course experiments were conducted to determine if LPS was an appropriate 
stimulant of a number of pro-and anti-inflammatory cytokines. All cytokines, with the 
exception of TGF-β were up-regulated by LPS stimulation compared to monocytes cultured in 
the absence of an exogenous stimulus (figures 5.1 to 5.6). Blockade of secreted and 
membrane bound TNF-α in this LPS model led to significant reductions in the mRNA output 
over time of CXCL8, IL-1β, IL-6, and IL-10 (figure 5.9) as hypothesised (hypothesis one). 
The degree of reduction varied between cytokines, for example only a slight reduction was 
observed for CXCL8. The clinical significance of the degree of reduction and whether this 
variation was stimulus specific is unknown. A statistically significant reduction in CXCL8 
protein concentration supported the hypothesis that reduction in cytokine production as a 
result of prevention of TNF-α autocrine binding translated through to the protein level (figure 
5.10).  
The second hypothesis that TNF-α autocrine feedback loops in monocytes occur via TNFR1 
for pro-inflammatory cytokine production and via TNFR2 for anti-inflammatory cytokine 
production was not found to be true (figure 5.11). Trends for reduction in the pro-
inflammatory cytokines IL-1β, CXCL8 and IL-6 and anti-inflammatory IL-10 when TNFR1 
alone was blocked were observed but did not reach statistical significance. A trend for 
reduction in IL-10 when TNFR2 alone was blocked and for additive reduction in the face of 
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dual receptor blockade suggests that IL-10 pathways are switched on by TNF-α activating 
either of its receptors, in contrast to the other cytokines. This requires further study with a 
larger sample size. That IL-10 was also produced by monocytes in response to LPS as 
previously shown (303), with an additional positive feedback effect of TNF-α on IL-10 
mRNA expression is in keeping with data from previous studies in monocyte/monocyte-
derived cells (222, 224, 302) and human and animal studies (266, 304). This illustrates the 
inherent complexity of the feedback loops of many cytokines as IL-10 itself plays a role in 
down regulating TNF-α (223, 305). If in repeat experiments IL-10 is shown to be up-regulated 
by both TNFR1 and TNFR2 this could have important clinical implications as IL-10 is a key 
immunoregulatory cytokine with anti-inflammatory effects in many diseases (306). 
Monocytes, in particular the dominant CD14+ CD16- monocyte and other cells of the 
monocyte lineage, are a major source of IL-10 (307). By blocking the TNF-α molecule itself, 
some autocrine up-regulation of IL-10 as result of TNF-α binding might be lost, disrupting the 
pro-inflammatory/anti-inflammatory balance. Thus selective blockade of TNFR1 in a clinical 
setting could ameliorate the pro-inflammatory effects of TNF-α, whilst allowing on-going 
synergistic effects of the predominantly anti-inflammatory IL-10. This might be especially 
relevant in diseases in which monocytes and/or macrophages play an important role, for 
example, inflammatory arthropathies, psoriasis, IBD and multiple sclerosis (308-312).  
An experiment was conducted to investigate the third hypothesis that the decrease in 
measurable sTNF-α over time in the supernatant of LPS-stimulated monocytes was due to 
autocrine binding to its receptors. This confirmed that blockade of TNFR2 led to a large 
increase in detectable sTNF-α as hypothesised (figure 5.7). The role of this possible extensive 
sTNF-α binding to TNFR2 is uncertain as only mTNF-α activates TNFR2 (165, 167). It is 
possible that the TNF-α-TNFR2 complex is internalised as shown previously (313) and the 
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cytokine degraded. This concept requires further study as the current experiments studied 
monocytes in isolation and hence did not assess competition for TNFR1 on other cell types. 
Alternative explanations for the rise in sTNF-α are also possible. For example, by blocking 
the receptor the TNFR2 mAb may have prevented mTNF-α from inducing intra-cellular 
signalling pathways that switch off further TNF-α production and/or secretion into the 
supernatant. As a result sTNF-α would be detected at higher concentration in the supernatant. 
In isolation this hypothesis does not explain why in figure 5.7 sTNF-α is observed to decrease 
with time rather than reach a plateau. A second explanation, such as protein degradation 
within the CM would also have to occur. In addition, the data presented in figure 5.11a do not 
support the hypothesis that mTNF-α acting via TNFR2 down-regulates further TNF-α mRNA 
production as blockade of TNFR2 had no significant effect on TNF-α mRNA expression. 
However, it remains theoretically possible that mTNF-α signalling via TNFR2 could 
negatively affect later steps in TNF-α production, such as translation, post-translational 
modification or cleavage from the cell surface membrane, and therefore blockade of TNFR2 
would lead to a rise in detectable sTNF-α. It must also be considered that the apoptotic 
monocytes present might be responsible for the reduction in sTNF-α over time, for example, 
if TNFR1 or TNFR2 increased at the cell surface during early apoptosis this might provide 
enhanced sTNF-α clearance from the supernatant. If TNF-α signalling via TNFR2 increased 
monocyte apoptosis then blocking this receptor could explain the increase in sTNF-α in the 
supernatant (figure 5.7) as reduced apoptosis of monocytes would occur. This seems an 
unlikely explanation though as Dreschers et al have recently shown that TNF-α driven 
monocyte apoptosis occurs specifically via TNFR1 ligation and endocytosis, rather than 
TNFR2 (289). 
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The final hypothesis in this chapter concerned the cell surface expression of TNFR1 and 
TNFR2, specifically that TNF-α autocrine feedback loops would influence their expression. 
The alternative hypothesis was only met in part. Figure 5.12 and the table of raw data 
provided show that there was a large intersubject variation in receptor expression pattern in 
freshly isolated (and LPS-stimulated) monocytes. This made showing a statistically 
significant difference in expression pattern difficult with a sample size of six. Certainly there 
was a trend for the least frequent phenotype to be that of monocytes expressing TNFR1 only. 
Figure 5.14a showed that the density of TNFR1 receptors per monocyte (as expressed by 
suurogate marker MFI ratio) decreased over the first 6 hours with a trend for a subsequent 
increase by 22 hours post LPS stimulation. This decrease may be due to internalisation of the 
TNF-α-TNFR1 complex that has been shown to occur in monocytes infected with bacteria 
(289) rather than a decrease in production of the receptor. Although no statistically significant 
comparisons with time 0 were observed, the density of TNFR2 receptors per monocyte 
showed a trend to increase by 22 hours (figure 5.14b).  
To determine if TNF-α autocrine feedback loops were involved in influencing expression 
density of either receptor, LPS-stimulated monocytes were incubated with TNF-α mAb or a 
mAb to TNFR1 or TNFR2. Subsequent comparison of receptor expression was determined 
and showed a trend for blockade of the TNF-α molecule itself to reduce TNFR1 expression by 
27% and selective TNFR2 blockade by 51% (figure 5.16). This supports but does not prove 
the hypothesis that TNF-α autocrine feedback loops contribute to some of the expression of 
TNFR1 at the monocyte surface in LPS-stimulated cells and that this occurs via TNFR2 
activation. Given the trend for greater reduction in TNFR1 expression when TNFR2 only is 
blocked one can hypothesise further that autocrine feedback via TNFR1 may either down-
regulate its own production or perhaps lead to greater internalisation of TNF-α-TNFR1 
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complexes with resultant decrease in cell surface expression. This would require further 
study. A 4% increase in TNFR2 expression was observed when TNF-α was blocked but the 
clinical significance of this is unknown (figure 5.16). Similarly, the trend observed of a slight 
increase in sTNFR1 in the supernatant of LPS stimulated monocytes incubated with TNF-α 
mAb (figure 5.18) is unlikely to reflect an autocrine feedback loop preventing TNFR1 
cleavage, at least not enough to explain the 51% reduction in surface TNFR1 when TNF-α 
autocrine binding to TNFR2 was prevented. Therefore, it remains more likely that TNF-α 
autocrine feedback via TNFR2 leads to greater production of TNFR1 or expression of it at the 
cell surface. However, this experiment was limited by being able to measure sTNFR1 and 
TNFR2 at one time-point only rather than as part of a time-course profile. 
The results presented in this chapter support other authors’ work regarding the function of 
both receptors. Both TNF-α receptors have high affinity for sTNF-α (164). Dissociation of 
TNF-α from TNFR1 is far slower than from TNFR2 and thus it had been assumed that most 
downstream effects occurred through the stable TNF-α-TNFR1 complex. TNFR2 has high 
“on-off” kinetics with the ligand moving on and off the receptor repeatedly due to its 
reasonable affinity and fast dissociation rates (163, 164). It was initially suggested that the 
purpose of the high on-off kinetics of TNFR2 was to create a peri-cellular environment in 
which soluble TNF-α is abundant at the cell surface and hence more readily available to bind 
to TNFR1, mediating downstream effects (ligand-passing) (163, 168). The data presented 
here argues against this and agrees with other authors (164, 169), as selective TNFR2 
blockade did not down-regulate IL-1β, CXCL8 or IL-6 mRNA expression (figure 5.11), 
which would be expected were sTNF-α ligand-passing by TNFR2 necessary for activation of 
TNFR1 pathways. The current experiments cannot differentiate TNFR1 pathway activation 
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due to mTNF-α from that due to sTNF-α binding, but sTNF-α is believed to be the main 
activator of TNFR1 (165, 167).   
Taken together, the studies presented here suggest that TNF-α autocrine feedback loops occur 
in monocytes and that pro-inflammatory cytokine up-regulation occurs via TNFR1 with both 
receptors allowing up-regulation of IL-10. In addition TNF-α autocrine feedback loops likely 
drive some of the expression of TNFR1 at the monocyte surface and this occurs via TNFR2 
autocrine feedback. Lastly, the studies suggest that much of the TNF-α secreted into the CM 
may bind back to the monocyte surface, via TNFR2. This may reflect a previously 
unrecognised homeostatic mechanism for clearing TNF-α from the peri-cellular environment 
as sTNF-α is not thought to activate intra-cellular signalling pathways (165). However, the 
presented data must be interpreted with caution due to a number of experimental limitations 
and the need for future experiments to verify these findings and/or eliminate alternative 
explanations. Strengths and limitations of the studies are considered further below and areas 
for future study are considered in detail in chapter 6. 
There are some limitations to the studies. For example, many of the experiments were 
conducted with insufficient control arms. Specifically, all experiments involving TNF-α or 
TNFR1/2 mAbs should have been run with an additional condition whereby the cells were 
exposed to the same experimental conditions but the mAb replaced with a matched isotype 
control at the same concentration (e.g. an IgG1 irrelevant antibody should be used alongside 
an IgG1 mAb binding TNF-α). This would rule out any effect of the mAb unrelated to its 
specific ligand binding effect, for example binding of the antibody to the monocyte Fc 
receptors via its Fc region. Although an early experiment (figure 3.7) had shown that an 
isotype control Ab did not reduce TNF-α induced CXCL8 secretion, compared to the presence 
of a TNF-α mAb, it would still be vital in future studies to include this negative control in 
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each experiment. The experiment in which TNFR1 and TNFR2 expression was considered 
over time in response to LPS (figure 5.14) should have had a negative control using CM 
without LPS, as without an unstimulated control arm to the experiment it is impossible to 
conclude that any effects observed are due to LPS rather than other factors within the culture 
process. This experiment would also have benefitted from the addition of further time-points 
between 6 and 22 hours. With respect to flow cytometry it would be optimal in future to 
purchase matched mAbs and isotype controls from a supplier that ensures the fluorophore to 
protein ratio are equal for both (and provides information on this). If the fluorophore to 
protein ratios vary then calculated MFI ratios may be erroneous. 
A further limitation in this chapter was the small sample sizes. Whilst trends were observed 
many results did not reach statistical significance and clearly greater numbers of subjects 
should be studied in future to determine if these trends were genuine, particularly where 
multiple comparisons were taking place with subsequent correction to p-values. Whilst 
corrections such as the Dunn-Bonferroni correction are important to reduce the incidence of 
type one statistical errors that can occur through multiple testing they will conversely reduce 
the power of a study and increase the chance of making a type two error (314). However, the 
results presented in this thesis can be considered preliminary and useful in powering future 
studies. 
Several limitations must be considered with respect to the accuracy of the flow cytometry data 
showing the proportions of monocytes bearing each combination of TNF-α receptor (figure 
5.12). Although it was possible to collect 10000 gated events for monocytes which had just 
been isolated, there was noted to be a considerable intersubject variation in the breakdown of 
expression patterns, and most commonly (but not always) it was cells expressing TNFR1 or 
neither receptor which fell into the category of rare events, in some cases making up only 0.1 
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to 5% of total monocytes in the gate. Expert opinion suggests that to obtain a CV% of 5% for 
positive events occurring with a frequency of only 1 in 20 it is necessary to collect 8000 
events, for 1 in 100, 40000 events and for 1 in 1000, 400000 events (315). It was not feasible 
to attempt to gate more than 10000 monocytes in the current study as even with freshly 
isolated cells it would require a considerable extra volume of blood to be taken from each 
subject. In addition, as previously discussed there was a notable loss in viable cells over time, 
the degree of which varied between subjects. This made the time taken to run each sample 
through the flow cytometer quite lengthy as the apoptosed cells, apoptotic bodies and debris 
had to be counted as well, before finally gating over the viable population of monocytes. To 
achieve 40000 viable monocyte events would therefore require large volumes of blood and 
time. The fastest flow cytometers (not available in our laboratory) can now process up to 
100,000 events per second, so should this equipment be available it would be useful to focus 
on this area of differential receptor expression patterns in more detail and repeat all 
experiments with more cells. 
CD14+CD16- monocytes were chosen to be studied in isolation as the CD14+CD16- subset 
constitutes 90% of total circulating monocytes, is capable of producing TNF-α and is also the 
subset that produces the greatest quantity of IL-10 (204). Results presented in chapter 3 
showed that the cell isolates may have been contaminated with CD14+CD16+ monocytes, 
which may or may not have been activated by bound anti-CD16 mAbs during the extraction 
process or alternatively some monocytes may have actually become CD16+. How this would 
affect the results is unknown as functional differences between monocyte subsets is currently 
an emerging research field. In redesigning these experiments it would be preferable to extract 
monocytes from whole blood using a flow cytometry cell sorter. This would allow a quicker 
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extraction process and permit the monocytes to be subdivided based upon CD14 and CD16 
status. 
Previous authors studying the respective roles of the two receptors in monocytes have been 
limited by the use of exogenous sTNF-α which can bind but not fully activate TNFR2 (165). 
Alternatively they have used mutant forms of TNF-α which can activate TNFR2 and/or 
commercially available cell lines where mTNF-α has been over-expressed (165, 316, 317). 
Whilst useful, these models may not bear close resemblance to the events occurring with 
naturally occurring mTNF-α. In the present experimental system LPS was used as a potent 
inducer of TNF-α (318) which overcomes this particular issue, as in order to release sTNF-α, 
mTNF-α must first be produced, hence providing confidence that activation of receptors could 
occur through both forms of the cytokine. The same batch of LPS, diluted and stored frozen in 
aliquots to reduce freeze thaw cycles to one per experiment, was used throughout this thesis 
as it is recognised that the properties of LPS can vary between bacterial sources and even 
between separate batches from the same strain (255) and this may introduce error into the 
results.  
The initial experiments demonstrated that the expression of pro-inflammatory cytokines in 
monocytes was up-regulated by autocrine binding of TNF-α (figure 5.9). No effect of TNF-α 
autocrine feedback on its own expression was observed, which contrasts with other studies 
that have shown that exogenous TNF-α can induce TNF-α gene transcription (217, 221). This 
may be one drawback of using LPS as a stimulant. As LPS is known to have wide ranging 
effects (296) it is possible that this observed lack of effect (and that in TGF-β expression also) 
is because other pathways activated by LPS ligation switch off TNF-α signalling after time, 
preventing further up-regulation by autocrine binding of secreted TNF-α. Despite this 
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accepted limitation, it is clear using the current model that TNF-α was having a number of 
autocrine effects on monocytes. 
It was common at later time-points, particularly in monocytes incubated in CM without LPS 
for varying proportions of the cells to be undergoing early or late stage apoptosis (as has been 
shown in other studies (319, 320)). The presence of apoptotic monocytes resulted in a number 
of technical issues, principally reduced numbers of viable cells to gate over and longer transit 
time of samples through the flow cytometer to achieve as many events within the monocyte 
gate as possible (presumably due to apoptotic bodies increasing the overall numbers of 
events). What remains unknown is the possible effects of the presence of apoptotic monocytes 
on the results of the presented experiments. Although generally apoptosis does not induce a 
pro-inflammatory environment in some cases this can occur. When the surrounding 
phagocytes (in this case live monocytes) are overwhelmed by the number of apoptotic cells 
and fail to effectively clear them via phagocytosis a process known as programmed necrosis 
may occur whereby the apoptotic cell membrane loses its integrity and intracellular contents 
such as DNA and heat shock proteins are released into the peri-cellular environment (287). 
These mediators can elicit pro-inflammatory effects. If this was occurring in the LPS-
stimulated monocytes and to varying degrees between subjects’ samples then these pro-
inflammatory mediators may have affected the outcomes obtained by influencing 
inflammatory pathways within live monocytes. Gating over the area on the forward-side 
scatter plot that contained debris and monocytes in late apoptosis (to the left of the plot as 
shown in figure 3.11a) demonstrated that these cells were still binding the TNFR1 and 
TNFR2 flow cytometry mAbs. As these monocytes were not concurrently labelled with 
markers of apoptosis one cannot know if monocytes in early or late apoptosis have a higher 
density of TNFR1 or TNFR2 than live monocytes and if so whether that might play a specific 
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role in removing sTNF-α from the cell culture supernatant. Lastly, as monocytes themselves 
act as phagoctyes (290, 291) it is likely that many of the live monocytes were phagocytosing 
the apoptotic monocytes which may also have activated them and altered their function, 
influencing the results obtained. 
Lastly it must be considered that limited information is available regarding the binding sites 
and possible effects of the mAbs used in this thesis, both the blocking mAbs and those used to 
bind TNFR1/2 in flow cytometry experiments. Exact binding sites to the epitopes in question 
are not characterised and the only information regarding the function of the blocking 
antibodies is from neutralisation experiments determining the concentration-dependent 
neutralising effect of the TNF-α and TNFR1/2 mAbs on TNF-α induced cytotoxicity in mouse 
fibroblasts (direct communication with Dr E. Fioravanti, Scientific Coordinator, R and D 
Systems, 27th November 2015). Whilst they are marketed for their general neutralising effect 
it is unknown whether they might inadvertently exert positive effects, for example through 
reverse signalling via binding to mTNF-α or by acting as partial agonists. Whilst other authors 
have shown that a soluble TNFR2:Ig receptor construct could induce TNF-α production by 
binding to mTNF-α and causing reverse signalling (321) the commercial anti-TNF-α mAb 
used in this thesis is unlikely to have had the same effect as TNF-α mRNA expression was 
unaffected in its presence. In addition, as full characterisation is unknown it is possible that 
the presence of blocking mAbs bound to their ligand might interfere with subsequent binding 
of one of the receptor flow cytometry mAbs. For example, it is possible that occupation of a 
TNFR2 receptor by TNFR2 mAb might impair binding of the TNFR1 flow cytometry mAb to 
an adjacent TNFR1 receptor. If this were the case then it would be incorrect for example to 
assume that the reduction in TNFR1 expression in LPS-stimulated monocytes incubated with 
TNFR2 mAb (figure 5.16) was due to interruption of autocrine feedback via TNFR2. It would 
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therefore be important to investigate receptor function using other methods to determine the 
validity of the data, for example using small interfering RNA molecules to knock out receptor 
expression and function.  
5.4 Conclusions 
In conclusion the studies presented here show that autocrine feedback loops do occur in 
monocytes and suggest that TNFR1 and TNFR2 have differential roles. Whilst TNFR1 may 
be the receptor through which pro-inflammatory cytokine production is up-regulated, with 
TNFR2 playing no role, both receptors may be able to up-regulate the anti-inflammatory 
cytokine IL-10 with an additive effect. A case for clear delineation into pro versus anti-
inflammatory roles for TNFR1 and TNFR2 in monocytes though cannot be made from the 
current studies as flow cytometry experiments suggested that TNF-α-TNFR2 binding led to 
up-regulation of TNFR1.  
The experiments presented here should be repeated with appropriate power analysis using the 
current preliminary data to do so, with adequate negative controls and using additional 
methods to verify findings (discussed in detail in chapter 6). It is generally accepted that in 
susceptible individuals TNF-α plays a key role in the pathogenesis of a number of chronic 
inflammatory diseases. TNFR1 is a ubiquitous receptor and as a result its ligation by the TNF-
α molecule has widespread pro-inflammatory effects, whereas TNFR2 expression is limited in 
the main to leukocytes and its function in humans has been less clear. Further studies should 
assist in clarifying the roles of the two receptors in monocytes and help to determine therefore 
if selective TNFR1 blockade might be a viable clinical treatment in diseases in which 
monocytes play a key role. 
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GENERAL DISCUSSION 
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6 General Discussion 
6.1 Summary of results 
The overarching hypothesis of this thesis was firstly that monocytes from A1ATD patients 
with COPD and the rs361525 TNF-A polymorphism (AG) would produce more TNF-α than 
monocytes from matched A1ATD patients with COPD and the wildtype allele (GG) and 
secondly that this increased TNF-α secretion would lead to greater autocrine up-regulation of 
pro-inflammatory cytokine production in the AG monocytes through an autocrine feedback 
loop occurring via TNFR1.  
The first component of the hypothesis was not found to be true, in fact in LPS-stimulated cells 
it was monocytes from GG subjects that secreted more TNF-α and CXCL8, although the 
validity of this finding is called into question when the high intrasubject variability of TNF-α 
secretion by monocytes over several weeks is considered. The results from these pilot 
experiments were used in power calculations to determine the numbers of patients that would 
be needed in repeat experiments to show a genuine difference between the groups, should this 
exist. The numbers required were prohibitive and as such the second component of the 
hypothesis was not investigated and further studies focussed on the autocrine effects of TNF-
α in monocytes from healthy subjects. 
There are many possible explanations for why the primary hypothesis was not met and an 
overview of these has been considered in chapter 4. However, it is worth considering some of 
these in greater detail.  
Firstly, the process beginning with a gene being transcribed and ending with the secretion of a 
final protein product is tremendously complex. Whilst the presence of a SNP in the promoter 
region of the gene may well affect transcriptional regulation of the coding portion of the gene 
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this might be confounded by the presence or absence of other regulatory steps under different 
circumstances.  
One example of this would be epigenetic processes, which are well recognised to affect TNF-
A transcription and post transcriptional modification of mRNA and these vary between cell 
types and in response to different stimuli. One form of epigenetic regulation which is being 
increasingly characterised is the effects of non-coding RNA transcripts, transcribed RNA but 
with no protein coding potential (145). For example, microRNA molecules have been 
demonstrated to suppress TNF-α output by LPS-stimulated monocytes through binding to 
complementary RNA in the TNF-α transcript, presumably by adversely affecting transcript 
stability (322, 323).  In a further example of how microRNAs can negatively regulate TNF-α, 
microRNA-346 has been shown to inhibit Bruton's tyrosine kinase expression in LPS-
stimulated THP-1 (monocytic cells) leading to increased tristetraprolin expression, a protein 
which inhibits TNF-α synthesis through binding to AU rich elements of TNF-α mRNA (324). 
In recent years there has been great interest in another type of non-coding RNA known as 
long-non coding RNAs (lncRNAs) which are more than 200 nucleotides in length. The full 
spectrum of mechanism of action of lncRNAs remains to elucidated but a number of authors 
have shown their repressive or stimulatory function in the control of pro-inflammatory 
cytokine gene expression in monocytes (325, 326). In monocyte cell lines, stimulated with 
LPS or PMA, knockdown of characterised lncRNAs upstream of the TNF-A gene led to 
increased TNF-α mRNA output, indicating a repressive function. Furthermore in this instance 
the transcribed lncRNAs were bound to chromatin and determined to work by binding a well 
known repressor protein, LRRFIP1, acting together as a complex to repress TNF-A 
transcription (325). Conversely, knockdown of lncRNA 1992 in stimulated THP-1 
macrophages strongly suppressed TNF-α production. The lncRNA was found to increase 
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TNF-α mRNA output by forming a complex with heterogenous nuclear ribonucleoprotein L 
which bound to the promoter region of the TNF-A gene to induce expression (327).  
These examples and other regulatory steps previously discussed in section 1.8 demonstrate 
that multiple processes, including epigenetic mechanisms, are involved in the control of TNF-
α production and it is likely that a large degree of cell and stimulus specificity and redundancy 
in these mechanisms exists. As such it is perhaps unsurprising that an association of the 
rs361525 polymorphism with high TNF-α output was not observed in monocytes from the 
systemic circulation in response simply to LPS or PMA, as an additional co-factor or 
epigenetic mechanism may need to be present to act in tandem with any change in 
transcription factor binding at the TNF-A polymorphism site to increase TNF-α output. 
Secondly, the effects of the rs361525 polymorphism may be specific to the airways rather 
than the systemic circulation and as such the monocyte may not have been the relevant cell to 
study. Many different cell types in the lungs are capable of secreting TNF-α, for example, 
macrophages (328), T-cells (144), neutrophils (75), epithelial cells (329) and vascular 
endothelial cells (78) and the effects of the polymorphism might be specific to one or more of 
these. Certainly, as monocytes and tissue macrophages are now recognised to have separate 
developmental pathways (208) it is likely that intra-cellular signalling pathways differ and 
this might apply to control of TNF-A transcription and hence possibly explain the lack of 
expected effect of the rs361525 polymorphism in blood monocytes, if its effects are only 
relevant in lung macrophages. A review of work conducted in human and murine monocytes 
and macrophages and monocyte/macrophage immortalised human cell lines does consider 
monocytes and macrophages largely as a single entity with respect to control mechanisms of 
TNF-A transcription (144, 145), however it is likely that there are differences in TNF-α 
pathways. For example, Lee et al showed that MDMs secreted more TNF-α than monocytes 
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and that this was partly dependent on epigenetic differences, specifically greater histone 
acetylation near to the promoter region in the macrophages, allowing transcription factor 
binding to the TNF-A promoter in a greater number of cells (147). As recent work in murine 
macrophages has shown, the effect of the rs361525 SNP is potentiated by multiple factors, in 
this case binding of transcription factors up-regulated by external stimuli but also binding of 
the thyroid hormone receptor preferentially to the A-allele (128). It is possible therefore that 
the polymorphism is relevant only in macrophages (or another cell type) in A1ATD subjects 
where other unknown co-factor molecules are present. 
Thirdly, it was the CB phenotype specifically that was shown to be associated with the 
rs361525 polymorphism by Wood et al (125) and it was spontaneous sputum samples from 
CB patients with and without the polymorphism that were studied by Sapey et al (17). It 
became evident after inital searching for suitable patients that matching individual pairs based 
on the presence or absence of the CB phenotype as well as other criteria would be difficult 
given that this is not the predominant phenotype in A1ATD (125). It is possible however that 
the polymorphism is only relevant within this phenotype of COPD, perhaps due to other 
interacting biological mediators present only in the CB phenotype which may interact with 
the polymorphism to affect TNF-α production. Should this be the case then matching would 
have been inadequate in the current studies.  
The second half of this thesis focused on investigating TNF-α autocrine feedback loops in 
monocytes from healthy subjects and the respective roles of TNFR1 and TNFR2. The studies 
for the most part were underpowered and hence many results could only be reported as trends. 
Never-the-less a number of the findings were interesting and warrant further study with 
greater subject numbers to determine if trends reflect true differences and the current studies 
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could be used to power these appropriately. In addition other experimental techniques should 
be used to corroborate the current findings and are described where appropriate. 
Whilst the first hypothesis that TNF-α autocrine feedback loops up-regulated the production 
of a number of cytokines was found to be true, the second, that pro-inflammatory cytokine 
production occurred via TNFR1 and anti-inflammatory cytokines via TNFR2, was not. As 
expected blocking TNFR2 had no effect on pro-inflammatory cytokines but there was a trend 
for reduction in IL-10 output. However, although TNFR1 blockade showed trends for 
reduction in pro-inflammatory cytokine output, it also demonstrated a trend for reduced IL-10 
suggesting that activation of TNFR1 pathways can not be clearly proscribed as having only 
pro-inflammatory effects.  
The third hypothesis that the decrease in measurable sTNF-α over time in the supernatant of 
cultured monocytes was due to autocrine binding to one or both of its receptors was suggested 
by the presented studies but not proven, and will require further study. Should this hypothesis 
be proven it is possible that differential TNF-α receptor expression on the surface of 
monocytes from A1ATD patients with and without the rs361525 polymorphism might be 
responsible for the findings in chapter 4. Specifically, should TNFR2 expression be greater on 
the surface of AG monocytes then any increased sTNF-α secretion may be negated in-vitro by 
an increase in its clearance from the supernatant by greater numbers of cell-bound TNFR2. 
Sapey et al reported differences in the concentration of TNFR1 in the sputum of AG patients 
(17) so it is possible that the increased TNF-α output in these patients may be influencing 
TNFR1 and/or TNFR2 pathways by some mechanism. 
The final hypothesis that TNF-α autocrine feedback loops in monocytes played a role in 
influencing the expression of TNFR1 and TNFR2 was suggested but not proven by the 
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current studies. TNF-α blockade and selective TNFR2 blockade led to trends for lower 
TNFR1 expression at the monocyte surface, falling short of statistical significance, suggesting 
that TNF-α autocrine feedback loops, occurring via TNFR2, positively affect TNFR1 
expression.  
Taken together these data suggest that the roles of TNFR1 and TNFR2 in monocytes cannot 
be clearly delineated into pro versus anti-inflammatory roles.  
In advancing the work from this thesis it would first be important to optimise current 
experimental protocols and address the issue of statistical power. Detailed discussion of 
experimental optimisation has been covered in individual chapters but are considered in brief 
here. 
Firstly, a cell sorting flow cytometer could be used to isolate monocytes, rather than the 
negative immunoselection bead-based kit used (330). This would be efficient, allow both 
classical, intermediate and non-classical monocytes to be studied and overcome the issue of 
possible contamination of isolates with CD14+CD16+ monocytes.  
Secondly, all experiments should include appropriate negative controls, for example, the use 
of isotype control antibodies as a negative control when studying the effect of TNF-α or TNF-
α receptor blockade on cytokine output by monocytes. This would control for any effect of 
binding of the Fc portion of a mAb to Fc receptors on the cell surface rather than that 
observed from targeted binding by the highly specific antigen binding fragment to an epitope 
on the cytokine or its receptor. 
Thirdly, flow cytometry work could be improved by running each set of cells as a multi-
coloured experiment, whereby cells are labelled with CD14, CD16, TNFR1 and TNFR2 
mAbs, allowing assessment of TNF-α receptor status to be further considered in the context of 
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monocyte subtypes. A viability dye should also be included as a marker in each tube to gate 
out dead cells from analysis.  
Finally, the data collected from the current experiments could be used to appropriately power 
future studies. The power of a study is affected by three factors, the sample size, the 
magnitude of true difference between the two groups and the SD of the group means (331). 
Sapey et al demonstrated a two log magnitude of difference in TNF-α concentration in the 
sputum of AG subjects with A1ATD and CB compared to GG subjects (17) but no 
preliminary data was available from AG and GG monocytes from A1ATD subjects with 
COPD. The data presented in chapter 4, in conjunction with that from studies of intrasubject 
variation in TNF-α secretion over a 3 week period by healthy subjects’ monocytes can 
therefore be considered as pilot data, useful in determining the sample size needed to power 
future studies in AG/GG monocytes. The sample sizes required to repeat these studies are 
prohibitive in terms of resources and practicality and as such would indicate that further 
investigation of the rs361525 polymorphism in A1ATD or usual COPD patients should not 
focus specifically on monocytes. Many of the data presented in chapter 5 from healthy subject 
monocytes showed trends rather than statistically significant differences and although these 
trends clearly cannot be assumed to reflect genuine differences the data could be used to 
perform power calculations to determine necessary sample sizes to show true differences 
(should these exist) with predetermined power level set at 80%.  
 
 
 
 
227 
 
6.2 Future direction of work 
6.2.1 The rs361525 TNF-A polymorphism in A1ATD and COPD 
Future studies of A1ATD subjects with the rs361525 polymorphism should focus on cells 
retrieved from the airways. For example, bronchial epithelial cells and airway macrophages 
could be harvested bronchoscopically, cultured and stimulated with a variety of stimuli, 
including pooled airway secretions to simulate in-vivo conditions, in order to investigate if the 
polymorphism is associated with increased TNF-α production at mRNA and protein level. In 
addition, cell surface expression of mTNF-α and TNFR1 and TNFR2 could be studied using 
flow cytometry to determine at which stages in TNF-α processing the polymorphism is most 
relevant and how increased TNF-α production might affect cell surface expression of its 
receptors. Other methods could also be employed, such as ChIP assays, whereby cell nuclear 
material is extracted and undergoes immunoprecipitation to determine if RNA polymerase 
preferentially binds to the A allele over the G allele. Detailed clinical characterisation of the 
A1ATD patients with the polymorphism could also be conducted and compared to all GG 
subjects within the available cohort, given that the difference in BMI between groups noted in 
Sapey et al’s work (17) was not observed in the current studies. 
A recently published GWAS of several large cohorts of COPD subjects and healthy controls 
identified six SNPs associated with the presence of either moderate or severe COPD (332). 
The rs361525 polymorphism was not one of the identified loci, nor it should be noted was any 
other TNF-A SNP. Whilst this would suggest that this polymorphism is not relevant to usual 
COPD that may not be the case. Wood et al (125) showed that the rs361525 polymorphism 
was associated with a particular phenotype of A1ATD-related COPD, namely CB, and hence 
this may explain why it was not detected in GWAS which tend to consider COPD as one 
homogenous condition.  In addition, SNPs causing A1ATD are not shown to be associated 
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with COPD at all when individuals of all ages are considered as opposed to a younger subset 
(123), proving the point that considering COPD as one single entity is not ideal.  
Whilst A1ATD is a useful model of COPD (333) there is a recognised interaction between 
A1AT and the TNF-α pathway, meaning that TNF-α may be more pertinent to A1ATD-
related COPD than usual COPD. A1AT has been shown to block the action of TACE which is 
responsible for cleaving mTNF-α to sTNF-α (76), and therefore in A1ATD patients enhanced 
TACE activity may occur leading to greater TNF-α and TNFR1 secretion by multiple cell 
types (75, 78). A1AT can also act as a competitor for TNF-α receptors and interrupt TNF-α 
autocrine feedback loops and hence its relative absence leads to increased TNF-α output from 
neutrophils (75) and monocytes (77). Given these findings it is probable that TNF-α plays a 
greater role in the pathogenesis of A1ATD-related COPD than in usual COPD and as such the 
rs361525 polymorphism, even if truely functional, may be of less relevance in a usual COPD 
population. Therefore, if the study of this particular polymorphism were to be continued it 
would be sensible to do this initially in usual COPD which is far more common than A1ATD 
(333) and thereby establish its relevance, if any, in the airway secretions of patients with the 
most prevalent form of the disease. It would be of benefit therefore to establish a large 
regional cohort of usual COPD patients who could be clinically phenotyped, genotyped for 
presence of the rs361525 polymorphism and take part in clinical and laboratory studies. Such 
a database is currently being established in the West Midlands to conduct a variety of COPD 
studies. This would address the logistical difficulties and hence make it more feasible to 
conduct repeated studies. However, it must also be considered that if the prevalence of the A 
allele is estimated at approximately 7% (124) (although if functional it may be higher in a 
COPD population) then it may still be too great a challenge to establish a regional cohort of 
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usual COPD patients and closely matched controls containing enough subjects with the 
polymorphism to power the suggested studies. 
6.2.2 The differential roles of TNFR1 and TNFR2 in monocytes 
A number of the findings from this aspect of the thesis merit further investigation. Firstly, it 
would be important to replicate and extend the current findings in monocytes or macrophages 
retrieved from patients with TNF-α associated disease, for example, rheumatoid arthritis or 
acute lung injury. Secondly, further delineation of the TNFR1 and TNFR2 intracellular 
signalling pathways in monocytes is also needed. That TNFR2 ligation may be able to induce 
downstream pathways that initiate IL-10 up-regulation in the absence of any significant up-
regulation of pro-inflammatory cytokines, whilst TNFR1 ligation may be able to do both is of 
great interest. Determining the steps in these pathways might make it possible to interrupt 
pro-inflammatory downstream cascades whilst leaving IL-10 production switched on. To 
investigate this, TNFR1 and TNFR2 could be sequentially blocked with a mAb or knocked-
down using a small interfering RNA (334) in order to allow TNF-α signalling via one receptor 
only. To then dissect the intracellular signalling pathways specific to each receptor one could 
employ increasing concentrations of commercially available inhibitors to a variety of known 
intra-cellular signalling messengers such as those shown in figures 1.6 and 1.7 and measure 
the effects on IL-10 and pro-inflammatory cytokine output at the mRNA and protein level 
using RT-qPCR and ELISA. To support these findings the Western blot technique could be 
used to demonstrate the presence of specific secondary messengers in their phosphorylated, 
i.e. activated state, when either TNFR1 or TNFR2 is stimulated. This involves separation of 
proteins from lysed cells by size using electrophoresis, followed by transfer to a membrane 
and application of mAbs specific to the proteins of interest (335). In addition, nuclear 
localisation of specific transcription factors could be determined using immunocytochemistry 
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whereby a primary mAb binds to the transcription factor of interest and is visualised by 
microscopy following addition of a secondary mAb conjugated to a fluorophore (329). 
Thirdly, further work is needed to clarify the role of TNFR2 on monocytes as the current 
studies suggest it may play a dual anti- and pro-inflammatory role. Confirmation of the 
hypothesis that the majority of sTNF-α is being cleared from the pericellular environment via 
TNFR2 binding should be sought and its clinical relevance explored. Does this same 
phenomenon occur when monocytes are co-cultured with other cell types, for example 
epithelial cells or T-lymphocytes? These questions could be addressed by using fluorescence 
microscopy and fluorescently labelled exogenous sTNF-α with monocytes alone or in co-
culture. Furthermore monocytes could be subdivided prior to fluorescence microscopy 
experiments by TNFR1/TNFR2 expression pattern and/or apoptotic markers, to determine if a 
particular monocyte group is responsible for sTNF-α clearance.  
It would also be important to confirm if the bound sTNF-α is simply being removed or is able 
to activate TNFR2, which would contradict previously held wisdom that it is only mTNF-α 
which can stimulate downstream signalling pathways via this receptor (7). This could be 
determined by comparing IL-10 output from monocytes (with TNFR1 blocked) stimulated 
with exogenous sTNF-α. Membrane TNF-α signalling could be prevented in one arm of the 
experiment by addition of a blocking mAb prior to washing and then subsequent addition of 
exogenous sTNF-α.  
Fourthly, changes to the expression of TNFR1 and TNFR2 on the monocyte surface over 
time, should be further investigated, initially by repeating experiments with greater subject 
numbers and more monocytes per sample. Dreschers et al have shown in monocytes that 
TNFR1 is down-regulated on monocytes by four hours post infection with Escherichia coli 
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and that this is due to internalisation of the receptor (289). It is possible therefore that the 
decrease in TNFR1 at the cell surface in LPS stimulated monocytes (as shown in figure 5.14) 
is also due to internalisation of the receptor complex rather than a down-regulation of the gene 
encoding the receptor or the translation of its mRNA sequence. However this could be 
confirmed by performing a time course profile of TNFR1 mRNA expression and comparing 
this with time course profiles of cell surface and internal TNFR1 MFI values using flow 
cytometry on intact and permeabilised monocytes respectively (289). A small interfering 
RNA molecule could also be used to knock out TNFR2 to clarify if signalling via this 
receptor up-regulates TNFR1 production and expression. 
Finally, it would be important to study the reasons why some isolated monocytes express only 
one of the TNF-α receptors, both or neither. Could this be related to the presence of both 
classical and possibly intermediate monocytes, or due to cell maturity or activation state? Of 
particular interest is whether monocytes which expressed both TNFR1 and TNFR2 differ 
substantially in function from the monocytes expressing only TNFR1 or only TNFR2 and 
whether an individual monocyte can change its expression pattern in response to a stimulus. 
These questions could be addressed by sorting monocytes on the basis of TNFR1 and TNFR2 
expression. The presence of other monocyte markers, such as CD14, CD16 and others as 
outlined in table 1.4 could then be studied to characterise these subsets further, as could 
changes to TNFR1 and TNFR2 expression before and after stimulation. Monocyte functions 
such as cytokine secretion, ROS production and phagocytotic capability could also be studied 
by subtype if wished. However, as discussed in chapter 5 this would require a lot more cells 
in order to accurately study rare events such as monocytes only expressing TNFR1. 
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6.3 Conclusions 
TNF-α is an important cytokine in the immune response of many chronic inflammatory 
disorders, particularly in A1ATD-related COPD. In COPD there is a need to identify markers 
of disease that could help to more accurately phenotype patients, to aid development of 
focussed disease modifying treatments and allow prognostic stratification. Identifying patients 
with functionally relevant SNPs is one way of phenotyping. Whilst the experiments presented 
here were negative, examining the effects of the rs361525 TNF-A polymorphism in 
monocytes, this data in conjuction with that showing a positive association of the SNP with 
TNF-α output in airway secretions from the same patient cohort (17) highlight the inherent 
complexity of investigating SNPs, beyond simply demonstrating an association with a 
disease. In this respect this thesis offers an important contribution to the field as it suggests 
that the effects of a SNP may be compartment, stimulus or cell type specific, and that negative 
findings in one setting may not negate a genuine effect of the SNP in an alternative setting. 
This thesis also presents data that suggests that in monocytes from healthy subjects TNFR1 
ligation leads to pro and anti-inflammatory (IL-10) cytokine production whereas TNFR2 
ligation up-regulates only IL-10, possibly clears sTNF-α from the peri-cellular environment 
but also up-regulates TNFR1 on the monocyte surface. In susceptible individuals disordered 
or excessive TNF-α signalling leads to chronic inflammatory disease. As TNFR1 is 
ubiquitous and TNFR2 expression is limited mainly to leukocytes these findings may support 
the strategy of selective TNFR1 blockade for TNF-α associated chronic inflammatory disease. 
Given the current interest in these therapies in a clinical setting (293, 294) it would be 
important to use the data presented here to power future studies further examining the 
differential effects of TNFR1 and TNFR2 in human monocytes, the principal TNF-α secreting 
cell. 
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7 Appendices 
7.1 Published articles 
Gane J, Stockley R, Sapey E. The rs361525 polymorphism does not increase production of 
tumor necrosis factor alpha by monocytes from alpha-1 antitrypsin deficient subjects with 
chronic obstructive pulmonary disease - a pilot study. J Negat Results Biomed. 2015; 14: 20. 
Published online 2015 Dec 1st.  doi:  10.1186/s12952-015-0039-3 
7.2 Published review articles 
Gane J, Stockley R. Mechanisms of neutrophil transmigration across the vascular 
endothelium in COPD. Thorax. 2012 Jun; 67(6):553-61. 
7.3 Published abstracts 
Gane J, Sapey E, Stockley R. Does tumour necrosis factor alpha induced by 
lipopolysaccharide have a positive feedback effect on the up-regulation of interleukin-8 
messenger RNA by monocytes from COPD patients? ERJ. 2013 Sep; 42(suppl 57):P3874 
Gane J, Stockley R, Sapey, E. The differential roles of TNF-α receptors 1 and 2 in influencing 
the balance of pro- and anti-inflammatory cytokine output from monocytes: towards a new 
therapeutic approach in TNF-α associated chronic inflammatory diseases. Immunology. 2013 
Nov; 140 (suppl s1):175 
7.4 Prizes 
Stephen Whittaker Prize (best scientific paper by a trainee physician)- awarded by the West 
Midlands Physicians Association for a spoken presentation at the 2013 Autumn meeting, 
entitled: The differential roles of TNF-α receptors 1 and 2 in influencing the balance of pro- 
and anti-inflammatory cytokine output from monocytes: towards a new therapeutic approach 
in TNF-α associated chronic inflammatory diseases. 
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